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ABSTRACT 
 
Neurotropic arboviruses are a group of pathogens capable of causing 
severe and fatal central nervous system infections for which there are few 
effective treatments or vaccines.  The extent of neurotropic arbovirus-mediated 
destruction of central nervous system neurons is often an important determinant 
in the severity and clinical outcome after infection.  Early cellular innate immune 
responses mediated by pattern recognition receptors (PRRs) are often vital for 
effective pathogen control, and an effective neuronal innate immune response 
may be crucial to prevent the essentially irreversible loss of critical central 
nervous system neurons by neurotropic arboviruses.  The work presented here 
describes efforts to preserve neurotropic arbovirus-infected neurons by: a) 
studying the interactions between neurotropic arboviruses and neuronal PRR 
pathways in order to indentify novel targets for future therapeutics, and b) 
identifying potential anti-neurotropic arbovirus medications which target viral 
replication.  
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Innate PRR pathways function in both a cell and pathogen-specific 
manner.  However, relatively little is known about the induction and regulation of 
neuronal PRR signaling.  Therefore, I assessed PRR pathway expression and 
function in neurons and found that neurons possess functional PRR pathways 
mediated by select receptors and signaling molecules which activate the 
downstream transcription factors NFB and IRF3 resulting in the production of 
genes with putative antiviral activity.  Next, I characterized how neuronal PRR 
pathways interact with neurotropic arboviruses using western equine encephalitis 
virus (WEEV) as a model neurotropic arbovirus.  From these studies I concluded 
that IRF3 mediates a neuron-protective response to WEEV; however, this 
response was independent of type-I IFN signaling, which possesses potent 
antiviral activity and is canonically activated downstream of IRF3 in alternate cell 
types.  Importantly, WEEV inhibited neuronal PRR-mediated induction of antiviral 
type-I interferons, and this inhibitory capacity was mapped to the WEEV capsid 
protein.  These data indicated that neuronal PRR pathways may be important 
determinants in neurotropic arbovirus pathogenesis and that neuronal PRR 
pathways and viral countermeasures to them may be exploited to develop anti-
neurotropic arboviral treatments.  Finally, I identified a novel class of small 
molecules which inhibit WEEV replication, protect neuronal cells from WEEV-
induced cell death, and may be a useful component of future anti-neurotropic 
arbovirus therapies.   
 
1 
 
Chapter I 
General Introduction 
Early cellular innate immune responses are vital for effective pathogen 
control, and an effective neuronal innate immune response may be crucial to 
prevent the essentially irreversible loss of critical central nervous system neurons 
by neurotropic arboviruses.  Neurotropic arboviruses are a group of viral 
pathogens transmitted by insect vectors, most often mosquitoes, capable of 
causing severe and potentially fatal central nervous system infections in humans.  
Unfortunately there are very few effective treatments or vaccines for these viral 
infections, which are classified as NIAID Category B Priority Pathogens due to 
their potential misuse as bioterrorism agents.  The extent of neurotropic 
arbovirus-mediated destruction of central nervous system neurons is often an 
important determinant in the severity and clinical outcome after infection.  The 
work presented here describes efforts to preserve neurotropic arbovirus-infected 
neurons by: a) studying the interaction between neurotropic arboviruses and the 
neuronal innate immune response to indentify novel targets for future 
therapeutics and vaccines; and b) identifying potential anti-neurotropic arbovirus 
medications which inhibit viral replication.  This introductory chapter provides 
background information on innate cellular immunity and neurotropic arbovirus 
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pathogenesis with a particular emphasis on the new world alphavirus western 
equine encephalitis virus which is the model neurotropic arbovirus primarily 
studied in this body of work. 
 
Neurotropic Arbovirus Epidemiology and Clinical Significance 
Neurotropic arboviruses preferentially infect central nervous system (CNS) 
neurons and include but are not limited to West Nile virus (Flaviviridae), St. Louis 
encephalitis virus (Flaviviridae), La Crosse virus (Bunyaviridae), and the equine 
encephalitic alphaviruses (Togaviridae genus alphavirus) (Table 1.1).  
Neurotropic arboviruses are transmitted via insect vectors and are responsible 
for sporadic epidemics of viral encephalitis (71).  Many neurotropic arboviruses 
are endemic to North America including West Nile virus (WNV), St. Louis 
encephalitis virus (SLEV), La Crosse virus (LACV), Western equine encephalitis 
virus (WEEV), Eastern equine encephalitis virus (EEEV), and Venezuelan equine 
encephalitis virus (VEEV) (26).  Most infections occur during warmer, moister 
months due to increased amounts of mosquito vectors and an increased amount 
of time spent outdoors by the human population in temperate regions (132).  
There are currently no recommended or approved anti-viral treatments for these 
viral infections, and the standard of care is purely supportive (132).  Ribavirin, an 
FDA-approved nucleoside analogue, may be beneficial for some neurotropic 
arboviruses in the Flaviviridae family (90), but definitive clinical evidence is 
lacking (8).  Initial studies have identified novel small molecules with  
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Table 1.1.  Neurotropic arboviruses.      
Family Genus Species Genome BSL Priority 
Togaviridae Alphavirus  Western equine 
encephalitis virus 
 Eastern equine 
encephalitis virus 
 Venezuelan 
equine 
encephalitis 
viruses 
Positive 
sense RNA 
(subgenome 
structural 
gene 
production) 
3 B 
Flaviviridae Flavivirus  St. Louis 
encephalitis virus  
 West Nile virus 
 Japanese 
encephalitis virus 
Positive 
sense RNA 
3 B 
Bunyaviridae Orthobunyavirus  La Crosse virus 
 California 
encephalitis 
viruses 
Segmented 
negative 
sense RNA 
2 B 
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anti-neurotropic arboviral properties (121, 122, 128), but it is unclear how 
clinically useful these will be.  Vaccines to some neurotropic-arboviruses exist, 
including WEEV, EEEV, VEEV, and Japanese encephalitis virus (JEV), but with 
the exception of JEV, which is not endemic to North America, they are all poorly 
protective, have significant side effects including mild encephalitic symptoms for 
the VEEV vaccine, and are not available to the general public (155).  
Development of better vaccines for neurotropic arboviruses is an active area of 
research, and several promising candidates have been identified (12, 54, 123, 
152, 168, 169, 174, 181).  To summarize, there is a great need for better 
vaccines and effective antivirals to treat neurotropic arbovirus infections.   
Most neurotropic arboviruses are listed as NIAID priority A, B, or C 
pathogens due to numerous characteristics that make them potential biological 
weapons including: a) high clinical morbidity and mortality; b) potential for aerosol 
transmission; c) lack of effective countermeasures for disease prevention or 
control; d) public anxiety elicited by CNS infections; e) ease with which large 
volumes of infectious materials can be produced; and f) potential for malicious 
introduction of foreign genes designed to increase virulence (23, 155).  
Unfortunately, it is widely thought that VEEV has been weaponized for aerosol 
delivery (80).  Due to many of the same reasons that contribute to their 
classification as potential biological weapons, many neurotropic arboviruses 
require biosafety level 3 containment (33), highlighting the importance of 
understanding and being able to combat these severe pathogens. 
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The clinical portrait of neurotropic arbovirus infection can range from 
moderate constitutional symptoms and uncomplicated resolution to fulminant 
encephalitis, especially in the young, old, immunocompromised, or chronically ill 
(64, 72, 132, 142, 151). The incubation period for neurotropic arbovirus 
encephalitis ranges from 2-21 days, and encephalitis is typically preceded by a 
prodrome of fever, malaise, headache, stiff neck, and occasionally sore throat 
and nausea/vomiting.  These symptoms can then progress to fulminant 
encephalitis including changes in mentation, stupor, coma, convulsions, and 
signs of upper motor neurons lesions such as exaggerated deep tendon reflexes 
and spastic paralysis. Diagnosis is usually accomplished by identifying pathogen-
specific IgM antibodies in the cerebral spinal fluid of symptomatic patients.  The 
acute encephalitic phase lasts from a few days to as long as 2-3 weeks, and full 
recovery, if achieved, may take months (64, 72, 132, 142, 151).  However, 
survivors, especially children, are often left with significant sequelae including 
changes in cognition, seizures, developmental delays, and motor deficits.  
The virulence of each neurotropic arbovirus as measured by case fatality 
rates varies on the high end from 50-75% for EEEV and 20-50% for JEV (132).  
On the low end, La Crosse virus case fatality rates are about 0.5 %, and the 
majority of neurotropic arboviruses including WEEV, SLEV, and WNV have 
intermediate case fatality rates of 5-10% (132). Neurotropic arboviruses also 
have a wide range of case-to-infection ratios where the more prevalent West 
Nile, St. Louis, and La Crosse viruses have ratios of 1:100, 1:200, and 1:1000, 
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respectively, whereas the equine encephalitic alphaviruses have ratios ranging 
from 1:1 to 1:1000 (132).  In the United States, there are about 5-10 cases of 
each of the equine encephalitis viruses and about 75 cases for LACV and SLEV 
annually; however, all of these viruses undergo sporadic epidemics in which the 
number of cases can soar into the thousands and historically reach as high as 
several hundred thousand (64, 132, 142).  For example, prior to the introduction 
of WNV to North America in 1999, WNV was not endemic to the continent; now, 
approximately 1000-3000 cases and 100-300 deaths can be attributed to it each 
year (132, 142).  However, neurotropic arbovirus epidemics do not necessarily 
involve geographical relocation to areas with immunologically naïve populations 
(64).      
Predilection for clinically apparent disease of specific age groups varies 
among the neurotropic arboviruses.  La Crosse encephalitis primarily infects 
children less than 15 years old whereas WNV typically causes disease in the 
elderly (132).  SLEV causes a milder disease in the young and a more severe 
disease in those greater than 40 years of age (132).  The equine encephalitic 
alphaviruses all have a predilection for children, which is most apparent for 
WEEV where the case to infection ratio is 1:1 for infants versus 1:1000 for adults 
(132).  Interestingly, WEEV also has a slight predilection for causing disease in 
males over females, a feature of WEEV epidemiology that remains relatively 
understudied (64, 132).  In summary, neurotropic arboviruses generally cause 
severe, sporadic epidemics, especially in vulnerable human populations including 
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the young and the old, and there are currently no broadly approved antiviral 
medications or vaccines to treat or prevent these infections.  
 
Neurotropic Arbovirus Biology 
Neurotropic arboviruses belong to one of three viral families: Flaviviridae, 
Bunyaviridae, and Togaviridae.  Each of these families has a unique genomic 
structure, and that of the equine encephalitic alphaviruses will be thoroughly 
reviewed in a later section.  The genomes of flaviviruses and togaviruses consist 
of a single positive-sense RNA that can be immediately transcribed upon entry 
into the cytosol (94, 106).  Both togavirus and flavivirus genomes contain 5’ cap 
structures analogous to that of cellular mRNAs, but only togavirus genomes are 
3’ polyadenylated (94, 106).  Furthermore, the togavirus structural proteins are 
translated as a polyprotein from a transcript whose production is controlled by a 
viral subgenomic promoter on the viral negative-sense genomic strand.  Due to 
this genomic architecture, expression of alphavirus structural proteins requires 
viral RNA replication (94).  In contrast, flavivirus structural proteins are 
synthesized directly from genomic RNA (106).  Unlike flavi- and togavirus 
genomes, bunyavirus genomes consist of three negative-sense RNA segments 
which lack 5’ caps and polyadenylated tails, and some bunyaviruses also have 
ambisense segments (151).  The negative orientation of the bunyavirus genomic 
segments necessitates the inclusion of at least one viral RNA-dependent RNA 
polymerase (RdRp) within each viral particle to initiate synthesis of positive-
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sense strands to produce viral proteins and negative-sense genomic strands for 
packaging into viral progeny (151).  Despite the obvious differences in genomic 
architecture and RNA replication strategies among the neurotropic arboviruses, 
important similarities among these viruses exist such as: a) they consist of an 
enveloped viral particle with an encapsidated RNA genome; b) they almost 
exclusively replicate in the cytoplasm of host cells; and c) they have the ability to 
directly infect and damage CNS neurons (64, 94, 106, 151).  Due to these 
important similarities and differences, interaction of these viruses with neuronal 
innate immune pathways may also have both unique and common features.     
The natural life cycle of neurotropic arboviruses involves an enzootic cycle 
generally between mosquitoes and birds or other small animals (64, 72, 132, 
142, 151).  Periodically, an epizootic cycle initiates resulting in the infection of 
larger mammals and humans; however, humans and large mammals are 
generally dead-end hosts and, except for VEEV epizootics and horses, do not 
sustain epizootic cycles (26, 64, 72, 132, 142, 151).  The involvement of 
abundant non-human reservoirs in the natural life cycle of neurotropic 
arboviruses makes them an important source of re-emerging pathogens with 
potentially increased virulence (71).  One example of a re-emerging arboviral 
pathogen is that of Chickungunya virus, a close relative to the equine 
encephalitic arboviruses.  From 2004-2009, this virus caused millions of cases of 
Chickungunya fever in south eastern Asia and the Indian subcontinent, which is 
characterized by fever, rash, and arthritis (157).  It is hypothesized that mutations 
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in its receptor binding protein allowed Chickungunya virus to infect more 
anthropophilic mosquito vectors, thereby contributing to a massive outbreak of 
what was a relatively uncommon human pathogen (157). 
Neurotropic arboviruses infect humans when an infected arthropod takes 
a blood meal from a human host.  Depending on the virus, it may infect tissues at 
the site of infection and undergo local replication and subsequent viremia, or it 
may infect cells of the reticuloendothelial system and secondary lymphoid organs 
followed by replication in these secondary tissues and viremia (47, 64, 72, 108, 
112, 130, 151).  Viremia leads to CNS invasion, which for most neurotropic 
arboviruses is not completely understood but may involve infection of the 
olfactory neuroepithelium with passage through the cribiform plate and/or 
infection of cerebral endovascular cells and subsequent multifocal entry into the 
CNS (47, 64, 72, 130, 132, 151).  Within the CNS, most neurotropic arboviruses 
primarily infect neurons with little infection of supporting neuronal cell types such 
as oligodendrocytes, astrocytes, and microglia (26, 47, 64, 72, 130, 132, 151).  
The areas of the CNS targeted by each neurotropic arbovirus varies slightly, but 
in general, the cortex, basal ganglia, and brainstem are most often affected (26, 
47, 64, 72, 130, 132, 151).  The histopathology of infected CNS tissue reveals 
wide-spread neuron destruction, perivascular cuffing with polymorphonuclear 
cells and mononuclear leukocytes, and vasculitis with vessel occlusion (26, 47, 
64, 72, 130, 132, 151).  Apoptotic glia and inflammatory cells are also often found 
near affected neurons, and the meninges can also become inflamed and/or 
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infected (26, 47, 64, 72, 130, 132, 151).  Important for this body of work, the 
clinical symptoms of encephalitis and subsequent sequelae arise directly from 
viral-induced damage of neurons and partly from indirect damage of neurons due 
to edema and inflammation, suggesting that discovering ways of preventing 
neuron damage may lead to novel treatments for these devastating infections. 
 
Immune Response to Neurotropic Arboviruses 
The immune response to neurotropic arbovirus infection is complex and 
ultimately pathogen-specific, but a couple of important parallels can be discerned 
among these viruses.  First, innate immune signaling is important for the 
response to many neurotropic arbovirus infections, as demonstrated by 
increased mortality, neurovirulence, viral load, and extraneural viral 
dissemination in the absence of an intact type-I IFN signaling pathway (18, 64, 
110, 146, 179).  Second, disease resolution and immune-mediated clearance of 
many neurotropic arboviruses requires adaptive B and T-cells (46, 64, 65).  
These observations indicate that a highly orchestrated immune response, 
involving both innate and adaptive branches of the immune system, is needed for 
successful resolution of neurotropic arboviral infections. 
  It is not particularly surprising that, like most viral infections, both the 
innate and adaptive immune systems are required for efficient resolution of 
neurotropic arbovirus infections, but immune-mediated clearance of virus from 
the CNS is likely more regulated than clearance from other sites of infection 
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because the brain is thought to be an immuno-privileged organ (65).  For 
instance, cerebral capillary endothelial cells are relatively unreactive and 
contribute to a blood-brain barrier, which is a physiologic barrier that normally 
ensures low levels of leukocytes and lymphocytes within the CNS (30, 65, 87).  
The blood-brain barrier is not an absolute barrier because a systemic immune 
response to a peripheral infection can increase its permeability, resulting in 
increased CNS immune surveillance (79, 105).  In addition to limiting immune 
system access to the CNS via the blood-brain barrier, the CNS also tightly 
regulates the adaptive immune response through limited MHC expression and 
active suppression of cytotoxic T-cell responses (65).  These data suggest that 
the immune response within the CNS is highly regulated, a finding that may 
reflect the need of the CNS to preserve vital CNS neurons, which have a very 
limited self-renewal capacity, from immune-mediated damage.   
Most cell-types in the CNS play an active role in the regulated immune 
response to neurotropic viral infections, including neurons, astrocytes, and 
microglia (46, 65, 72, 100, 131, 151).  For instance, neurons may participate in 
the innate response by generating antiviral type-I and II interferons (44, 65, 125, 
131), but these same cytokines can also be neurotoxic when produced in excess 
(5, 65, 131).  Like neurons, glial cells (astrocytes, oligodendrocytes, and 
microglia) are capable of producing an innate response, and microglia, which are 
the myeloid-derived resident cell-type in the CNS, contain highly active TLR-
mediated pathways (103, 140).  Importantly, glial cell PRR signaling may mediate 
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the neuropathology of several diseases, including viral encephalomyelitis (103, 
140).  These observations further demonstrate the intricacy and the participation 
of multiple CNS resident cell types in immune responses within the CNS. 
Neurons are relatively resistant to both viral-induced death and T-cell 
killing, which is consistent with their limited capacity for self-renewal, and 
suggests that immune-mediated clearance of virus from the CNS is neuron 
sparing (65).  Furthermore, clearance of virus from neurons is generally heavily 
dependent on antibody and cytokine responses, whereas cytotoxic T-cell 
responses may not be required  for all neurotropic pathogens (46, 65).  Due to 
the general neuron-sparing nature of the immune response in the CNS, symptom 
resolution may be due to an immune response that checks viral replication and 
spread and may not completely eliminate all viral RNA (65).  Consistent with this, 
viral RNA can be detected in the CNS throughout the life of recovered animals 
along with antiviral antibody, which suggests that low-level, non-cytolytic, 
immune-mediated control may be required for long-term resolution of viral-
induced disease (64, 65, 127).  In summary, all arms of the immune system are 
involved in neurotropic arbovirus resolution, including innate responses from 
neurons, and the clearance of virus from the CNS is highly regulated and neuron-
sparing. 
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Neurotropic Alphavirus Basic Biology and Replication Cycle 
Alphaviruses have long been used as model neurotropic arbovirus 
pathogens and are generally subdivided into new and old world viruses based on 
their location primarily in the western or eastern hemispheres, respectively (150).  
The commonly studied old world alphaviruses, Sindbis (SIN) and Semliki Forest 
(SFV) viruses, cause a febrile illness associated with rash and polyarthropathy, 
whereas the more virulent new world alphaviruses WEEV, EEEV, and VEEV 
typically cause CNS infections (26, 45, 51).  The new world alphaviruses 
naturally infect the CNS (26, 32, 75).  Thus, we chose WEEV as our model 
alphavirus to study the interaction of neurotropic arboviruses with neuronal innate 
immune pathways.  However, most of the knowledge regarding alphavirus 
biology and neuropathogenesis was gained by studying old world pathogens 
such as SFV and neuro-adapted SINV, suggesting that our knowledge of 
encephalitic alphavirus pathogenesis may be incomplete.  
The alphavirus genome is roughly 11-12 kb in length and encodes the 
non-structural proteins, which are required for RNA replication, on the 5’ two-
thirds, and the viral structural genes on the 3’ one-third (Fig 1.1) (94).  Non-
structural protein-1 (nsP1) is a methyl-transferase involved in 5’-capping (118).  
Non-structural protein-2 (nsP2) contains both helicase and protease activity. The 
nsP2 helicase is required for efficient replication, and the protease activity is 
required for polyprotein processing (62, 171).  Non-structural protein-3 (nsP3) is 
a phosphoprotein with no known function, although it appears to play a role in     
14 
 
 
 
Figure 1.1.  Alphavirus genome architecture and replication.  Upon entry into 
the cytosol, the non-structural proteins are translated, autocatalytically 
processed, and mediate production of negative-sense templates and subsequent 
positive-sense genomic strands.  Viral replicase proteins also produce 
subgenomic templates, which encode the structural proteins, via a subgenomic 
promoter encoded on the negative-sense genomic template.  For further details 
see text. 
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replication and may mediate neurovirulence in old world alphaviruses (98, 167, 
177).  The viral RdRp and core of the alphavirus replication complex is encoded 
by nsP4 (135).  The structural components include the capsid, which  
encapsidates the RNA genome, and the envelope glycoproteins, which mediate 
viral attachment and entry (94, 158).   
Alphavirus entry into host cells requires clathrin-mediated endocytosis and 
is highly pH-dependent (94, 158).  A specific cellular receptor has not been 
identified, and it is proposed that several may be sufficient given the broad tissue 
tropism and species host range of alphaviruses (94, 158).  Due to the complex 
and incomplete understanding of host receptors required for alphavirus 
attachment and entry, the neurotropism of the new world alphaviruses remains 
poorly understood but may be dependent on increased heparin sulfate binding 
relative to old world alphaviruses (143).  Consistent with this, serially passaged 
old world alphaviruses develop mutations in envelope protein-2  which enhances 
heparin sulfate binding and correlates with increased neurovirulence (143).  
Furthermore, old world viruses, versus naturally encephalitic new-world 
alphaviruses, poorly bind heparin sulfate (143).  These observations indicate that 
alphavirus attachment to and entry into host cells requires clathrin-mediated 
endocytosis, but host and viral factors mediating attachment and neurotropism 
remain poorly defined and may be complex and multifactorial. 
The alphavirus glycoproteins E1 and E2, which span the viral envelope, 
mediate the entry process, where cell binding is largely attributed to E2 (94, 158).  
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Upon acidification, E1, which is a type-II fusion protein, exposes its fusion 
peptide and, through large conformational changes, mediates the fusion of the 
viral envelope with the endosomal membrane resulting in the release of the 
nucleocapsid core into the cytosol (94, 158).  After entering the cytosol, the RNA 
genome is immediately translated by host machinery (Fig 1.1) (64, 158).  This 
generates the predominant polyprotein, nsP123, and the minor polyprotein, 
nsP1234, via read-through of an opal codon (94, 158).  These polyproteins are 
autocatalytically processed via the protease activity of nsP2 (94, 158).  The 
sequential processing of these polyproteins into their constituent parts forms 
distinct replication complexes which preferentially produce negative-sense RNA 
strands followed by positive-sense genomic RNA strands and finally sub-
genomic RNA strands (94, 158).  The viral replication complexes recognize and 
bind promoter-like elements termed conserved sequence elements (CSE) 
located at the 5’ and 3’ ends of the viral RNA and at the sub-genomic promoter 
near the junction of the nsP4 and capsid genes (94, 158).  Within host cells, the 
viral replication complexes are located on the cytosolic surface of cellular 
membranes.  These membranes are thought to be derived from endosomes or 
lysosomes but are often ambiguously termed cytopathic vacuoles (94, 158).  
Following subgenomic RNA synthesis, the structural genes are translated via 
host machinery into a poly-protein with capsid on the N-terminus and E1 on the 
C-terminus (Fig 1.1) (94, 158).  Immediately following translation, capsid is 
released via autoproteolytic activity of a protease domain located in the C-
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terminus of capsid (94, 158), a fact that, along with polyprotein processing of the 
nsPs, will be important for understanding the design of constructs used in 
chapter III.  Release of capsid exposes a signal peptide on the N-terminus of the 
new polyprotein containing the envelope proteins (94, 158).  This signal 
sequence directs the envelope proteins to the ER-Golgi network for further post-
translational processing, including glycosolation and modification by host 
proteases, before being translocated to the cellular membrane (94, 158).  
Meanwhile, capsid associates with viral RNA genomes via packaging sequences 
on its N-terminus and forms neucleocapsid cores that then interact with envelope 
proteins near the cell membrane (94, 158).  Finally, viral particles bud from the 
cell surface (94, 158). 
 
Alphavirus Phylogeny 
Alphaviruses are believed to be derived from an unknown protoalphavirus 
that originated in the Americas and gave rise to the new and old world 
alphaviruses in existence today (64).  Alphavirus phylogeny is based on both 
sequence analysis and envelope protein antigenic complexes.  Generally these 
two methods produce similar phylogenetic trees except for where on these trees 
each method places WEEV. The reason for this is that WEEV is a recombinant 
alphavirus in which the non-structural proteins and capsid are derived from an 
EEEV-like common relative, and the envelope glycoproteins are derived from a 
Sindbis virus-like relative (74).  This will be important for this body of work 
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because the old and new world alphaviruses utilize either nsP2 or capsid, 
respectively, to mediate important virulence mechanisms described below.   
 
Immune Response to Neurotropic Alphaviruses 
Neurotropic alphavirus pathogenesis and the immune response mounted 
against alphaviruses are generally similar to the description given above 
regarding all neurotropic arboviruses; however, some aspects of 
neuropathogenesis are far better characterized for alphaviruses than other 
neurotropic arboviruses.  For instance, the humoral immune response is 
incredibly important for alphavirus encephalitis resolution, and passive 
administration of protective antibodies can be therapeutic for established 
infections (73).  These protective antibodies don’t have to be neutralizing, are 
independent of complement, are generally directed against viral E1 or E2, can 
decrease intracellular replication, are non-lytic, and are synergistic with type-I 
IFNs (64, 65, 85, 116, 156).  Furthermore, WEEV patients lacking an antibody 
response at the time of presentation are more likely to die (64, 65).  Another 
particularly well-studied area of alphavirus neuropathogenesis is that type-II IFN, 
namely IFN can clear virus from certain neuronal populations in the absence of 
a B-cell response (27).  Finally, increased neuronal maturation is inversely 
proportional to alphavirus virulence and cytopathic effect (17).  This phenomenon 
is independent of developmental changes in the adaptive immune system and 
the induction of type-I IFN (32, 67, 70).  In fact, younger animals, and possibly 
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immature neurons, actually produce more inflammatory cytokines and type-I 
IFNs than older animals, which may contribute to the increased severity of 
neurotropic alphaviruses in younger animals (68).  While seemingly unrelated to 
developmental changes in the adaptive immune system and induction of type-I 
IFNs, the resistance of mature neurons to neurotropic alphavirus infections has 
been attributed to neuronal resistance to virus-induced apoptosis (164-166) and 
may be augmented by increased IFN responsiveness of mature neurons relative 
to immature neurons (66, 67, 69, 70, 101, 102).  These observations outline 
many of the similarities of the immune response to diverse alphaviruses and 
suggest that significant amounts of alphavirus biology can be learned by studying 
model alphaviruses.     
As described above, there are important similarities in the immune 
response to most alphaviruses.  However, the majority of alphavirus 
pathogenesis studies examined old world alphaviruses, which in humans are not 
naturally encephalitic, and recently, important differences in pathogenic 
mechanisms between new and old world alphaviruses have emerged.  For 
instance, the ability of alphaviruses to induce a cytopathic effect and shut down 
host macromolecular synthesis has long been a proposed virulence mechanism.  
For the old world alphaviruses, nsP2 mediates neurovirulence, cytopathic effect 
(CPE), shut off of host macromolecular synthesis, and interference with type-I 
IFN induction (32, 96).  In contrast, the capsid protein of new world alphaviruses 
mediates CPE, shut off of host macromolecular synthesis, and may mediate 
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interference with type-I IFN induction (22, 25, 60, 63).  This difference is 
important because shut down of host macromolecular synthesis may inhibit the 
induction of an innate antiviral response.  In support of this, attenuated strains of 
new world alphaviruses contain mutations in critical residues of capsid 
responsible for inhibition of host macromolecular synthesis (2, 3, 59, 60); and 
chimeric viruses containing new world non-structural proteins and old world 
structural proteins were cleared from IFN/ competent cells but replicated 
similar to their wild-type counterparts in IFN/deficient cells (10).  The capsid 
protein from the new world virus VEEV also blocks nuclear import (60); however, 
it is unclear whether capsid-mediated inhibition of nuclear import blocks nuclear 
translocation of innate antiviral transcription factors.  In contrast, old world nsP2 
does not appear to affect virus-induced nuclear translocation of innate antiviral 
transcription factors (10, 11).  Furthermore, it is unclear whether new world 
capsid-mediated CPE, shut off of host macromolecular synthesis, and 
interference with type-I IFN induction are the result of one common mechanism 
or are all independent functions of capsid.  In the case of old world nsP2, these 
functions may be distinct given that nsP2 mutants have been identified that no 
longer inhibit either type-I IFN induction, host transcription, or host translation 
(22, 25).  In addition to nsP2, virulence determinants mapped to the cleavage site 
between nsp1 and 2 also influence inhibition of type-I IFN induction independent 
of shut off of host macromolecular synthesis (22, 63).  These studies highlight the 
fact that while much can be learned about alphavirus pathogenesis by studying 
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model old world viruses, important differences between the encephalitic new 
world and non-encephalitic old world alphaviruses exist, especially with regard to 
how each group of viruses shuts down host gene expression and interferes with 
innate immune responses.  
Just as old and new world alphaviruses have distinct pathogenic 
mechanisms, there are also important pathogenic differences among the 
encephalitic new world alphaviruses.  For instance, VEEV pathogenesis has a 
prominent lymphoid component, whereas EEEV largely spares the lymphatic 
system and appears to avoid replication in myeloid lineage cells altogether (38).  
In addition, VEEV robustly increases serum type-I IFNs as do old world 
alphaviruses (57), whereas EEEV fails to do so (154, 164-166).  In fact, 
attenuated strains of EEEV correlated with increased induction of type-I IFNs in 
vivo (57). Altogether, these alphavirus pathogenesis studies demonstrate that 
parallels among alphaviruses exist in terms of pathogenic mechanisms and 
immune responses mounted against them, but, as with many closely related 
viruses, important differences are also present.  In this body of work, I chose 
WEEV as a model neurotropic arbovirus for two main reasons.  First, it is the 
least studied of the new world encephalitic alphaviruses and may be particularly 
illuminating for alphavirus pathogenesis because it is a recombinant virus 
between new and old world alphaviruses.  Second, while WEEV requires BSL3 
containment, it is safer than other new world encephalitic alphaviruses for healthy 
lab personnel to manipulate due to its lower case to infection ratio for adults.  
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Ultimately, all observations presented in this body of work will need to be verified 
for the other new world encephalitic alphaviruses and, more generally, 
neurotropic arboviruses, but I reasoned that studying the lesser characterized 
and recombinant alphavirus, WEEV, would reveal novel insight about alphavirus 
and potentially neurotropic arbovirus biology.         
 
Innate Antiviral Pattern Recognition Receptor Pathways 
Gerneral Characteristics 
Innate immune pathways are early responses important for pathogen control, 
and are activated by pattern recognition receptors that bind ligands containing 
pathogen- or danger-associated molecular patterns, such as modified 
carbohydrate or nucleic acid structures (58).  For antiviral innate immune 
responses, ligation of these receptors induces a signal transduction cascade that 
results in the production of type-I IFNs, other proinflammatory cytokines, and cell-
intrinsic factors important for the generation of an antiviral cellular 
microenvironment (99, 133).  In addition, antiviral PRR signaling is important for 
activating an appropriate adaptive immune response (133), which is required for 
the eventual clearance of most viral infections (7).  Thus, PRR-mediated innate 
immune signaling serves a pivotal role in stimulating rapid yet nonspecific 
antiviral activity while also providing activation signals for more specialized 
adaptive immune responses. 
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There are three general steps in innate antiviral immune responses: 
recognition, amplification, and effector production (Fig 1.2).  Activation is 
achieved by receptors that activate several transcription factors via 
phosphorylation events or degradation of transcription factor inhibitors.  These 
activation events often result in transcription factor dimerization and nuclear 
translocation.  Once in the nucleus, activated transcription factors then induce 
the expression of many genes important for mounting a cellular antiviral 
response including the type-I IFNs (24).  Type-I IFNs then signal in either a 
paracrine or autocrine manner through the type-I IFN receptor (IFNAR).  The 
interferon receptor signals in a JAK/STAT-dependent manner and activates the 
transcription factor complex interferon-stimulated gene factor-3 (ISGF3) (95).  
ISGF3 binds interferon-stimulated response elements (ISREs) present in the 
promoters of interferon-stimulated genes (ISGs) and promotes their expression 
(143).  There are several IFN-stimulated genes that act directly as antiviral 
effectors, but many are also components of antiviral PRR pathways, which 
provides a mechanism for positive feedback regulation and amplification (143). 
PRR pathway activation is initiated by four groups of antiviral PRR receptors: the 
cytosolic retinoic acid gene-I-like (RLR) receptors; the cytosolic nucleotide-
binding oligomerization domain (NOD)-like receptors (NLR); the cytosolic DNA 
recognition receptors; and the transmembrane toll-like receptors (TLR) (95, 133).  
Due to differential expression, ligand specificity, and pathogen- 
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Figure 1.2.  Innate antiviral signaling pathways.  1. Recognition. Innate 
antiviral signaling is initiated via ligation of pattern recognition receptors (PRR), 
which signal the induction of cytokines, antiviral effector genes, and type-I IFNs 
(IFN/).  2. Amplification. Type-I IFNs are then secreted and undergo 
autocrine/paracrine signaling through the type-I IFN receptor (IFNAR) resulting in 
the induction of interferon-stimulated genes (ISGs) that contain interferon-
stimulated response elements (ISRE) in their promoters.  ISGs encode pattern 
recognition receptor pathway components, thereby providing amplification and 
positive feedback on pattern recognition receptor-mediated signaling.  3. 
Antiviral Effectors. Many ISGs and genes directly induced by PRR signaling 
encode proteins with potent antiviral effects. 
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mediated interference, PRRs respond to viral infections in both a 
pathogen and cell type-specific manner (161, 184). 
 
Cytosolic Antiviral PRR Pathways 
The RLR pathways are initiated by the receptors RIG-I, melanoma differentiation-
associated gene 5 (MDA5), and laboratory of genetics and physiology-2 (LGP2)  
(Fig 1.3) (95, 161, 184, 185).  RLRs recognize non-self RNAs via a DexD/H-box 
RNA helicase domain and signal via two N-terminal caspase recruitment 
domains (CARDs) that mediate downstream protein-protein interactions required 
for antiviral signaling (95, 161, 184).  However, LGP2 lacks CARD domains and, 
depending on the context, appears to function as either a positive or negative 
regulator of RLR signaling (185).  RIG-I and LGP2 contain C-terminal regulatory 
domains that inhibit CARD-mediated signal transduction in the absence of ligand 
(184).  In contrast, MDA5 lacks a regulatory domain (184), and overexpression of 
MDA5 robustly activates downstream signal transduction in the absence of ligand 
(184).  Despite being highly similar, the RLRs appear to differentially recognize 
specific, non-self RNA moieties and viral pathogens (9).  For instance, RIG-I 
recognizes 5’ triphosphorylated double-stranded RNAs, homopolymeric RNA 
motifs, short dsRNAs (<2 kb), unanchored polyubiquitin chains, and many 
families of RNA viruses, whereas MDA5 recognizes picornaviruses and long 
dsRNAs (>2 kb) often mimicked by the synthetic dsRNA molecule polyinosinic-
polycytidylic acid (poly(I-C)) (92, 93, 161, 184).   
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Figure 1.3.  Cytosolic antiviral PRR signaling pathways.  Receptor ligation 
results in the formation of signaling complexes dependent on the adaptors IPS-I 
and MITA, which mediate the activation of kinases.  These kinases then activate 
antiviral transcription factors, which translocate into the nucleus and induce 
cytokines, antiviral effectors, and type-I IFNs.  For further details see text. 
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RLR-mediated signal transduction requires the CARD-containing 
mitochondrial adaptor protein interferon- promoter stimulator protein-1 (IPS-1) 
(also referred to as Cardif, MAVS, and VISA) (139, 161, 184, 185, 187).  IPS-I, 
when localized to peroxisomes, can also mediate an antiviral signal transduction 
pathway that is independent of type-I IFNs (185).  IPS-I serves as a scaffold for 
the formation of a large signaling complex that is formed when ligand-bound 
RLRs interact with IPS-1 via intermolecular CARD interactions (49).  This large 
signaling complex mediates the assembly of several important signaling 
molecules, including TRAF3, TRAF6, and FADD, resulting in the activation of 
numerous kinases including MAPKs, IKK, IKK, IKK, and TBK1 (161, 184).  
These kinases then activate the transcription factors NF-B, IRF3, IRF7, and 
AP1, which induce the expression of antiviral genes, inflammatory cytokines, and 
type-I IFNs (161, 184).   
In addition to antiviral signaling, RLRs also activate inflammatory 
pathways which classically involve NFB-dependent induction of the prototypic 
inflammatory cytokine, pro-IL-1, and formation of an inflammasome that 
activates Caspase-1 which cleaves pro-IL-1 to form mature, bioactive IL-
1(161, 184, 185).  RLRs induce inflammatory NFB-dependent cytokines IL-6 
and IL-1 in a manner dependent on IPS-I and CARD9, whereas type-I IFN 
induction is independent of CARD9 (186).  Interestingly, RIG-I and MDA5-
mediated IL-1 maturation is independent of IPS-1, and each receptor induces a 
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slightly different inflammasome (136).  For instance, RIG-I-mediated maturation 
of pro-IL-1 requires the inflammasome adaptor ASC and activates Caspase-1, 
but the process is independent of the well characterized but relatively non-
specific NLRP3-containing inflammasome (136).  In contrast, MDA5-mediated 
maturation of pro-IL-1 induces an inflammasome containing NLRP3 (136).  
Unlike canonical IPS-I-dependent RLR signaling, it is unclear if inflammatory 
RLR signaling pathways mediate a direct antiviral effect, but an indirect antiviral 
effect may be important given the long standing link between inflammatory 
responses and induction of adaptive immunity (136).    
 RLR pathways are highly regulated, and several negative and positive 
regulators have been identified.  Mediator of IRF3 activation (MITA) (also known 
as stimulator of interferon genes (STING)), a transmembrane protein potentially 
located on ER and mitochondria, positively regulates RLR signaling (6, 86, 162).  
Another mitochondrial protein and member of the NLR family, NLRX1, negatively 
regulates RLR signaling (161, 184).  Ubiquitination mediated via several 
enzymes has both negative and positive effects on RLR signaling.  The ring-
finger protein, RNF125, ubiquitinates MITA, and potentially other molecules in 
the RLR pathway, resulting in decreased signal transduction (120).  In contrast, 
the E3 ubiquitinase, tripartite motif protein-25 (TRIM25), specifically ubiquitinates 
RIG-I, which is required for RIG-I and IPS-I interaction and subsequent signal 
transduction (161, 184).  In addition, Riplet (also termed RNF135 and REUL) 
ubiquitinates and positively regulates RIG-I independent of TRIM25 (161, 184).  
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Finally, the ubiquitin ligase A20 and the ubiquitin modifying enzymes CYLD and 
DUBA negatively regulate RLR signaling (161, 184).  The autophagy-related 
complex, Atg5-Atg12, also negatively regulates RLR signaling despite having a 
positive regulatory role for TLR-mediated signaling (161, 184).  Specific negative 
regulation of MDA5 is achieved by dihydroacetone kinase (DAK) (161, 184).  
Interestingly, small self RNAs generated by the antiviral effector genes OAS and 
RnaseL amplify RLR signal transduction (48).  These studies highlight the 
intricate and complex nature of these pathways and demonstrate the many 
mechanisms the host employs to fine-tune and appropriately regulate RLR 
pathways.  
 In additon to RLRs, the NLR NOD2 also recognizes viral RNA in the 
cytoplasm and induces an antiviral signal transduction pathway requiring IPS-I 
and IRF3 (Fig 1.3) (113).  NOD2 recognizes ssRNA and protects mice from 
respiratory syncytial virus pathogenesis, but the role this receptor plays in other 
viral infections needs further investigation (144). 
 The induction of an innate antiviral response by cytosolic DNA requires 
the classic PRR pathway transcription factors IRF3 and NFB as well as the 
kinases TBK1 and IKK(Fig 1.3) (144).  Just as cytoplasmic recognition of RNA 
is achieved by a variety of receptors, the recognition of cytoplasmic DNA is 
complex, redundant, cell type-, and species-specific (84, 161, 184).  One 
mechanism involves the transcription of 5’ triphosphorylated dsRNA from 
cytoplasmic dsDNA by RNA polymerase III (84, 161, 184).  These transcribed 
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RNAs then serve as ligands for RIG-I (1, 35, 84, 161, 184).  RNA polymerase III 
templates include the mimetic of B-form DNA, poly(dA-dT), and the viruses 
adenovirus, herpes virus, and Epstein-Barr virus (1, 35).  Another candidate 
cytoplasmic DNA sensor is DNA-dependent activator of IFN-regulatory factors 
(DAI; also known as ZBP1), which activates IRF3 and NFB in response to 
poly(dA-dT) (35); however, deletion of DAI in mice had no effect on DNA-induced 
interferon production, suggesting redundant mechanisms for cytoplasmic DNA 
detection (160).  Recent reports also indicate that an AIM2-containing 
inflammasome recognizes dsDNA and requires ASC for the activation of 
caspase-1 and subsequent release of the inflammatory cytokine IL-1(84, 88, 
160, 161, 184).  However, this pathway does not induce type-I interferons, and it 
is unclear if it produces a direct antiviral effect.            
Several signaling molecules, in addition to STING and downstream 
kinases and transcription factors, mediate antiviral signal transduction in 
response to both cytoplasmic dsDNA and dsRNA.  High mobility group box-1 
(HMGB1) is regarded as an universal sentinel for nucleic acid-mediated innate 
immune responses (53, 83, 84, 161, 184).  HMGB1 appears to mediate the early 
capture and delivery of nucleic acids to their appropriate receptors for induction 
of antiviral signaling (182).  In addition to HMGB1, a coactivator pathway 
responsive to both dsDNA and dsRNA increases type-I IFN induction (161, 182).  
This pathway is mediated by the nucleic acid receptor LRRFIP1, which upon 
ligation leads to the activation of -catenin (183).  Activated -catenin then 
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interacts with IRF3 and the IRF3 coactivator p300 resulting in enhanced 
transcription of IRF3 antiviral target genes (183).  However, the requirement of 
LRRFIP1 for antiviral responses in vivo remains to be tested.  These studies 
further demonstrate the intricate mechanisms cells employ to detect and respond 
to cytosolic viral pathogen associated molecular patterns, and this intricacy 
generates a plethora of unanswered questions suggesting that much remains to 
be learned about these pathways. 
 
TLR-mediated Antiviral PRR Pathways   
The transmembrane toll-like receptors mediate antiviral signaling by detecting 
pathogen-associated molecular patterns at the cell membrane or within 
endosomes (Fig 1.4) (183).  At the cell membrane, TLR4 recognizes viral 
glycoproteins (95), whereas the ligand for the antiviral activity of cell-surface 
localized TLR2 remains to be determined (95).  While TLR4 and 2 likely 
recognize their ligands at the cell surface, induction of an antiviral response 
following ligation of these receptors requires internalization (13).  In contrast to 
TLR 4 and 2, TLR3, TLR7/8, and TLR9 are localized to endosomes where they 
recognize dsRNA, ssRNA, and hypomethylated CpG DNA motifs, respectively 
(13, 19, 95).  Generation of signaling-competent TLR9, and possibly TLR7, 
requires proteolytic cleavage of the ectodomain within endosomes (19, 137), but 
no cleavage of TLR3 has been observed (19, 52, 129).  Trafficking of TLR3, 
TLR7/8, and TLR9 to endosomes requires the ER protein UNC93B1    
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Figure 1.4.  Toll-like receptor-mediated antiviral PRR signaling pathways.  
Receptor ligation results in the formation of signaling complexes dependent on 
the adaptors MYD88 and TRIF, which mediate the activation of kinases.  These 
kinases then activate antiviral transcription factors, which translocate into the 
nucleus and induce cytokines, antiviral effectors, and type-I IFNs.  For further 
details see text. 
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(19, 95, 161), and mutations in UNC93B1 increase human susceptibility to viral 
pathogens including HSV encephalitis (19, 95, 161).  TLR3 has also been 
observed on the surface of certain cell types including neuronal cells (31), but it 
is unclear if this population of TLR3 mediates antiviral signal transduction. 
Like the RLRs, the TLRs require specific adaptor proteins for efficient 
antiviral signal transduction.  TLRs 2, 7, 8, and 9 all require the adaptor molecule 
myeloid differentiation primary response gene 88 (MYD88) for antiviral signal 
transduction (19).  In contrast, TLR3 requires the adaptor TIR-domain-containing 
adapter-inducing interferon-β (TRIF) (13, 95).  Both TIR-domain-containing 
adaptors interact with the cytoplasmic TIR domains of ligand-bound TLRs (95).  
Most antiviral TLRs utilize TRAF3 and TRAF6 for signal transduction and activate 
the kinases MAPK’s, IKK, IKK, IKK, and TBK1 (95). In addition, 
phophatidylinositol-3 kinases (PI3K) are positive signal transducers for TLR7 (19, 
95, 161, 184), may be negative signal transducers for TLR4 (29), and are 
reported to be both positive and negative regulators of TLR3 (4).  As with RLR-
mediated antiviral signaling, these kinases activate the transcription factors AP1, 
NFB, IRF3, and IRF7; however, TLR7/8 and 9 largely depend on IKK and 
IRAK1 for activation of primarily IRF7 and not IRF3 (4, 50, 147).  In contrast, 
TLR3 and 4 activate both IRF3 and IRF7 via the kinases TBK1/IKK(19, 95, 161, 
184).  
 Similar to the RLR pathways, the TLR pathways are highly regulated, a 
topic that has been extensively reviewed (19, 95, 161, 184).  Of note, there are 
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parallels between the regulation of antiviral RLR and TLR signal transduction 
pathways, suggesting that some communication and integration of signals 
between the cytosolic and TLR pathways takes place.  This is best exemplified 
by the negative regulation of TLRs and RLRs by the ubiquitin modifying enzymes 
DUBA and A20 (19, 95, 161, 184).  In addition to common regulatory 
mechanisms between RLR and TLR pathways, regulatory mechanisms favoring 
distinct TLR-mediated signals have also been described.  For instance, the E3 
ubiquitin ligase NRDP1 promotes the activation of TRIF-dependent activation of 
IRF3 while inhibiting MYD88-dependent activation of NFB (19, 95, 161, 184), 
suggesting that NRDP1 promotes antiviral TLR signaling and blocks 
inflammatory TLR signaling.  Just as with the cytosolic PRRs, regulation of the 
TLR pathways is also complex and suggests that further study is likely to reveal 
novel biology underlying these important antiviral pathways.   
 
Ligands and Viruses Recognized by PRRs  
Due in part to ligand specificity, differential expression, and pathogen-mediated 
interference, PRRs differentially recognize and respond to distinct viral infections, 
but some pathogens are recognized by several receptors (Table 1.2) (173).  
Limited information is available regarding what receptors recognize neurotropic 
arboviruses in neurons, but WNV is recognized by both RIG-I and MDA5 in non-
neuronal cell types (19, 95, 161, 184, 185) and TLR3 in neurons (55, 56).  
Japanese encephalitis virus is recognized by RIG-I (40), but it is unclear if  
35 
 
Table 1.2.  Antiviral PRRs.    
PRR Location Ligand Virus Family 
RLR    
LGP2 Cytoplasm dsRNA + Picornaviruses 
and 
paramyxoviruses 
- Rhabdoviruses 
MDA5 Cytoplasm dsRNA Picornaviruses 
Caliciviruses 
Coronaviruses 
Reoviruses 
Flaviviruses 
Togaviruses 
RIG-I Cytoplasm Short, 5’-
triphosphorylated 
dsRNA and poly-
ubiquitin chains 
Orthomyxoviruses 
Rhabdoviruses 
Paramyxoviruses 
Flaviviruses 
Reoviruses 
Togaviruses 
NLR    
NOD2 Cytoplasm ssRNA Paramyxoviruses 
Cytosolic DNA    
DAI Cytoplasm B-form DNA Herpesviruses 
RNApol III/RIG-I Cytoplasm B-form DNA Herpesviruses 
Adenoviruses 
TLR    
TLR2 Plasma membrane/ 
intracellular 
 Herpeseviruses 
Poxviruses 
TLR3 Endosome dsRNA Reoviruses 
Flaviviruses 
Picornaviruses 
Paramyxoviruses 
Rhabdoviruses 
Herpesviruses 
Arenaviruses 
TLR4 Plasma 
membrane/intracellular 
Viral 
glycoproteins 
Paramyxoviruses 
Retroviruses 
TLR7/8 Endosome ssRNA Rhabdoviruses 
Orthomyxoviruses 
TLR9 Endosome CpG DNA Herpesviruses 
“+/-” indicates positive/negative regulation of signal transduction.   
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neurons have this capability.  To date, it is unknown what PRRs recognize new 
world encephalitic alphaviruses, but evidence exists for the recognition of old 
world alphaviruses, which are not naturally encephalitic, via RIG-I or MDA5 
depending on the cell type and virus (93).  The non-arboviral encephalitic rabies 
and herpes viruses are recognized by RIG-I and TLR9, respectively (25, 134), 
and TLR3 may recognize rabies virus in neuronal cells (95, 185).  Further work 
will need to clarify what receptors recognize neurotropic arboviruses and if they 
do so in neurons. 
 
Antiviral Mechanisms of PRR Pathways       
The ability of PRR pathways to induce an antiviral effect is partly due to the direct 
or indirect induction of antiviral effector genes.  There are a multitude of these 
genes, many of which have uncharacterized mechanisms of action.  However, 
one well-characterized antiviral effector system involves the oligoadenylate 
synthetase (OAS) genes and RNaseL.  OAS, upon ligation of viral RNA, 
synthesizes 2’-5’-linked oligoadenylate which then binds and activates RNaseL 
resulting in the degradation of host and viral RNA and the subsequent inhibition 
of viral propagation (137).  The antiviral activity of PRR pathways can also be 
attributed to altruistic induction of apoptosis in virally infected cells, thereby 
limiting viral replication and spread (20, 145).  Direct PRR pathway-mediated 
induction of apoptosis is achieved by activation of IRF3 triggering the interaction 
of IRF3 with the pro-apoptotic protein Bax (16, 78, 81, 153).  IRF3 and Bax then 
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translocate to the mitochondria and activate the mitochondrial apoptosis pathway 
(34).  Interestingly, IRF3-dependent induction of apoptosis in conjuction with Bax 
does not require IRF3’s DNA binding domain, suggesting that this process is 
independent of an IRF3-mediated transcriptional response (34).  In addition to 
direct PRR pathway-mediated induction of altruistic apoptosis, there are multiple 
indirect mechanisms for viral activation of apoptosis including damage of host 
cell machinery by OAS-RNaseL (34).  Paradoxically, PRR pathway activation can 
be both cell sparing and cell death promoting when activated by viral pathogens.  
Presumably cells are spared when antiviral effectors are sufficient to control viral 
replication, but when antiviral effectors are insufficient to control viral replication, 
cells undergo altruistic apoptosis.  In the end, the effectiveness of either antiviral 
effectors or altruistic apoptosis to produce a net antiviral effect may depend on 
the pathogen, the pathogen load, and the responding cell type.     
In addition to immediate local antiviral effects, PRR pathway activation has 
profound effects on the entire immune response (20).  These effects are largely 
due to type-IFNs, but other inflammatory cytokines induced by PRR signaling 
may also play a role.  Early after infection, chemokines, cytokines, and type-I 
IFNs induced by PRR signaling mediate the upregulation of adhesion molecules 
and promote the migration of inflammatory cells (7).  PRR-mediated induction of 
type-I IFN alerts and helps activate natural killer cells and local antigen 
presenting cells, such as dendritic cells, which are important for activating 
adaptive responses (7).  In addition, type-I IFNs directly influence adaptive 
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responses by regulating T-cell activation and memory and influencing B cell 
functions such as antibody secretion and isotype switching (7).  The influence of 
PRR pathways on adaptive responses to neurotropic arboviruses has been 
studied for WNV: virus-infected IPS-1-/- mice mount an altered inflammatory 
response and ultimately ineffective humoral and T-cell responses (7).  These 
studies indicate that early PRR pathway responses are crucial for producing not 
only early, non-specific antiviral responses, but also for mediating highly effective 
and specific adaptive responses and eventual disease resolution.   
 
Cell Type-Specific PRR Signaling 
The molecular mechanisms of antiviral PRR signaling have been defined 
primarily using a limited number of cell lines and primary cell types, many of 
which are derived from small rodent models; and these include professional 
immune cells such as dendritic cells or macrophages.  These studies have 
revealed important cell type-specific differences in antiviral PRR pathways.  For 
example, dendritic cells express relatively high basal levels of TLR7 and TLR9, 
and as a result vigorously respond to ligands for these receptors (159).  In 
contrast, “non-professional” immune cells, such as fibroblasts, use primarily 
cytoplasmic RLRs for innate antiviral pathway activation (36), although some cell 
types such as keratinocytes (92) and respiratory epithelial cells (175) can also 
mount vigorous TLR-mediated antiviral responses.  Plasmacytoid dendritic cells 
also constitutively express the transcription factor IRF7, which is thought to 
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contribute to their ability to produce IFN rapidly after PRR-mediated stimulation 
(91), whereas IFN production in other cell types occurs later if at all, and is 
linked to IFN-mediated induction of IRF7 (14, 36, 82).  Interestingly, TLR2 
antiviral signaling is unique to an inflammatory monocyte population (115, 148, 
149), and myeloid cells remain responsive to WNV virus even when the key 
transcription factors IRF3 and IRF7 are deleted, which is in contrast to both 
WNV-infected fibroblasts and cortical neurons (13).  Additional examples of cell 
type-specific differences in innate antiviral immunity include a lower basal activity 
of PRR pathways in cardiac fibroblasts compared to cardiac myocytes (43), 
differential responses of specific human hepatocyte cell lines to poly(I-C) and 
Sendai virus (SeV) stimulation (190), and cell type-specific roles for IRF3 and 
IRF7 in response to West Nile virus infection (104).  Furthermore, species-
specific differences also exist with respect to DAI (107) and TLR expression, 
regulation, and function (39, 41).  These observations suggest that caution 
should be exercised in extrapolating results on innate antiviral pathway activity 
between species and cell types. 
 
Neuronal Antiviral PRR Pathways      
Little is known regarding the PRR antiviral pathways that are active in CNS 
neurons or how these pathways may influence neurotropic arbovirus 
pathogenesis, but important observations have been made.  For instance, 
several studies have examined the role of TLR3 in response to CNS viral 
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infections (76, 77, 138, 178).  These studies demonstrated expression of TLR3 in 
human neurons (28, 40, 89, 117, 137) and enhanced West Nile virus replication 
in cortical neurons isolated from TLR3-/- mice (28, 89, 117, 137, 189).  However, 
the potential antiviral role of TLR3-mediated pathways is controversial and may 
be pathogen-specific (40).  For example, humans with a TLR3 deficiency have a 
genetic predisposition to herpes simplex virus encephalitis (172), but mice are 
protected from rabies virus encephalitis when TLR3 is deleted (188).  
Furthermore, TLR3-/- mice have been shown to have both increased (117) and 
decreased (176) susceptibility to West Nile virus (WNV) encephalitis.  However, 
these studies cannot fully separate the neuron-specific activity of TLR3 from 
other cell types, including professional immune cells such as macrophages and 
dendritic cells.  Although CNS neurons from TLR3-/- mice have a modest 
increase in WNV production, when infected in culture (40), suggesting that 
neuronal TLR3-mediated responses can have antiviral effects, further studies in 
mice with conditional cell-specific TLR3 deletions will be required to fully 
delineate the potential antiviral activity of TLR3-activated innate immune 
pathways in neurons and their role in viral pathogenesis.  In addition to the 
neuronal TLR3 studies, many groups have demonstrated virus-mediated and, in 
some cases, neurotropic arbovirus-mediated induction of type-I IFNs in CNS 
neurons both in vitro (40) and in vivo (39-41, 137). The interaction between 
neurotropic arboviruses and RLR pathways is best characterized for West Nile 
virus encephalitis in which replication is enhanced and type-I IFN induction is 
41 
 
reduced in cortical neurons isolated from IPS-1-/-, IRF7-/-, and IRF7/3-/- mice (44). 
In addition to putative antiviral functions, PRR pathways have also been 
implicated in neuronal development (39-41, 43, 159), neuronal regeneration 
(141), and neuroinflammatory diseases (28, 111).  Altogether, these reports 
suggest that CNS neurons possess active PRRs that may have multiple 
physiologic functions, but the full extent of their activity and influence on 
neurotropic arbovirus pathogenesis remain to be determined.   
 
Viral Countermeasures to Antiviral PRR Pathways 
Antiviral PRR pathways protect host cells and tissues against viral infections, yet 
many viruses, including neurotropic arboviruses, possess PRR pathway 
countermeasures allowing them to efficiently replicate, avoid immune detection, 
and cause disease (37, 119).  Often, viruses encode more than one PRR 
pathway evasive or inhibitory protein, and many of these viral proteins mediate 
evasion or subversion of PRR signaling in multiple ways.  Two of the best 
characterized mechanisms for viral interference of PRR pathways involve the 
NS1 protein of influenza virus and the NS3-4A protein of hepatitis C virus.  
Influenza NS1 sequesters viral dsRNA and binds RIG-I, thereby suppressing 
RIG-I signaling (21).  Hepatitis C NS3-4A inhibits TLR3 signaling by degrading 
TRIF, disables RLR signaling by cleaving IPS-I from its mitochondrial tether, and 
decreases IRF3 phosphorylation by disrupting the TBK1-IRF3 interaction (170).  
Neurotropic arboviruses also interfere with antiviral PRR signaling.  For instance, 
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the NS2A and NS1 proteins of WNV inhibit the activation of antiviral PRR 
pathways (170) resulting in higher viral replication and enhanced virulence in a 
manner that may be both viral strain- and cell type-dependent.  The neurotropic 
arbovirus LACV also interferes with host antiviral signaling.  The NSs protein of 
LACV mediates this effect by potently inhibiting type-I IFN induction, and mutant 
LACV lacking NSs robustly induces type-I IFNs resulting in reduced virulence 
(42, 46, 109, 180).  These studies demonstrate that viruses are not just passive 
agents that activate PRR signaling, but that they likely co-evolved with their 
respective hosts and actively interact and modulate the antiviral effects of PRR 
pathways.   
   
PRR Pathway Associated Diseases and Pathologies 
PRR pathways mediate potent antiviral responses, and these pathways are 
checked by a large number of negative regulators.  Unfortunately, misregulation 
of antiviral PRR pathways can also drive or influence a multitude of diseases 
including carcinogeneis and autoimmune diseases such as systemic lupus 
erythematosus, Crohn’s disease, and antiphospholipid antibody syndrome (18).  
Furthermore, human variants in MDA5 protect against type-I diabetes (161, 184), 
and within the CNS, unchecked or inappropriately activated antiviral PRR 
pathways may mediate neuroinflammatory diseases such as multiple sclerosis, 
amyotrophic lateral sclerosis, and Alzheimer’s disease (124).  Additionally, 
antiviral PRR pathways within CNS cells may play a role in chronic pain and 
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seizure development (15, 61, 97, 100, 114, 119, 126, 163).  These observations 
highlight the importance of studying PRR pathways so that we can better 
understand the disease processes they mediate.  Ultimately, the study of PRR 
pathways may lead to the development of therapies to treat viral infections by 
activating PRR pathways or inhibiting viral countermeasures to PRR pathways.  
Alternatively, therapies may be designed to inhibit the inappropriate activation of 
PRR signaling to treat autoimmune disorders and cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Summary 
 Neurotropic arboviruses cause devastating CNS infections where the 
extent of virus-mediated destruction of neurons is often an important determinant 
in the severity and clinical outcome after infection.  Early cellular innate immune 
responses are often vital for effective pathogen control, and I hypothesized that 
an effective neuronal innate immune response may be crucial to prevent the 
essentially irreversible loss of critical central nervous system neurons by 
neurotropic arboviruses.  To begin testing this hypothesis, chapter II describes 
efforts to identify highly active neuronal innate antiviral pathways, and chapter III 
tests the impact these pathways have on neurotropic arbovirus infection of 
neurons and how these viruses counteract neuronal innate immune pathways.  In 
chapter IV, I take a different approach to preventing neurotropic arbovirus-
mediated neuronal death by identifying small molecules that inhibit neurotropic 
arbovirus replication and enhance cell viability, which may be useful for mono-
therapy or in combination with potential therapeutics designed to enhance the 
neuronal innate immune response or inhibit viral countermeasures to the innate 
immune response.  Chapter V discusses the overall relevance of these studies 
and potential future directions.   
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Chapter II 
 
Human Neuronal Cells Possess Functional Cytoplasmic and Toll-Like 
Receptor-Mediated Innate Immune Pathways Influenced by 
Phosphatidylinositol-3 Kinase Signaling 
 
 Innate immune pathways are early defense responses important for the 
immediate control and eventual clearance of many pathogens, where signaling is 
initiated via pattern recognition receptor-mediated events that occur in a ligand- 
and cell-type specific manner.  Within CNS neurons, innate immune pathways 
are likely crucial to control pathogens that target these essential yet virtually 
irreplaceable cells.  However, relatively little is known about the induction and 
regulation of neuronal pattern recognition receptor signaling.  In this report, we 
used human neuronal cell lines and primary rat neuronal cultures to examine 
pattern recognition receptor expression and function.  We found that several 
innate immune receptor ligands, including Sendai virus, the dsRNA mimetic 
polyinosinic-polycytidylic acid, and LPS all activated differentiation-dependent 
neuronal innate immune pathways.  Functional genetic analyses revealed that 
interferon regulatory factor 3-mediated pathways that resulted in IFN 
transcriptional upregulation were activated in cultured human neuronal cells by 
the pattern recognition receptors TLR3, melanoma differentiated-associated 
gene 5, or retinoic acid inducible gene I in a ligand-specific manner.  
Furthermore, genome-wide transcriptional array and targeted genetic and 
pharmacologic analyses identified PI3K signaling as crucial for the induction of 
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innate immune pathways in neurons.  These results indicate that human 
neuronal cells possess specific and functional pattern recognition receptor 
pathways essential for the effective induction of innate immune responses, and 
suggest that neurons can play an active role in defense against neurotropic 
pathogens. 
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Introduction 
 Innate immune pathways are early responses important for pathogen 
control, and are activated by pattern recognition receptors (PRRs) that bind 
ligands containing pathogen- or danger-associated molecular patterns, such as 
modified carbohydrate or nucleic acid structures (39).  For antiviral innate 
immune responses, ligation of these receptors induces a signal transduction 
cascade that results in the production of type-I IFNs, other proinflammatory 
cytokines, and cell-intrinsic factors important for the generation of an antiviral 
cellular microenvironment (51).  In addition, antiviral PRR signaling is important 
for activating an appropriate adaptive immune response, which is required for the 
eventual clearance of many viral infections.  Thus, PRR-mediated innate immune 
pathway signaling serves a pivotal role in stimulating rapid yet nonspecific 
antiviral activity while also providing activation signals for the production of more 
specialized adaptive immune responses. 
 There are three general steps in innate antiviral immune responses: 
activation, amplification, and effector production.  Antiviral PRR signaling is 
initiated by a variety of receptors, including the transmembrane TLR proteins 2, 
3, 4, 7/8, and 9, and the cytoplasmic retinoic acid inducible gene I (RIG-I)-like 
receptors (RLRs) RIG-I and melanoma differentiated-associated gene 5 (MDA5) 
(51).  TLR3, TLR7/8, and TLR9 recognize the non-self nucleic acid moieties 
dsRNA, ssRNA, and hypomethylated CpG DNA, respectively, whereas TLR4 
recognizes viral glycoproteins and the viral ligand for TLR2 remains to be 
identified.  In the cytoplasm, RIG-I binds double-stranded 5’ triphosphorylated 
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RNAs, homopolymeric RNA motifs, and short dsRNAs less than 2 kb in length 
(63, 64), whereas MDA5 recognizes complex dsRNAs greater than 2 kb in length 
(52) that can be mimicked by the synthetic dsRNA molecule polyinosinic-
polycytidylic acid (poly(I-C)) (74).  Due in part to this ligand specificity, PRRs 
differentially recognize and respond to distinct viral infections (39).  After PRR 
ligation, signal transduction is mediated by several distinct adaptor proteins, 
including MyD88, TIR-domain-containing adapter-inducing IFN-β (TRIF), and 
IFN- promoter stimulator protein 1 (IPS-1; also referred to as Cardif, MAVS, and 
VISA) (39, 51).  These adaptor protein complexes activate the transcription 
factors NFB and IFN regulatory factor 3 (IRF3) via multiple downstream 
kinases.  Activated NFB and IRF3 subsequently upregulate the expression of 
many genes important for mounting a robust antiviral response, including type-I 
IFNs (56), which function in either a paracrine or autocrine manner to induce IFN-
stimulated genes that contain IFN-stimulated response elements (ISREs) within 
their promoters.  There are several IFN-stimulated genes that act directly as 
antiviral effectors, but many are also components of antiviral PRR pathways, 
which provides a mechanism for positive feedback regulation and amplification 
(39, 51). 
The molecular mechanisms of antiviral PRR signaling have been defined 
primarily using a limited number of cell lines and primary cell types, many of 
which are derived from small rodent models and are professional immune cells 
such as dendritic cells or macrophages.  These studies have revealed important 
cell type-specific differences in antiviral PRR pathways.  For example, dendritic 
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cells express relatively high basal levels of TLR7 and TLR9, and as a result 
vigorously respond to ligands for these receptors (8).  In contrast, “non-
professional” immune cells such as fibroblasts use primarily cytoplasmic RLRs 
for innate antiviral pathway activation (34), although some cell types such as 
keratinocytes (32) and respiratory epithelial cells (70) can also mount vigorous 
TLR-mediated antiviral responses.  Plasmacytoid dendritic cells also 
constitutively express the transcription factor IRF7, which is thought to contribute 
to their ability to produce IFN rapidly after PRR-mediated stimulation (2, 8, 27), 
whereas IFNproduction in other cell types occurs later, if at all, and is linked to 
IFN-mediated induction of IRF7 (44, 61, 62).  Additional examples of cell type-
specific differences in innate antiviral immunity include a lower basal activity of 
PRR pathways in cardiac fibroblasts compared cardiac myocytes (80), differential 
responses of specific human hepatocyte cell lines to poly(I-C) and Sendai virus 
(SeV) stimulation (42), and cell type-specific roles for IRF3 and IRF7 in response 
to West Nile virus infection (13, 15).  Furthermore, species-specific differences 
also exist with respect to TLR expression, regulation, and function (25, 26, 57, 
72).  These observations suggest that caution should be exercised in 
extrapolating results on innate antiviral pathway activity between species and cell 
types. 
Viruses from several families preferentially infect CNS neurons, and the 
extent of neurotropic virus-mediated cell death can be an important determinant 
in the severity and clinical outcome of infection (22).  Thus, an effective neuronal 
innate antiviral response that controls virus replication until an adaptive immune 
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response can be generated may be crucial to prevent the essentially irreversible 
loss of these critical cells.  However, we have limited knowledge regarding the 
PRR antiviral pathways that are active in CNS neurons.  TLR3 expression has 
been reported in human neurons (3, 30, 45, 54, 79), West Nile virus replication is 
enhanced in cortical neurons isolated from TLR3-/- mice (14), and neural 
progenitor cells respond to poly(I-C) stimulation by reducing proliferation and 
neurosphere formation in a TLR3-dependent manner (41).  Furthermore, studies 
have demonstrated virus-mediated induction of type-I IFNs in CNS neurons both 
in vitro (13-15, 54) and in vivo (16).  In addition to putative antiviral functions, 
PRR pathways have been implicated in neuronal development (58), neuronal 
regeneration (3, 43), and neuroinflammatory diseases (12, 46).  Altogether, these 
reports suggest that CNS neurons possess active PRRs that may have multiple 
physiologic functions, but the full extent of their activity and the downstream 
components that mediate their activation remain to be determined. 
In this report, we use both global and targeted approaches to examine 
PRR expression and pathway activity in response to RLR and TLR ligands.  We 
found that human neuronal cells show differentiation-dependent selective 
responses to TLR3-, TLR4-, MDA5-, and RIG-I-mediated stimulation.  
Furthermore, detailed genetic and pharmacologic studies revealed that select 
neuronal innate immune pathways were dependent on PI3K activity.  These 
results demonstrate that human neuronal cells are immunologically active and 
possess specific and non-redundant functional PRR pathways that may play a 
protective role in neurotropic virus pathogenesis. 
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Materials and Methods 
Plasmids 
We purchased the reporter plasmids pISRE-SEAP and pNFB-SEAP, the wild 
type expression plasmid pTLR3, the dominant negative-expression plasmids 
pDN-TLR3(TIR), pDN-TRIF(TIR), and pDN-RIG-I(N), and the short-hairpin 
RNA expression plasmid pshRNA-MDA5 from InvivoGen (San Diego, CA).  The 
dominant negative expression plasmid pDN-IRF3(N) was generously provided 
by Rongtuan Lin (McGill University, Montreal).  We purchased the lentivirus 
short-hairpin RNA expression plasmids pGIPZ-shCD14 and pGIPZ-
shPI3K110from Open Biosystems (Huntsville, AL).  The lentivirus helper 
plasmids pCMV-VSV/G and pCMV-Gag/Pol were generously provided by David 
Markovitz (University of Michigan, Ann Arbor, MI). 
 
Virus 
Recombinant SeV that contains a GFP tag between the viral P and M genes was 
generously provided by Valery Grdzelishvilli (University of North Carolina at 
Charlotte, Charlotte, NC) and was expanded twice through Vero cells at a low 
multiplicity of infection to generate viral stocks.  SeV growth curves were 
analyzed by monitoring GFP accumulation in infected cells using a FLUOstar 
Omega plate reader (BMG Labtech, Durham, NC) and black-walled, translucent-
bottomed 96-well tissue culture plates. 
Lentivirus production for shRNA knockdown was done as previously 
described (33).  Briefly, HEK293FT cells at 90% confluence were incubated with 
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25 g/ml chloroquine and transfected either pGIPZ-shCD14 or pGIPZ-
shPI3K110 and the packaging plasmids pCMV-VSV/G and pCMV-Gag/Pol 
using calcium chloride.  Virus was harvested from clarified supernatants at 24 
and 48 h after transfection and stored at 4°C in the dark prior to cell infections. 
 
Antibodies, Cytokines, PRR Ligands, and Kinase Inhibitors 
Antibodies against GAPDH and IRF3 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), antibodies against synaptophysin, 
neurofilament 200, and glial fibrillary acidic protein were purchased from Sigma 
(St. Louis, MO), antibodies against TLR3 were purchased from either Santa Cruz 
Biotechnology (clone TLR3.7, catalog no. sc-32232) or Imigenex (San Diego, 
CA; clone 40C1285.6, catalog no. IMG-315A), antibodies against PI3K p110 
were purchased from Cell Signaling Technology (Danvers, MA), and antibodies 
against RIG-I were purchased from Alexis Biochemical (San Diego, CA).  
Antibodies against MDA5 were generously provided by Paul Fisher (Columbia 
University, New York, NY).  Neutralizing antisera against type I IFNs and the 
corresponding control sera were obtained from the Biodefense and Emerging 
Infections (BEI) Research Resources Repository (Manassas, VA).  All secondary 
antibodies for immunoblotting and immunofluorescence staining were purchased 
from Jackson Immunoresearch (West Grove, PA). 
Recombinant human IFN-A/D and rat IFN were purchased from PBL 
Biomedical Laboratories (Piscataway, NJ), recombinant human TNF was 
purchased from R&D Systems (Minneapolis, MN), and human leukocyte IFN 
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and fibroblast IFN were obtained from the BEI Repository.  All cytokines were 
stored in single use aliquots at -80°C.  Ultrapure E. coli K12 LPS, the 
imidazoquinoline derivative CLO97, and the CpG-containing synthetic 
oligonucleotide ODN2006 were purchased from InvivoGen.  Poly(I-C) was 
purchased from either Sigma or InvivoGen and stored as a 5-10 mg/ml solution 
in sterile water at -20°C.  We transfected poly(I-C) using Lipofectamine 2000 
(Invitrogen) at a ratio of 200 g poly(I-C) per 60 l of Lipofectamine 2000 in a 
total volume of 150 l Opti-MEM I (Gibco) media. 
The kinase inhibitor library was provided by the University of Michigan 
Center for Chemical Genomics and was originally purchased from TimTec 
(Newark, DE).  The kinase inhibitors LY294002 and TGX-221 were purchased 
from Calbiochem (San Diego, CA) and the kinase inhibitors AS-252424 and 
p110 inhibitor 2 were purchased from Cayman Chemical (Ann Arbor, MI). 
 
Cell Culture 
BE(2)-C, SHSY-5Y, HCN-1A, U937, and Vero cells were all obtained from the 
American Type Culture Collection (Manassas, VA).  We differentiated BE(2)-C 
cells with all-trans retinoic acid as previously described (5), the non-malignant 
human cortical neuronal cell line HCN-1A with nerve growth factor, 1-isobutyl-3-
methylxanthine, and dibutyryl cAMP as previously described (59), and human 
monocytic U937 cells with 15 nM PMA for 48 h.  To avoid potential confounding 
effects of cell differentiation on transfection or transduction efficiency, we 
generated stable cell lines prior to differentiation.  BE(2)-C and SH-SY5Y cells 
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were transfected with reporter gene-, dominant negative-, or shRNA-expressing 
plasmids using Lipofectamine 2000 according to the manufacturer’s instruction 
(Invitrogen, Carlsbad, CA), whereas U937 cells were transfected by 
electroporation using a GenePulser Xcell according to the manufacturer’s 
instructions (Bio-Rad, Hercules, CA).  For lentiviral transduction, cells were 
infected with recombinant lentiviruses in the presence of 8 g/ml polybrene.  Cell 
lines were passed at least three times in the presence of selection antibiotic prior 
to use in experiments, and selection agents were removed for retinoic acid- or 
PMA-induced differentiation. 
 Primary rat neuronal cultures were prepared from embryonic day 18 
Sprague-Dawley rat cortices according to the supplier’s recommendations 
(BrainBits LLC, Springfield, IL).  Briefly, cortices were digested with 2 mg/ml 
papain (Worthington, Lakewood, NJ) for 30 minutes at 30°C in HibernateE 
solution (BrainBits LLC) without calcium followed by gentle trituration.  Cell 
suspensions were allowed to settle by gravity for 1 min to remove large debris, 
supernatants were collected and centrifuged at 500 x g for 5 min, cell pellets 
were gently resuspended in Neurobasal E media supplemented with 2% B27 
(Gibco, Grand Island, NY), 500 M L-glutamine, 10 units/ml penicillin, and 10 
g/ml streptomycin, dispensed into poly-D-lysine-coated plates at 1 x 105 
cells/cm2, and incubated at 37°C with 5% CO2.  Eighteen to twenty-four h after 
plating the media was completely replaced and on subsequent days half of the 
culture volume was replaced.  Cells were routinely used at 12-14 days after 
plating, at which time immunofluorescence staining showed that ~95% of cells 
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expressed the transmembrane synaptic vesicle glycoprotein synaptophysin and 
neurofilament 200, which are both markers of mature neurons, but not the 
astrocyte marker glial fibrillary acid protein (Supplemental Fig S2.1.A and B).  
Furthermore, primary rat neuronal cultures were also highly sensitive to 
glutamate-mediated excitotoxicity (Supplemental Fig S2.1.C), which is a well 
described phenotype of mature cortical neurons in vitro (77). 
 
Cell Viability and SEAP Assays 
Cell viability was determined with either Alamar Blue according to the 
manufacturer’s instructions (AbD Serotec, Oxford, UK) or an MTT assay as 
previously described (5).  Secreted alkaline phosphatase (SEAP) assays were 
conducted using Quanti-Blue substrate according to manufacturer’s instructions 
(InvivoGen).  Fluorescence and absorbance endpoint values for viability and 
SEAP assays were obtained with a FLUOstar Omega plate reader. 
 
Immunoblotting, Immunofluorescence, and RT-PCR Analysis 
Immunoblotting, immunofluorescence staining of cultured cells, and RT-PCR 
were done as previously described (5, 49) with the following modifications.  For 
TLR3 immunoblotting, membranes were blocked with PBS containing 1% BSA 
and 1% polyvinylpyrrolidone, and TLR3-specific bands were detected with the 
Imigenex monoclonal antibody, a biotinylated secondary antibody, and 
streptavidin-conjugated HRP.  For TLR3 immunofluorescence staining, cells 
were permeabilized with 0.1% Triton X-100 after paraformaldehyde fixation, 
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immunostained with the Santa Cruz monoclonal antibody, a biotinylated 
secondary antibody, and streptavidin-conjugated PE.  Primer sequences for PCR 
are available upon request. 
 
Microarray, Pathway Analysis, and Validation 
Total RNA was isolated from five independent sets of cultures containing similar 
numbers of immature BE(2)-C or differentiated BE(2)-C/m cells using TRIzol 
(Invitrogen), digested with RQ1 DNaseI (Promega), and repurified using an 
RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions.  
RNA integrity and quantity were assessed using a microfluidics-based Agilent 
2100 Bioanalyzer (Foster City, CA).  RNA labeling, hybridization, and array 
scanning was done by either SeqWright DNA Technology Services (Houston, 
TX) or the University of Michigan Microarray core facility using biotinylated 
amplified cRNAs and Affymetrix Human U133 Plus 2.0 microarray chips.  
Complete original data files for all microarray experiments have been deposited 
in the Gene Expression Omnibus (GEO) database 
(http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE16452. 
 The Genomatix ChipInspector software package (Genomatix Software 
Inc., Ann Arbor, MI; www.genomatix.de) was used for primary microarray data 
analysis.  This program uses a single probe method with an enhanced statistics 
package based on the original SAM algorithm (67) that incorporates a t-test with 
a permuted artificial background to reduce false-positives.  The following 
parameters were chosen to identify sets of differentially regulated transcripts: (i) 
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false-discovery rate of 1%; (ii) three probe minimum coverage; and (iii) 
expression level log2 change ≥ 0.5 (~1.4-fold) compared to control.  Similar 
results were obtained when microarray data were analyzed with the Affymetrix 
package of Bioconductor (29).  The list of genes preferentially upregulated in 
differentiated BE(2)-C/m cells were analyzed using Ingenuity Pathway Analysis 
software (Ingenuity Systems, Redwood, CA; www.ingenuity.com).  This analysis 
used the Ingenuity Pathway Analysis library of 103 signaling and 80 metabolic 
canonical pathways to identify those that were most significant to the data set.  
This significance was measured by determining the ratio of the number of genes 
from the data set that map to a particular canonical pathway to the total number 
of genes for that pathway, and calculating a subsequent p-value using a 
Fischer’s exact test.  The association with a particular canonical pathway was 
considered significant if the p-value < 0.05. 
 To validate microarray results, PI3K-AKT pathway real-time RT-PCR 
arrays (SABiosciences, Frederick, MD) were used to analyze transcript 
expression level differences between two independent sets of immature BE(2)-C 
and differentiated BE(2)-C/m cultures.  Total RNA was isolated as described 
above and RNA integrity and quantity was assessed using non-denaturing 
agarose gel electrophoresis and spectrophotometry, respectively.  cDNA 
synthesis and real time PCR were conducted using the manufacturer’s 
recommended reagents and protocols for the BioRad iCycler iQ thermocycler, 
and fluorescence threshold cycle (Ct) values were calculated using SDS 700 
system software (Bio-Rad).  Results were normalized to the average Ct for 5 
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housekeeping genes contained on the RT-PCR array and Ct values were 
calculated to determine expression changes.  Genes that reached the Ct 
maximum of 35 in either trial were excluded from the analysis. 
 
Statistical Analysis 
Microarray and pathway statistical analyses are described above.  For 
comparative analyses we used a two-tailed Student’s t-test assuming unequal 
variances where a p-value of < 0.05 was considered significant.  Quantitative 
EC50 and IC50 values were calculated using Prism GraphPad 3.0 software.  
Unless otherwise indicated, presented results are representative of at least three 
independent experiments, where quantitative data represent the mean ± SEM. 
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Results 
Poly(I-C) Induces PRR Pathway Activation and IFNProduction in 
Differentiated Human Neuronal Cells 
To initially study neuronal PRR pathway activity, we used the previously 
characterized human BE(2)-C neuronal culture model (50).  This neuroblastoma 
cell line can be differentiated in the presence of retinoic acid to form cells with 
morphological, biochemical, and physiological characteristics of mature human 
neurons, and it has been used to demonstrate differentiation-dependent 
responses of human neuronal cells to type-I IFN stimulation and neurotropic virus 
infection (5).  We generated stable cell lines that expressed either an NFB 
promoter-driven or IRSE promoter-driven SEAP reporter gene, induced 
differentiation with retinoic acid, and examined reporter gene activity in tissue 
culture supernatants of cells stimulated with poly(I-C), which is a dsRNA mimetic 
and potent inducer of PRR pathway activation (74).  We used increasing 
concentrations of poly(I-C) delivered either extracellularly for cell surface or 
endosomal TLR activation or complexed with Lipofectamine and transfected for 
intracellular RLR stimulation, and examined responses in both undifferentiated 
and differentiated BE(2)-C cell lines (Fig 2.1).  Both NFB (Fig 2.1.A) and ISRE 
(Fig 2.1.B) promoter-driven reporters showed dose responsive expression in 
differentiated BE(2)-C/m cells with both extracellular and transfected poly(I-C), 
whereas essentially no responses were seen in undifferentiated cells.  Calculated 
poly(I-C) concentrations that produced 50% maximal responses (EC50 values) in 
differentiated BE(2)-C/m cells were between ~10 ng/ml and 10 g/ml (Table 2.1).   
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Figure 2.1.  Poly(I-C) activates NFB and ISRE promoters and induces IFN 
production in human neuronal cells.  A and B.  Similar numbers of NFB (A) 
or ISRE (B) promoter-reporter cells were stimulated with increasing amounts of 
extracellular poly(I-C) (upper graphs) or transfected poly(I-C) (lower graphs), and 
SEAP reporter activity in culture supernatants was measured 20 h after 
stimulation.  C.  BE(2)-C (lanes 1-6) or BE(2)-C/m (lanes 7-12) cells were 
stimulated with 100 g/ml extracellular poly(I-C) (lanes 3, 4, 9, and 10) or 700 
ng/ml transfected poly(I-C) (lanes 5, 6, 11, and 12) for 10 h, and IFNand rRNA 
transcript levels were assessed via RT-PCR.  Adjacent lanes for individual 
samples represent results using 10-fold dilutions of cDNA.  D.  BE(2)-C/m ISRE 
reporter cells were stimulated with either 20 IU/ml human leukocyte IFN, 20 
IU/ml human fibroblast IFN, 100 g/ml extracellular poly(I-C) (pIC), or 600 ng/ml 
transfected poly(I-C) (T-pIC) in the presence of neutralizing IFN or 
IFNantisera at concentrations capable of neutralizing 4000 IU/ml of IFN or 
IFN respectively.  Results are expressed as the percent SEAP activity 
compared to control samples incubated with pre-immune serum. 
76 
The inability of undifferentiated BE(2)-C cells to respond to poly(I-C) was not due 
to inactive ISRE or NFB promoters, as universal type I IFN-A/D stimulated 
ISRE-SEAP activity, albeit with a 4-fold higher IFN-A/D EC50 compared to 
differentiated BE(2)-C/m cells (5).  Furthermore, TNF, a potent NFB inducer, 
stimulated NFB-SEAP activity in undifferentiated BE(2)-C cells, although EC50 
values were approximately 30-fold higher in undifferentiated compared to 
differentiated cells (850 vs 25 pg/ml, respectively).  We obtained similar results 
using reporter cell lines generated from SH-SY5Y cells, another human neuronal 
cell line unrelated to BE(2)-C cells (19) (Supplemental Fig S2.2.A). 
The poly(I-C) stimulated ISRE promoter-driven SEAP expression seen in 
differentiated BE(2)-C/m cells could have been due to type-I IFN production and 
autocrine activity or IFN-independent ISRE activation (48).  To initially examine 
endogenous IFN transcription in response to poly(I-C) stimulation we used 
semi-quantitative RT-PCR (Fig 2.1.C).  Poly(I-C) delivered both extracellularly 
and by transfection stimulated IFN mRNA upregulation in differentiated BE(2)-
C/m cells, whereas undifferentiated cells showed no responses, consistent with 
the reporter gene expression results (Figs 2.1.A and B).  We also observed 
poly(I-C)-stimulated IFN mRNA induction with differentiated HCN-1A cells 
(Supplemental Fig S2.2.C), a non-malignant human cortical neuronal cell line 
(59).  Furthermore, we observed ~10- and 100-fold increases in IFN mRNA up 
regulation in differentiated primary rat cortical neurons stimulated with 
extracellular or transfected poly(I-C), respectively (see Fig 2.5.B below).  These 
results suggested that transcriptional upregulation of type-I IFNs in response to 
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PRR stimulation in differentiated BE(2)-C/m cells was not due to their derivation 
from neuroblastoma cells. 
To further examine the potential for autocrine type I IFN activity in human 
neuronal cells we conducted antibody neutralization experiments (Fig 2.1.D).  
We simultaneously incubated cells with poly(I-C) and control pre-immune serum 
or antisera specific for human IFN or IFN, and measured SEAP activity in 
tissue culture supernatants.  To determine antibody specificity and neutralization 
efficiency, we stimulated control wells with either human leukocyte IFN or 
fibroblast IFN instead of poly(I-C).  The ISRE-SEAP responses of differentiated 
BE(2)-C/m cells to both extracellular and transfected poly(I-C) were significantly 
reduced by IFN- but not IFN-specific antisera (Fig 2.1.D).  We obtained similar 
results with differentiated SH-SY5Y cells (Supplemental Fig S2.2.B).  These 
results indicated that differentiated human neuronal cells activated NFB and 
ISRE promoters in response to poly(I-C) stimulation, and that ISRE promoter 
activation was due to IFN production and autocrine activity. 
 
SeV Infection Activates PRR Pathways in Human Neuronal Cells 
To determine if neuronal PRR pathways are also activated in the context of a 
virus infection we used SeV, which has been shown to potently induce innate 
immune responses in other cell types (42).  We infected undifferentiated and 
differentiated BE(2)-C cells expressing an NFB promoter-driven reporter gene 
with increasing doses of recombinant GFP-tagged SeV and measured SEAP 
activity in tissue culture supernatants 30 h post-infection (hpi).  We observed 
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dose-dependent NFB responses only in differentiated BE(2)-C/m cells (Fig 
2.2.A), which was not due to differences in SeV replication kinetics (Fig 2.2.B).  
Furthermore, SeV infection also induced endogenous IFN mRNA upregulation 
in both differentiated BE(2)-C/m cells (Fig 2.2.C) and primary rat cortical neurons 
(Supplemental Fig S2.1.F).  However, the response in BE(2)-C/m cells was 
delayed until 20 hpi (Fig 2.2.C, compare lanes 3 and 6), whereas the 
transcriptional response to poly(I-C) stimulation was much more rapid (Fig 2.2.C, 
lane 2).  The delayed IFN transcriptional response until 20 hpi corresponded 
with early logarithmic replication of SeV (Fig 2.2.B), suggesting that active viral 
replication was required for IFN mRNA induction.  In support of this conclusion, 
UV inactivation of SeV abrogated IFN mRNA transcriptional responses 
(Supplemental Fig S2.3).  Thus, both synthetic and natural PRR ligands were 
capable of activating innate immune pathways and IFN transcriptional 
upregulation in differentiated human neuronal cells. 
 
Human Neuronal Cells Show Restricted Responses to PRR Ligands 
Poly(I-C) and SeV are stimuli that are frequently used to activate innate immune 
pathways via TLR3, MDA5, or RIG-I.  To determine whether the differentiation-
dependent responses of BE(2)-C cells to poly(I-C) and SeV extended to other 
stimuli, we examined several additional PRR ligands (Table 2.1).  We stimulated 
NFB or ISRE promoter-driven reporter cell lines with increasing concentrations 
of LPS, the imidazoquinoline compound derivative CLO97, or the CpG-containing 
oligonucleotide ODN2006, which are ligands for TLR4, TLR7/8, or TLR9, 
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Figure 2.2.  SeV infection induces a neuronal PRR response.  A.  NFB 
reporter cells were infected with GFP-tagged SeV using an increasing multiplicity 
of infection (MOI), and SEAP reporter activity was assessed at 30 hpi.  B.  Cells 
were infected as in A and SeV replication, assessed by GFP fluorescence, was 
measured.  C.  BE(2)-C/m cells were stimulated with 100 g/ml extracellular 
poly(I-C) (pIC, lanes 2 and 5) or infected with SeV at an MOI of 10 (lanes 3 and 
6), and IFN mRNA or rRNA accumulation was assessed via RT-PCR 5 h (lanes 
1-3) or 20 h (lanes 4-6) later. 
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Table 2.1.  Human neuronal responses to PRR ligands. 
 NFB promoter ISRE promoter 
Stimulus BE(2)-C BE(2)-C/m BE(2)-C BE(2)-C/m 
Extracellular 
poly(I-C) 
> 1000 g/ml
* 
0.093 ± 0.036 g/ml
 
> 1000 g/ml 8.0 ± 3.5 g/ml 
Transfected 
poly(I-C) 
> 400 g/ml
 
0.015 ± 0.007 g/ml
 
> 400 g/ml 0.043 ± 0.003 g/ml 
LPS > 100 g/ml 0.012 ± 0.004 g/ml > 100 g/ml > 100 g/ml 
Imidazoquinoline > 25 g/ml > 25 g/ml > 25 g/ml > 25 g/ml 
CpG DNA > 25 M > 25 M > 25 M > 25 M 
 
*Results represent EC50 values for the indicated stimulus, promoter reporter, and cell line 
combination.  Where appropriate, values are presented as the mean ±  
SEM. 
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respectively (39).  BE(2)-C cells showed a differentiation-dependent response to 
LPS using an NFB promoter-driven reporter, whereas the ISRE promoter-driven 
reporter was not stimulated by LPS regardless of cell differentiation.  This 
observation was consistent with the differentiation-dependent expression of 
TLR4 and its co-receptor CD14 identified by microarray analyses (see below, 
Supplemental Tables S2.1 and S2.2 available online with publication 
doi/10.4049/jimmunol.0904133), and published studies demonstrating TLR4 
expression in primary CNS neurons and neuronal cell lines (66, 79).  Neither 
CLO97 nor ODN2006 stimulated reporter gene activity in BE(2)-C cells 
regardless of differentiation (Table 2.1), even though these TLR ligands were 
able to activate an NFB promoter-driven reporter in differentiated U937 cells, a 
human macrophage cell line (21) (Supplemental Fig S2.4).  We did not 
specifically examine TLR7/8 or TLR9 expression, and therefore cannot exclude 
the possibility that the inability of BE(2)-C cells to respond to CLO97 or ODN2006 
was secondary to the absence of these TLRs.  However, published data suggest 
that mRNAs for TLR7, 8, and 9 are present in some primary neurons and 
neuronal cell lines (79).  Nevertheless, these results suggested that human 
neuronal cells possess restricted PRR-mediated responses, and ligands that 
stimulated predominantly antiviral innate immune pathways via TLR3- , MDA5-, 
or RIG-I-mediated responses were particularly active.  Thus, we specifically 
focused subsequent studies on these pathways. 
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Differentiated Neurons Express TLR3, MDA5, and RIG-I 
We initially examined the expression of TLR3, MDA5, and RIG-I in neuronal cells 
by immunoblotting and immunofluorescence microscopy (Fig 2.3).  Previously 
published studies have demonstrated TLR3 expression in both cultured human 
and rodent neurons and CNS tissue sections (3, 30, 45, 54, 66), and we also 
observed TLR3 expression in lysates from undifferentiated BE(2)-C cells (Fig 
2.3.A, lane 1), differentiated BE(2)-C/m cells (Fig 2.3.A, lanes 2-4), and primary 
rat neurons (Fig 2.3.A, lane 5).  To validate the specificity of TLR3 
immunoblotting, we used lysates from BE(2)-C/m cells transfected with plasmids 
overexpressing either wild-type TLR3 (Fig 2.3.A, lane 3) or a dominant-negative 
mutant that contains a deletion of the TIR domain (Fig 2.3.A, lane 4).  We also 
examined TLR3 expression in BE(2)-C/m cells by immunofluorescence 
microscopy, and observed a punctate cytoplasmic distribution (Fig 2.3.B,upper 
right image), that was particularly evident at higher magnification (Fig 2.3.B, 
lower left image).  We observed a similar distribution pattern but increased TLR3 
immunofluorescent signal intensity in cells transfected with a plasmid 
overexpressing wild-type TLR3 (Fig 2.3.B, lower right image).  These 
immunofluorescence results were consistent with the previously described 
endosomal localization of TLR3 in cultured human neuronal cells (45).  
Furthermore, immunoblot analysis revealed that both MDA5 and RIG-I were 
expressed in human BE(2)-C cells (Fig 2.3.C, lanes 1-4) and primary rat neurons  
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Figure 2.3.  Human neuronal cells and differentiated rodent neurons express 
antiviral PRRs.  A.  Lysates from BE(2)-C cells (lane 1), differentiated BE(2)-C/m cells 
(lanes 2-4), or primary rat neurons (lane 5) were immunoblotted for TLR3 levels.  To 
validate antibody specificity, BE(2)-C/m cells were transfected with either empty vector 
(lane 2) or plasmids expressing wild-type TLR3 (lane 3) or a dominant-negative (dn) 
TLR3 (lane 4) that contains a TIR domain deletion.  The human TLR3 gene encodes a 
904 amino acid protein with a predicted MW of 103 kDa, although it is heavily 
glycosylated.  The TLR3 TIR mutant contains a 162 amino acid deletion that reduces 
the predicted MW by approximately 18 kDa.  The GAPDH-specific monoclonal antibody 
used for immunoblotting cross-reacted poorly with the rat lysate (lane 5), but total protein 
staining showed that the rat lysate sample contained approximately 2- to 3-fold more 
total protein than the other lanes (data not shown).  B.  Immunofluorescent staining of 
TLR3 expression in BE(2)-C/m cells.  The primary TLR3-specific antibody was excluded 
during incubation in control cells (upper left image).  Nuclei were stained with DAPI 
(blue), whereas the punctate PE-staining (red) indicates TLR3 expression.  Cells in the 
upper right and lower left images were transfected with empty vector, whereas cells in 
the lower right image were transfected with a plasmid expressing wild-type TLR3.  We 
also saw a similar punctuate pattern but increased TLR3 signal intensity in cells 
transfected with the dnTLR3 expression plasmid (data not shown).  C.  Lysates from 
BE(2)-C cells (lanes 1 and 3), differentiated BE(2)-C/m cells (lanes 2 and 4), or primary 
rat neurons (lanes 5 and 6), were immunoblotted for RIG-I, MDA5, and GAPDH (human) 
or tubulin (rat) levels.  Lysates from cells treated with 100 IU/ml human IFN-A/D for 6 h 
(lanes 3 and 4) or 50 IU/ml rat IFN for 24 h (lane 6) were used as controls to validate 
the identity of RIG-I and MDA5 as IFN-stimulated genes. 
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(Fig 2.3.C, lanes 5 and 6).  Interestingly, although RIG-I expression increased 
with BE(2)-C differentiation, probably due to the use of retinoic acid to induce 
neuronal maturation, MDA5 expression levels were independent of differentiation 
(Fig 2.3.C, lanes 1 and 2).  However, the expression of both PRRs increased in 
response to type-I IFN stimulation in both human BE(2)-C neuronal cells (Fig 
2.3.C, lanes 3 and 4) and primary rat neurons (Fig 2.3.C, lane 6).  These results 
suggested that the three PRRs associated with potent antiviral innate immune 
responses, TLR3, MDA5, and RIG-I, are expressed in human neuronal cells and 
differentiated neurons. 
 
Specific PRRs are Required for Poly(I-C)- and SeV-Mediated Activation of 
Innate Immune Pathways in Human Neuronal Cells 
We next examined the functional impact of PRR expression on neuronal innate 
immune responses using genetic disruption of receptor function (Fig 2.4).  To 
disrupt TLR3- or RIG-I-mediated pathway activation in BE(2)-C/m cells, we used 
stable cell lines expressing specific dominant-negative mutants.  Initial 
experiments using transient transfection with the TLR3 TIR mutant described 
above showed an approximate 50% reduction in extracellular poly(I-C)-
stimulated ISRE-SEAP activity (Supplemental Fig S2.5.A).  However, we were 
unable to generate stable cell lines constitutively expressing this construct, and 
therefore we subsequently targeted a downstream signaling molecule.  Since 
TLR3 is the only known dsRNA-sensing PRR to use the adaptor protein TRIF for  
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Figure 2.4.  Human neuronal cells possess functional PRR-mediated innate 
immune pathways.  A.  BE(2)-C/m cells stably overexpressing dominant negative forms 
of IRF3, TRIF, or RIG-I were stimulated with 100 g/ml extracellular poly(I-C) or 700 
ng/ml transfected poly(I-C) for 10 h, or infected with SeV for 30 h, and IFN mRNA 
levels were measured by quantitative RT-PCR using rRNA transcript levels as the 
loading control.  Results are expressed as the fold-change compared to similarly 
stimulated cells stably transfected with an empty vector.  B.  Lysates from BE(2)-C/m 
cells stably transfected with plasmids expressing shRNAs targeted against either a 
control protein (lanes 1 and 3) or MDA5 (lanes 2 and 4) were immunoblotted for MDA5, 
RIG-I, and GAPDH expression levels.  The level of MDA5 suppression in cells 
expressing an MDA5-specific shRNA was 44.5 ± 7.4% compared to control cells.  Live-
cell imaging of differentiated cells also demonstrated that greater than 95% of cells 
expressed the control GFP reporter gene encoded on the shRNA expression plasmid 
(data not shown).  Lysates from cells treated with 1000 IU/ml IFN-A/D for 12 h (lanes 3 
and 4) served as positive controls to validate the specificity of shRNA-mediated 
knockdown of MDA5 under enhanced expression levels.  C.  IFN mRNA levels in 
BE(2)-C/m cells stably expressing an MDA5-targeted shRNA after stimulation with 
extracellular poly(I-C) (pIC), transfected poly(I-C) (T-pIC), or infected with SeV as 
described above.  Transcript levels were determined by quantitative RT-PCR and results 
are expressed as the fold-change compared to similarly stimulated cells stably 
transfected with an shRNA-encoding vector targeting an irrelevant control protein.  *p-
value < 0.05. 
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signal transduction (51), we used a TRIF mutant that contains only the TIR 
domain (73) to disrupt TLR3 function.  In contrast, both RIG-I and MDA5 use the 
adaptor protein IPS-1 (51).  We therefore used an N-terminal RIG-I deletion 
mutant (75) to disrupt RIG-I function.  As a positive control we used a dominant 
negative IRF3 mutant (6), since this transcription factor is a central regulator of 
innate antiviral responses (51).  We generated BE(2)-C cell lines stably 
transfected with individual constitutive expression plasmids encoding the 
dominant negative mutants described above, differentiated cells with retinoic 
acid, stimulated with either extracellular or transfected poly(I-C) or infected with 
recombinant SeV, and measured IFN mRNA induction by quantitative RT-PCR 
(Fig 2.4.A).  Dominant negative IRF3 expression inhibited the IFN 
transcriptional responses to all three stimuli, where the largest decrease (~130-
fold) was seen with SeV infection.  In contrast, dominant negative TRIF 
expression specifically inhibited extracellular poly(I-C)-stimulated responses, 
whereas dominant-negative RIG-I expression specifically inhibited SeV-
stimulated responses. 
To disrupt MDA5-mediated pathway activation in BE(2)-C/m cells, we 
depleted receptor levels through stable expression of a plasmid encoding a short 
hairpin RNA (shRNA) specifically targeting MDA5 (Fig 2.4.B and C).  We initially 
optimized conditions and obtained a 40-50% reduction in MDA5 expression 
levels in BE(2)-C/m cells without significantly altering expression levels of the 
related RLR, RIG-I (Fig 2.4.B, compare lanes 1 and 2).  Depletion of MDA5 
inhibited the IFN transcriptional response to stimulation with transfected poly(I-
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C) but not with extracellular poly(I-C) or SeV infection (Fig 2.4.C).  These results 
indicated that human neuronal cells possess functional TLR3-, MDA5-, and RIG-
I-activated pathways that respond to specific stimuli. 
 
Neuronal Cell Differentiation Modulates Innate Immune Signaling Pathway 
Component Expression 
There are multiple signal transduction events that occur between PRR interaction 
with its ligand and downstream antiviral effector production.  To identify potential 
neuronal components involved in these events, we used genome-wide 
transcriptional microarray results combined with pathway analyses and 
compared BE(2)-C cells before and after retinoic acid-mediated differentiation.  
This approach was feasible since BE(2)-C cells showed minimal responsiveness 
to select PRR ligand stimulation (Figs 2.1 and 2.2, Table 2.1) prior to 
differentiation.  We identified 1,002 upregulated and 863 downregulated genes in 
differentiated BE(2)-C/m cells.  The complete list of differentially regulated genes 
is provided in Supplemental Table A.1. 
We subsequently conducted an in silico analysis with upregulated genes 
that were assigned to known cellular pathways using Ingenuity Pathway software 
to identify potential innate immune networks active in neuronal PRR signaling.  
We identified 29 canonical signaling pathways preferentially upregulated in 
differentiated BE(2)-C/m cells, 9 of which have been linked with innate immunity 
(Table 2.2).  We were particularly interested in the identification of the PI3K/AKT 
signaling pathway, as PI3Ks have been implicated as positive and negative  
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Table 2.2.  Signaling pathways preferentially upregulated in differentiated 
human BE(2)-C/m neuronal cells. 
SIGNALING PATHWAY* NO. OF GENES P-VALUE 
14-3-3-mediated signaling 21 0.0016 
α-Adrenergic signaling 13 0.0089 
Axonal guidance signaling 38 0.0044 
cAMP-mediated signaling† 18 0.0162 
Cardiac β-adrenergic signaling 15 0.0129 
Caveolar-mediated endocytosis 11 0.0155 
Ephrin receptor signaling 23 0.0010 
ERK/MAPK signaling† 20 0.0158 
Fcγ receptor-mediated phagocytosis in 
macrophages and monocytes 
12 0.0269 
G-protein coupled receptor signaling† 24 0.0025 
Hepatic fibrosis/stellate cell activation 21 0.0001 
IGF-1 signaling 17 0.0001 
IL-8 signaling† 20 0.0098 
Insulin receptor signaling 15 0.0209 
Integrin signaling† 24 0.0029 
Leukocyte extravasation signaling 19 0.0457 
Neuregulin signaling 15 0.0006 
Neurotrophin/TRK signaling† 10 0.0112 
Notch signaling 8 0.0037 
p53 signaling† 11 0.0355 
PI3K/AKT signaling† 15 0.0102 
PTEN signaling 15 0.0008 
PXR/RXR activation 9 0.0417 
RAR activation 25 0.0002 
Synaptic long term potentiation 14 0.0115 
TGF-β signaling† 14 0.0007 
Tight junction signaling 18 0.0174 
VDR/RXR activation 13 0.0021 
Wnt/β-catenin signaling 22 0.0011 
 
*The listed pathways were identified as significantly associated with BE(2)-C 
differentiation using Ingenuity Pathway Analysis software and datasets derived from both 
Genomatix and Affymetrix Bioconductor analyses of microarray data.  Only those 
pathways identified with both datasets are shown, where the number of genes and p-
values listed are from the Genomatix dataset analysis. 
 
†Signaling pathways associated with innate immunity in the literature are shown in bold.  
These pathways were identified by the presence of at least 10 Medline co-references 
with the keywords “innate” and “immunity”. 
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regulators of TLR3-mediated signaling events (1, 18, 23, 60, 65, 78), TLR3 
expression and function have been implicated in neuronal antiviral responses (3, 
14, 30, 45, 54), and the extracellular poly(I-C) stimulation experiments implicated 
an active TLR3-mediated pathway in differentiated BE(2)-C/m cells (Figs 2.1 and 
2.4).  To validate the microarray results with a particular focus on the PI3K/AKT 
pathway, we used a microplate-based quantitative RT-PCR array that included 
71 genes associated with this pathway.  Using this targeted array we validated 
the transcriptional upregulation of 19 genes in differentiated BE(2)-C/m cells that 
are associated with PIK3 signaling, including AKT3, APC, CD14, CTNNB1, 
FOXO1, FOXO3, FRAP, GSK3B, ITGB1, JUN, MAPK8, PAK1, PDPK1, PI3KCA, 
PI3KR1, RASA1, TLR4, TSC2, and YWHAH (Supplemental Table S2.2).  
Furthermore, we validated increased protein expression levels of the PI3K 
regulatory subunit isoform p85 encoded by the PI3KR1 gene in differentiated 
BE(2)-C/m cells by immunoblotting (Supplemental Fig S2.6).  These results 
suggested that canonical PI3K/AKT pathway components were involved in 
neuronal innate immune responses. 
 
PI3K Inhibition Blocks Poly(I-C)-Mediated Innate Immune System Activation 
in Neuronal Cells 
To examine the potential functional role of PI3K in neuronal PRR pathway 
signaling we initially used the universal PI3K inhibitor LY294002 (11).  We 
incubated differentiated BE(2)-C/m cells expressing ISRE or NFB promoter-
driven reporter genes with increasing concentrations of LY294002, stimulated 
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with extracellular or transfected poly(I-C), LPS, IFN-A/D, or TNF, and 
measured SEAP activity in tissue culture supernatants after 20 h (Fig 2.5.A).  
Initial viability studies showed minimal cytotoxicity with up to 25 M LY294002 in 
BE(2)-C/m cells (Supplemental Fig S2.7).  LY294002 potently inhibited both 
extracellular and transfected poly(I-C) stimulation in ISRE reporter cells with an 
IC50 of approximately 7 M (Fig 2.5.A, top graph), but had no effect on NFB 
promoter activation in response to poly(I-C), LPS, or TNF (Fig 2.5.A, bottom 
graph).  The inhibition of LY294002 on the IRSE promoter-driven reporter gene 
was due to disruption of autocrine IFN production rather than feedback 
signaling and amplification, as LY294002 had no effect on exogenous IFN-A/D 
stimulation of ISRE promoter reporter cells (Fig 2.5.A, top graph) but did 
suppress poly(I-C)-stimulated IFN mRNA transcriptional upregulation (see 
below, Fig 2.6.B).  Furthermore, LY294002 suppressed poly(I-C)-stimulated 
IFN mRNA transcriptional upregulation in primary rat cortical neurons (Fig 
2.5.B).  These results suggested that PI3K is involved in NFB-independent 
neuronal PRR pathways stimulated by poly(I-C) and mediated through TLR3 and 
MDA5. 
To gain further insight into the signaling molecules involved in neuronal 
PRR pathway activation, we used a defined library of kinase inhibitors and 
examined their effects on poly(I-C)-mediated activation of differentiated BE(2)-
C/m cells expressing an ISRE promoter-driven reporter.  This library contains 99 
inhibitors targeting 48 different kinases, including several involved in canonical 
PI3K/AKT signaling networks (Supplemental Table S2.3).   
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Figure 2.5.  Neuronal response to poly(I-C) is mediated by PI3K.  A.  BE(2)-C/m 
ISRE (upper graph) and NFB (lower graph) promoter-driven reporter cells were treated 
with an increasing concentration of LY294002, stimulated with 100 g/ml extracellular 
poly(I-C) (pIC), 700 ng/ml transfected poly(I-C) (T-pIC), 100 IU/ml IFN-A/D, 50 ng/ml 
TNF, or 500 ng/ml LPS, and SEAP reporter activity was measured 24 h later.  Results 
are expressed as the percentage of SEAP activity compared to DMSO-treated controls.  
TNF and LPS were used as controls only with NFB promoter-driven reporter cells as 
the ISRE reporter cells did not respond to either stimuli even in the absence of 
LY294002 (see Table 2.1 and data not shown).  B.  Primary rat cortical neurons were 
treated with either DMSO (lanes 1 and 2) or 10 M LY294002 (lane 3), stimulated with 
50 g/ml of extracellular poly(I-C) for 8 h (lanes 2 and 3), and IFN mRNA levels were 
assessed by RT-PCR. 
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Each inhibitor was serially diluted in duplicate from 100 to 0.8 M, incubated with 
reporter cells stimulated with extracellular or transfected poly(I-C), and SEAP 
activity was measured after 20 h.  To control for non-specific cytotoxicity, we 
conducted parallel viability assays.  We identified 23 kinase inhibitors that 
blocked either extracellular or transfected poly(I-C)-mediated activation of an 
ISRE promoter-driven reporter gene in differentiated BE(2)-C/m cells (Table 2.3).  
Interestingly, there was not a complete overlap between the lists of inhibitors that 
disrupted extracellular vs. transfected poly(I-C) stimulation.  For example, 
inhibitors of epidermal growth factor receptor kinase were more active against 
transfected poly(I-C) (Supplemental Table S2.3), suggesting that further studies 
using these pharmacologic probes may provide additional information regarding 
potential divergences in neuronal PRR signaling pathways. 
One noteworthy observation from the kinase inhibitor library studies in the 
context of our previous results was the identified activity of several PI3K 
inhibitors (Table 2.3).  However, these active compounds were either general 
PI3K inhibitors or targeted to the PI3K p110 subunit, where compounds 
targeted to the PI3K p110 or p110 subunits were not active in this medium 
throughput assay.  The PI3K complex consists of a receptor subunit that binds 
activated membrane-associated receptors and recruits a p110 catalytic subunit 
(, , or ) that mediates the conversion of phosphatidylinositol (4,5)-
bisphosphate to phosphatidylinositol (3,4,5)-trisphosphate, which is generally 
required for downstream signaling (68).  To validate the kinase inhibitor library 
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Table 2.3.  Kinase inhibitors that suppressed poly(I-C)-mediated ISRE promoter 
stimulation in human neuronal cells. 
INHIBITOR* TARGET(S)† 
BML-257 AKT 
Triciribine AKT 
Terreic acid BTK 
Flavopiridiol CDK 1,2,4 
Apigenin CK-II 
PI-103 DNA-PL, PI3K p110, mTOR 
Tyrphostin 25 EGFRK 
Tyrphostin 51 EGFRK 
BML-265 EGFRK 
5-Iodotubercidin ERK2, Adenosine kinase, CK1, CK2 
PK412 FTL3, Src, ABL 
GSK3 Inhibitor XIII GSK3 
Purvalanol A GSK3-, CDKs 
ZM 449829 JAK-3 
Rapamycin mTOR 
2-Aminopurine P58 PITSLRE-1 
LY294002 PI3K 
Quercetin dehydrate PI3K 
PI3K Inhibitor 2 PI3K p110 
H8 PKA, PKG 
Palmitoyl-DL-carnitine Cl PKC 
HBDDE (2,2',3,3',4,4'-Hexahydroxy-1,1'-
biphenyl-6,6'-dimethanol dimethyl ether) 
PKC, PKC 
Rottlerin PKC 
Tyrphostin AG 1288 Tyrosine kinases 
 
*The listed inhibitors suppressed ISRE promoter-driven reporter gene activity in BE(2)-
C/m cells with IC50 values < 20 M for either extracellular or transfected poly(I-C) and 
had CC50 values > 20 M.  Inhibitors with activity against PI3K are shown in bold italics 
type. 
 
†Kinase abbreviations: AKT, protein kinase B; BTK, Bruton’s tyrosine kinase; CDK, 
cyclin-dependent kinase; CK, creatine kinase; EGFRK, epidermal growth factor receptor 
kinase; ERK, extracellular signal-regulated kinase; FLT3, FMS-like tyrosine kinase 3; 
GSK3, glycogen synthase kinase 3; JAK, Janus kinase; mTOR, mammalian target of 
rapamycin; PKA/PKC/PKG, protein kinase A/C/G. 
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results, we purchased new inhibitors specifically targeting p110 (PI3K p110 
Inhibitor 2), p110 (TGX-221), or p110 (AS-252424), and used these 
compounds in detailed dose-titration studies with the same reporter cell line used 
for the kinase inhibitor library medium throughput assays (Fig 2.6.A).  The PI3K 
p110-specific inhibitor blocked both extracellular and transfected poly(I-C)-
activated ISRE reporter activity with IC50 values of 0.5 and 1.6 M, respectively 
(Fig 2.6.A, upper graph).  In contrast, neither the p110-specific (Fig 2.6.A, 
middle graph) nor p110-specific (Fig 2.6.A, lower graph) inhibitor significantly 
suppressed poly(I-C)-stimulated reporter gene activity until reaching 
concentrations greater than 10 M, at which point their subunit specificity 
decreases significantly (31, 53).  To verify the ability of PI3K subunit-specific 
inhibitors to block the induction of endogenous IFN mRNA, we examined the 
effects of LY294002, p110 Inhibitor 2, and AS-2552424 on IFN mRNA 
transcription after poly(I-C) stimulation in BE(2)-C/m cells (Fig 2.6.B).  We found 
that both LY294002 and the PI3K p110-selective inhibitor significantly 
suppressed IFN mRNA transcriptional activation when stimulated with either 
extracellular or transfected poly(I-C), whereas the p110-selective inhibitor had 
no effect. 
Finally, to provide genetic validation for the inhibitor studies, we depleted 
protein levels through stable shRNA expression targeted against the PI3K p110 
subunit (Fig 2.7).  We obtained an approximate 60% reduction in PI3K p110 
levels in differentiated BE(2)-C/m cells (Fig 2.7.A), which resulted in 
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Figure 2.6.  PI3K catalytic subunit p110 mediates human neuronal cell 
responses to poly(I-C).  A.  BE(2)-C/m ISRE reporter cells were treated with 
increasing concentrations of a selective PI3K p110 (p110a Inhibitor 2), p110 
(TGX-221), or p110 (AS-252424) catalytic subunit inhibitor, stimulated with 100 
g/ml extracellular poly(I-C) (pIC), 700 ng/ml transfected poly(I-C) (T-pIC), or 100 
IU/ml IFN-A/D, and SEAP reporter activity was measured 20 h later.  Results 
are presented as the percent reporter gene activity compared to DMSO-treated 
controls.  B.  BE(2)-C/m cells were treated with 10 M LY294002, 5 M p110 
Inhibitor 2, or 5 M AS-252424, stimulated with poly(I-C) as described above, 
and IFN mRNA levels were measured 4 h later by quantitative RT-PCR.  *p-
values < 0.05. 
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Figure 2.7.  The PI3K p110 catalytic subunit mediates a TLR3-dependent 
response in neuronal cells.  A.  Lysates from BE(2)-C/m cells stably 
transduced with lentiviruses expressing an empty vector (lane 1) or shRNAs 
targeted against either a control protein (CD14, lane 2) or PI3K p110 (lane 3) 
were immunoblotted for p110 and GAPDH expression levels.  The level of 
suppression in cells expressing a p110-specific shRNA was 60.4 ± 4.9% 
compared to control cells.  Live-cell imaging of differentiated cells also 
demonstrated that greater than 95% of cells expressed the control GFP reporter 
gene encoded on the shRNA expression plasmid (data not shown).  B.  IFN 
mRNA levels in BE(2)-C/m cells stably expressing a p110-targeted shRNA after 
stimulation with extracellular poly(I-C) (pIC) or transfected poly(I-C) (T-pIC) as 
described in Fig 2.6.  Transcript levels were determined by quantitative RT-PCR 
and results are expressed as the fold-change compared to similarly stimulated 
cells stably transfected with an shRNA-encoding vector targeting an irrelevant 
control protein.  *p-value < 0.05. 
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significant inhibition of extracellular poly(I-C)-mediated stimulation of IFN mRNA 
transcription (Fig 2.7.B).  However, in contrast to results with p110-specific 
inhibitors (Fig 2.6), shRNA-mediated knockdown of p110 protein levels did not 
suppress the ability of transfected poly(I-C) to stimulate IFN mRNA transcription 
(Fig 2.7.B).  The ability of the p110-depleted neuronal cells to remain 
responsive to transfected poly(I-C) may have been due to an insufficient 
depletion of p110levels, which is consistent with a reproducible three-fold 
higher IC50 of the p110-specific inhibitor for transfected versus extracellular 
poly(I-C) mediated neuronal responses (Fig 2.6.A).  Nevertheless, these results 
indicated that PI3K, and in particular the p110 subunit, modulates TLR3- and 
possibly MDA5-dependent innate immune pathway activation in human neuronal 
cells. 
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Discussion 
The innate immune system plays a critical role in both the initial response 
to an invading pathogen, which frequently limits or contains pathogen replication 
and dissemination, and the induction of an effective adaptive immune response, 
which is most often the primary mechanism for pathogen clearance.  The 
characteristics of the innate immune response are determined in part by the 
pathogen initiating the response but can also be influenced by the type of cell in 
which the response is generated.  In this report we examined the functional PRR-
mediated pathways present in human neuronal cells and differentiated primary 
rat neurons, with a particular focus on those pathways previously identified as 
being important for antiviral innate immune responses in other cell types.  We 
drew four main conclusions.  First, human neuronal cells possess functional 
TLR3-, TLR4-, RIG-I-, and MDA5-mediated PRR pathways whose activity was 
maturation-dependent.  Second, both extracellular and transfected poly(I-C) 
induced potent IFN induction in neurons that resulted in autocrine ISRE 
activation.  Third, the neuronal antiviral innate immune pathways mediated by 
TLR3, RIG-I, and MDA5 are non-redundant and preferentially respond to distinct 
ligands.  Fourth, TLR3- and possibly MDA5-mediated neuronal responses are 
positively regulated by the PI3K pathway, and in particular the PI3K p110 
subunit.  These results indicate that human neuronal cells possess a relatively 
broad complement of PRR-mediated innate immune pathways, and that those 
pathways typically stimulated by viral pathogens via nucleic acid recognition are 
particularly active. 
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Previous studies on PRR pathways in CNS neurons have focused 
predominantly on TLR-mediated pathways and have examined their impact on 
multiple aspects of brain physiology, including development and regeneration 
(40).  Several studies have examined the role of TLR3 in response to CNS viral 
infections (3, 14, 30, 45, 54), although the potential antiviral role of TLR3-
mediated pathways is controversial and may be pathogen-specific (69).  For 
example, humans with a TLR3 deficiency have a genetic predisposition to herpes 
simplex virus encephalitis (76), but TLR3-/- mice have decreased susceptibility to 
rabies virus encephalitis (45).  Furthermore, TLR3-/- mice have been shown to 
have both increased (71) and decreased (14) susceptibility to West Nile virus 
(WNV) encephalitis.  However, these studies cannot fully separate the neuron-
specific activity of TLR3 from other cell types, including professional immune 
cells such as macrophages and dendritic cells.  Although CNS neurons from 
TLR3-/- mice have a modest increase in WNV production when infected in culture 
(14), suggesting that neuronal TLR3-mediated responses can have antiviral 
effects, further studies in mice with conditional cell-specific TLR3 deletions will be 
required to fully delineate the potential antiviral activity of TLR3-activated innate 
immune pathways in neurons and their role in viral pathogenesis. 
In contrast to TLR3, neuronal innate immune responses mediated by the 
cytosolic PRRs RIG-I and MDA5 have been less well studied.  The expression of 
both RIG-I or MDA5 could be induced by IFN or WNV infection in cultured 
mouse cortical neurons, but basal expression was not detected by 
immunoblotting (13).  Although we also found that both RLRs were upregulated 
100 
with type-I IFN treatment of human neuronal cells, we did detect basal 
expression, especially in differentiated cells.  Furthermore, we found that both 
RIG-I- and MDA5-mediated pathways were active in human neuronal cells.  The 
presence of functional cytosolic PRR-activated innate immune pathways in 
neurons is not surprising, as the innate antiviral responses to several neurotropic 
viruses has been shown to involve RIG-I- and/or MDA5-mediated pathways in 
non-neuronal cells (20, 35).  However, the outcome of these responses may 
differ significantly between neuronal and non-neuronal cells, where mature CNS 
neurons are essentially irreplaceable and therefore initiation of an altruistic 
apoptotic cascade may result in irreversible damage to the host, despite 
simultaneously preventing virus spread.  One intriguing hypothesis is that 
neuronal PRR responses, potentially augmented or modulated by PRR-initiated 
responses in other CNS-resident cells such as astrocytes or microglia, control 
virus replication and promote neuronal survival through either previously 
unrecognized or uncharacterized pathways.  Consistent with this hypothesis, 
results presented in chapter III suggest that the neurotropic alphavirus western 
equine encephalitis virus activates an IRF3-dependent pro-survival pathway in 
human neuronal cells.  Detailed studies in chapter III will describe efforts to 
examine the roles of TLR3-, RIG-I, and MDA5-activated pathways in human 
neurons in response to a variety of neurotropic viruses in an attempt to more fully 
explore this hypothesis. 
The signal transduction pathways that mediate PRR-activated immune 
responses are complex and interconnected at multiple levels.  Several steps in 
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these pathways are mediated by cellular kinases, and we found that the PI3K 
pathway was important for optimal TLR3- and possibly MDA5-activated 
responses in human neuronal cells.  The PI3K pathway has previously been 
implicated in innate immune pathway regulation, and in particular TLR3-mediated 
signaling (24).  However, both stimulatory (18, 60) and inhibitory (1) effects on 
TLR3-mediated signaling have been observed, which may be explained in part 
by cell type differences.  Our results suggest that the PI3K pathway plays a 
stimulatory role in neuronal TLR3-mediated responses, and is necessary for full 
IFN mRNA induction.  Furthermore, both pharmacologic and genetic 
approaches identified a potential role for PI3K, and in particular the PI3K p110 
subunit, in neuronal MDA5-mediated signaling.  Although the PI3K pathway has 
been tentatively implicated in cytoplasmic RLR-initiated signaling (50), the 
majority of work thus far has focused on its effects during TLR-initiated signaling 
(24).  Cellular PI3K/AKT pathways are essential for neuronal development and 
survival (9, 10, 28), suggesting a potential link between antiviral PRR pathway 
activation and the ability of neurons to overcome an infection until an adaptive 
immune response can be fully established.  Additional studies will be required to 
further delineate the precise PI3K pathway components involved in neuronal 
antiviral PRR activation, but our kinase inhibitor library studies suggest that 
protein kinase B (AKT), mammalian target of rapamycin (mTOR), and glycogen 
synthase kinase 3 may be involved.  All of these kinases participate in PI3K 
signaling and have been implicated in innate immunity in non-neuronal model 
systems (4, 7, 36-38, 47). 
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Innate immune pathway stimulation via TLRs or RLRs eventually results in 
the activation of multiple genes involved in immune responses (39, 51).  For 
antiviral pathway stimulation via TLR3, RIG-I, or MDA5, one important group of 
upregulated genes are type-I IFNs, and in particular IFN in non-professional 
immune cells (56).  Indeed, IFN mRNA upregulation is a convenient marker of 
innate antiviral pathway activation, which we used to monitor responses to TLR3, 
RIG-I, and MDA5 ligands.  Furthermore, we found that BE(2)-C/m human 
neuronal cells are capable of synthesizing and excreting IFN in response to 
specific PRR stimulation, consistent with previously published studies in other 
cultured human neuronal cell lines (54) and rodent neurons both in vitro (13-15) 
and in vivo (16).  However, whether neuronal IFN production in vivo in response 
to neurotropic pathogens or other CNS inflammatory conditions plays an 
important role in either the amelioration or augmentation of disease is 
controversial.  Studies in conditional knockout mice that have disrupted type-I 
IFN receptor expression in neuroectodermal cells, which includes neurons, 
indicate that responses to type-I IFNs are important to control virus spread within 
the CNS (17) but not in the progression of experimental autoimmune 
inflammatory disease (55).  Similar studies with mice containing conditional 
disruption of IFN production in CNS-resident cells will be needed to definitively 
examine the potential importance of neuronal type-I IFN production in vivo. 
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Supplemental Figure S2.1.  Validation of primary cortical neuronal cultures.  
A.  3 or 14 day in vitro (DIV) rat primary cortical neuron lysates were 
immunoblotted for synaptophysin, NF68, or -tubulin.  B.  Immunofluorescence 
images of 14 DIV rat neurons were stained with DAPI, NF200, or synaptophysin.  
400X images are shown.  C and D.  Primary (C) or BE(2)-C-derived (D) neuronal 
cultures were treated with glutamate (Glu) as indicated, and viability was 
measured 24 hours later via a luminescent ATP (C) or MTT (D) assay.  E.  14 
DIV primary neurons were infected with WEEV, and supernatants were titered 
via plaque assay.  F.  14 DIV cortical neurons were infected with SeV MOI 0.1, 
RNA was harvested 72 hours later, and IFN mRNA was analyzed via 
quantitative RT-PCR.  Data are representative of 3 independent trials for A, B, 
and C and 2 trials for D, E, and F. 
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Supplemental Figure S2.2.  PRR signaling in SYSY-5Y and HCN-1A 
neuronal cells.  A.  Undifferentiated and differentiated SHSY-5Y human 
neuroblastoma cells stably expressing an ISRE-SEAP reporter were stimulated 
with pIC (1.5 g/ml) or T-pIC (0.015 g/ml), and SEAP was measured 24 hours 
later.  B.  Differentiated SHSY-5Y ISRE reporter cells were stimulated with pIC or 
T-pIC along with either a control, IFN(10,000 neutralizing units), or IFN (2000 
neutralizing units) neutralizing antibody.  SEAP activity was measured 24 hours 
later.  C.  Differentiated HCN-1A neuronal cells were mock-treated or treated with 
10 or 100 g/ml pIC.  20 hours later RNA was harvested, and IFN and rRNA 
transcripts were assessed via RT-PCR.  Adjacent lanes represent ten-fold 
dilutions of cDNA.  Data are representative of 2 independent trials for A and B 
and one trial for C.  Error bars represent standard deviations of duplicate wells.  
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Supplemental Figure S2.3.  UV-treated SeV fails to robustly induce IFN 
mRNA in neuronal cells.  BE(2)-C/m cells were mock treated, treated with pIC, 
infected with SeV (MOI 5), or UV-treated SeV.  RNA was harvested 20 hours 
later, and IFN and actin transcripts were measured via RT-PCR.  Data are 
representative of 2 independent trials.   
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Supplemental Figure S2.4.  PRR responses in U937 human monocyte-
derived macrophages.  U937 monocytes stably expressing an NFB- or ISRE-
SEAP reporter were differentiated and stimulated with a panel of PRR ligands.  
All ligands were tested at starting concentrations at least 5 times the 
manufacturer’s suggested concentration and at dilutions covering at least 3 
orders of magnitude.  Stimuli were delivered for 24 hours followed by 
assessment of SEAP activity.  Representative concentrations are shown.  A.  
NFB reporter cells were stimulated with TNF (100 ng/ml), IFN-A/D (10 U/ml), 
LPS (10 ng/ml), CLO97 (5 g/ml), CpG (10 M), pIC (5 g/ml), or T-pIC (5 
ug/ml).  B.  ISRE reporter cells were stimulated as in A except 1 g/ml of LPS, 50 
g/ml of T-pIC, or 100 g/ml of pIC was used.  Data are representative of 3 
independent trials.  Error bars represent standard deviations of duplicate wells. 
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Supplemental Figure S2.5.  TLR3- and PI3K p110-dependent responses in 
neuronal cells.   A.  ISRE reporter BE(2)-C/m cells were transfected with a 
vector control or a dominant negative TLR3 (pdn.TLR3) for 48 hours.  Cells were 
then stimulated for 24 hours with pIC (50 g/ml) or IFN-A/D (100 U/ml) for 24 
hours.  B.  Cells were treated as in A except a wild-type TLR3 (pTLR3) or 
constitutively active PI3K p110 (p110.CAAX) were transiently expressed, and 
cells were stimulated with pIC at either 10 (pIC-10) or 50 (pIC-50) g/ml.  In A, 
averages and SEMs are displayed from 2 trials.  Data are representative of 1 trial 
for B where error bars represent standard deviations of duplicate wells.  *p < 
0.05.        
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Supplemental Figure S2.6.  PI3KR1 protein expression increases upon 
neuronal differentiation.  BE(2)-C or BE(2)-C/m lysates were analyzed by 
Western blot for PI3KR1 or GAPDH expression.  Data are representative of 2 
trials.  
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Supplemental Figure S2.7.  LY294002 cytotoxicity in BE(2)-C/m cells.  
BE(2)-C/m cells were treated with the indicated concentrations of LY294002 for 
24 hours.  Percent viability relative to DMSO treated controls was measured via 
an AlamarBlue assay.  Averages and SEMs are displayed from 2 trials.  
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Supplemental Table S2.1.  BE(2)-C Genomatix Microarray Analysis.     
Differentiated BE(2)-C/m vs. Undifferentiated BE(2)-C cells 
Parameters: 5 independent experiments (biological replicates) 
  Genomatix ChipInspector program with exhaustive pairwise analysis 
  FDR 1%, minimum 3 probe coverage, log2 fold change >= 0.5 (approx 1.4-fold) 
Genes Increased with Neuronal Differentiation 
Gene Symbol Gene Name Fold 
Change 
A1BG alpha-1-B glycoprotein 1.5 
AAK1 AP2 associated kinase 1 1.4 
AATK apoptosis-associated tyrosine kinase 1.6 
ABAT 4-aminobutyrate aminotransferase 1.6 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 1.8 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.8 
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 1.5 
ABHD14A abhydrolase domain containing 14A 1.5 
ABI3BP ABI gene family, member 3 (NESH) binding protein 2.7 
ACADVL acyl-Coenzyme A dehydrogenase, very long chain 1.4 
ACCN4 amiloride-sensitive cation channel 4, pituitary 2.1 
ACP6 acid phosphatase 6, lysophosphatidic 1.7 
ACTA2 actin, alpha 2, smooth muscle, aorta 4.6 
ACTG2 actin, gamma 2, smooth muscle, enteric 1.5 
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1.7 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 
(aggrecanase-2) 
1.5 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 1.6 
ADCY1 adenylate cyclase 1 (brain) 1.8 
ADD3 adducin 3 (gamma) 2.5 
ADH5 alcohol dehydrogenase 5 (class III), chi polypeptide 1.6 
ADM adrenomedullin 1.7 
AK3L1 adenylate kinase 3-like 1 1.7 
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 1.4 
AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) 
1.5 
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid 
dehydrogenase, type III) 
1.8 
AKTIP AKT interacting protein 1.5 
ALCAM activated leukocyte cell adhesion molecule 1.5 
ALS2 amyotrophic lateral sclerosis 2 (juvenile) 1.5 
AMHR2 anti-Mullerian hormone receptor, type II 1.6 
ANGPT1 angiopoietin 1 1.5 
ANGPTL6 angiopoietin-like 6 1.4 
ANK2 ankyrin 2, neuronal 1.9 
ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 1.6 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 1.9 
ANKRD6 ankyrin repeat domain 6 1.5 
ANTXR2 anthrax toxin receptor 2 2.1 
ANXA1 annexin A1 2.9 
ANXA3 annexin A3 1.7 
ANXA6 annexin A6 1.5 
AP1G2 adaptor-related protein complex 1, gamma 2 subunit 1.5 
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AP1S2 adaptor-related protein complex 1, sigma 2 subunit 1.7 
AP2B1 adaptor-related protein complex 2, beta 1 subunit 1.5 
APBA1 amyloid beta (A4) precursor protein-binding, family A, member 1 
(X11) 
1.6 
APC adenomatous polyposis coli 1.5 
APC2 adenomatosis polyposis coli 2 1.6 
APLP2 amyloid beta (A4) precursor-like protein 2 1.7 
AQP1 aquaporin 1 (Colton blood group) 1.5 
AQP3 aquaporin 3 (Gill blood group) 2.0 
AQP6 aquaporin 6, kidney specific 1.4 
ARG2 arginase, type II 1.5 
ARHGAP17 Rho GTPase activating protein 17 1.4 
ARHGAP26 Rho GTPase activating protein 26 2.1 
ARHGAP29 Rho GTPase activating protein 29 2.1 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 1.6 
ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 1.4 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 3.1 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 1.4 
ARL15 ADP-ribosylation factor-like 15 1.4 
ARL6 ADP-ribosylation factor-like 6 1.7 
ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 1.5 
ARMC9 armadillo repeat containing 9 1.5 
ARMCX1 armadillo repeat containing, X-linked 1 1.5 
ARMCX3 armadillo repeat containing, X-linked 3 1.5 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 2.0 
ARNTL aryl hydrocarbon receptor nuclear translocator-like 1.5 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 2.0 
ASL argininosuccinate lyase 1.6 
ASTN1 astrotactin 1 2.0 
ATAD1 ATPase family, AAA domain containing 1 1.4 
ATCAY ataxia, cerebellar, Cayman type (caytaxin) 1.7 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 1.8 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 1.5 
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 1.8 
ATP2B3 ATPase, Ca++ transporting, plasma membrane 3 1.4 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 1.5 
ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 1.5 
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 1.7 
ATP6V1G2 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 1.6 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 1.4 
ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) 3.4 
AUTS2 autism susceptibility candidate 2 1.7 
AXL AXL receptor tyrosine kinase 1.6 
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 1.8 
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 
2 
1.9 
BAI3 brain-specific angiogenesis inhibitor 3 1.5 
BASP1 brain abundant, membrane attached signal protein 1 1.7 
BCAS3 breast carcinoma amplified sequence 3 1.7 
BCL2 B-cell CLL/lymphoma 2 1.6 
BDKRB2 bradykinin receptor B2 1.5 
BEX2 brain expressed X-linked 2 1.8 
BEX4 BEX family member 4 1.7 
BEX5 BEX family member 5 2.0 
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BLCAP bladder cancer associated protein 1.5 
BMP6 bone morphogenetic protein 6 1.6 
BMP7 bone morphogenetic protein 7 (osteogenic protein 1) 2.1 
BMPR1B bone morphogenetic protein receptor, type IB 1.4 
BMPR2 bone morphogenetic protein receptor, type II (serine/threonine 
kinase) 
1.8 
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 1.7 
BOK BCL2-related ovarian killer 1.8 
BRSK1 BR serine/threonine kinase 1 1.4 
BSCL2 Bernardinelli-Seip congenital lipodystrophy 2 (seipin) 1.4 
BTG2 BTG family, member 2 1.6 
BVES blood vessel epicardial substance 1.8 
C16orf5 chromosome 16 open reading frame 5 1.4 
C17orf28 chromosome 17 open reading frame 28 1.5 
C19orf63 chromosome 19 open reading frame 63 1.6 
C1orf76 chromosome 1 open reading frame 76 1.5 
C4orf6 chromosome 4 open reading frame 6 15.0 
C5orf13 chromosome 5 open reading frame 13 2.6 
C5orf5 chromosome 5 open reading frame 5 1.4 
C6orf134 chromosome 6 open reading frame 134 1.7 
C7 complement component 7 1.6 
C8orf4 chromosome 8 open reading frame 4 1.4 
C8orf70 chromosome 8 open reading frame 70 1.5 
C9orf127 chromosome 9 open reading frame 127 1.5 
C9orf19 chromosome 9 open reading frame 19 1.6 
C9orf95 chromosome 9 open reading frame 95 1.8 
CA11 carbonic anhydrase XI 2.0 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 1.8 
CACNB1 calcium channel, voltage-dependent, beta 1 subunit 1.4 
CACNB3 calcium channel, voltage-dependent, beta 3 subunit 1.8 
CACNG2 calcium channel, voltage-dependent, gamma subunit 2 1.5 
CADM1 cell adhesion molecule 1 1.7 
CADM3 cell adhesion molecule 3 1.6 
CADM4 cell adhesion molecule 4 1.5 
CADPS Ca2+-dependent secretion activator 2.2 
CALCA calcitonin-related polypeptide alpha 1.5 
CALCB calcitonin-related polypeptide beta 25.7 
CALCOCO1 calcium binding and coiled-coil domain 1 1.5 
CALM1 calmodulin 1 (phosphorylase kinase, delta) 1.6 
CAMK2B calcium/calmodulin-dependent protein kinase (CaM kinase) II beta 1.7 
CAMTA1 calmodulin binding transcription activator 1 1.7 
CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 1.5 
CASD1 CAS1 domain containing 1 1.5 
CASP6 caspase 6, apoptosis-related cysteine peptidase 1.4 
CASZ1 castor zinc finger 1 1.6 
CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence 1.5 
CCDC80 coiled-coil domain containing 80 1.5 
CCL2 chemokine (C-C motif) ligand 2 3.6 
CCNA1 cyclin A1 1.7 
CCNDBP1 cyclin D-type binding-protein 1 1.9 
CCNG2 cyclin G2 2.2 
CD14 CD14 molecule 1.9 
CD151 CD151 molecule (Raph blood group) 1.6 
CD177 CD177 molecule 3.4 
121 
CD200 CD200 molecule 1.9 
CD24 CD24 molecule 3.8 
CD276 CD276 molecule 1.5 
CD44 CD44 molecule (Indian blood group) 2.1 
CD59 CD59 molecule, complement regulatory protein 2.1 
CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) 1.4 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 1.5 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 1.9 
CDH12 cadherin 12, type 2 (N-cadherin 2) 1.7 
CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) 1.5 
CDK5R2 cyclin-dependent kinase 5, regulatory subunit 2 (p39) 1.6 
CDK6 cyclin-dependent kinase 6 1.5 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.6 
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2.1 
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 1.6 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.2 
CFI complement factor I 2.1 
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 1.5 
CHRM1 cholinergic receptor, muscarinic 1 1.6 
CHRM3 cholinergic receptor, muscarinic 3 2.0 
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 2.1 
CLASP2 cytoplasmic linker associated protein 2 1.8 
CLCN5 chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease) 2.5 
CLCN6 chloride channel 6 1.5 
CLIP1 CAP-GLY domain containing linker protein 1 1.5 
CLIP2 CAP-GLY domain containing linker protein 2 1.7 
CLIP3 CAP-GLY domain containing linker protein 3 2.3 
CLSTN2 calsyntenin 2 1.6 
CLSTN3 calsyntenin 3 1.6 
CMAH cytidine monophosphate-N-acetylneuraminic acid hydroxylase 
(CMP-N-acetylneuraminate monooxygenase) pseudogene 
1.7 
CMIP c-Maf-inducing protein 1.5 
CNN1 calponin 1, basic, smooth muscle 1.6 
CNN2 calponin 2 1.7 
CNTN1 contactin 1 1.5 
COL12A1 collagen, type XII, alpha 1 1.5 
COL13A1 collagen, type XIII, alpha 1 2.0 
COL1A1 collagen, type I, alpha 1 3.6 
COL3A1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, 
autosomal dominant) 
3.5 
COL4A1 collagen, type IV, alpha 1 1.9 
COL4A2 collagen, type IV, alpha 2 2.0 
COL5A1 collagen, type V, alpha 1 1.8 
COL6A3 collagen, type VI, alpha 3 1.4 
COLQ collagen-like tail subunit (single strand of homotrimer) of 
asymmetric acetylcholinesterase 
1.8 
CORO1A coronin, actin binding protein, 1A 1.7 
COTL1 coactosin-like 1 (Dictyostelium) 1.8 
CPA4 carboxypeptidase A4 4.6 
CPE carboxypeptidase E 2.9 
CPEB4 cytoplasmic polyadenylation element binding protein 4 1.9 
CPNE3 copine III 1.5 
CPT1C carnitine palmitoyltransferase 1C 1.5 
CPVL carboxypeptidase, vitellogenic-like 1.6 
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CRABP2 cellular retinoic acid binding protein 2 8.6 
CRB1 crumbs homolog 1 (Drosophila) 1.8 
CREB5 cAMP responsive element binding protein 5 1.4 
CRH corticotropin releasing hormone 2.2 
CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) 4.8 
CRMP1 collapsin response mediator protein 1 1.4 
CRYGC crystallin, gamma C 4.7 
CRYM crystallin, mu 1.7 
CSRP1 cysteine and glycine-rich protein 1 1.4 
CSRP2 cysteine and glycine-rich protein 2 1.5 
CTGF connective tissue growth factor 7.0 
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 1.5 
CTNNA2 catenin (cadherin-associated protein), alpha 2 1.5 
CTSB cathepsin B 3.1 
CTSC cathepsin C 1.4 
CTSH cathepsin H 3.2 
CXADR coxsackie virus and adenovirus receptor 1.8 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 1.4 
CYB5R3 cytochrome b5 reductase 3 1.5 
CYFIP2 cytoplasmic FMR1 interacting protein 2 2.1 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 1.7 
CYP26A1 cytochrome P450, family 26, subfamily A, polypeptide 1 37.5 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 4.2 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 1.7 
CYR61 cysteine-rich, angiogenic inducer, 61 1.6 
CYTL1 cytokine-like 1 2.3 
DAAM1 dishevelled associated activator of morphogenesis 1 2.0 
DACH1 dachshund homolog 1 (Drosophila) 2.0 
DACT3 dapper, antagonist of beta-catenin, homolog 3 (Xenopus laevis) 1.7 
DCHS1 dachsous 1 (Drosophila) 1.8 
DCLK1 doublecortin-like kinase 1 6.8 
DCLK2 doublecortin-like kinase 2 2.0 
DCTN4 dynactin 4 (p62) 1.5 
DCX doublecortex; lissencephaly, X-linked (doublecortin) 5.4 
DDAH2 dimethylarginine dimethylaminohydrolase 2 1.7 
DDEF1 development and differentiation enhancing factor 1 1.6 
DDEF2 development and differentiation enhancing factor 2 2.5 
DDIT3 DNA-damage-inducible transcript 3 1.4 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 1.5 
DFNA5 deafness, autosomal dominant 5 1.6 
DHRS3 dehydrogenase/reductase (SDR family) member 3 2.2 
DIRAS3 DIRAS family, GTP-binding RAS-like 3 2.1 
DKK2 dickkopf homolog 2 (Xenopus laevis) 2.5 
DLG2 discs, large homolog 2, chapsyn-110 (Drosophila) 5.8 
DLL3 delta-like 3 (Drosophila) 1.7 
DOCK11 dedicator of cytokinesis 11 1.4 
DOCK4 dedicator of cytokinesis 4 1.8 
DPP6 dipeptidyl-peptidase 6 3.1 
DPYSL3 dihydropyrimidinase-like 3 2.0 
DPYSL4 dihydropyrimidinase-like 4 2.8 
DRAM damage-regulated autophagy modulator 1.7 
DST dystonin 1.6 
DUSP1 dual specificity phosphatase 1 1.5 
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DUSP6 dual specificity phosphatase 6 5.3 
DUSP8 dual specificity phosphatase 8 1.6 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 2.0 
DYRK1B dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 1.5 
DYSF dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) 1.5 
E2F7 E2F transcription factor 7 1.4 
EDG1 endothelial differentiation, sphingolipid G-protein-coupled receptor, 
1 
1.6 
EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled 
receptor, 2 
1.5 
EDN1 endothelin 1 1.8 
EDNRA endothelin receptor type A 1.7 
EFHA2 EF-hand domain family, member A2 1.6 
EGR1 early growth response 1 1.9 
EGR3 early growth response 3 2.8 
EHD3 EH-domain containing 3 1.6 
EIF4E3 eukaryotic translation initiation factor 4E family member 3 1.7 
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R) 
1.6 
ELAVL2 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 (Hu 
antigen B) 
1.4 
ELAVL3 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu 
antigen C) 
1.6 
ELAVL4 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu 
antigen D) 
2.3 
ELMO2 engulfment and cell motility 2 1.4 
ELMOD1 ELMO/CED-12 domain containing 1 1.7 
EMCN endomucin 1.6 
ENO2 enolase 2 (gamma, neuronal) 1.5 
ENO3 enolase 3 (beta, muscle) 1.6 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) 1.4 
ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative 
function) 
1.6 
ENSA endosulfine alpha 1.5 
EPAS1 endothelial PAS domain protein 1 1.9 
EPB41L1 erythrocyte membrane protein band 4.1-like 1 1.4 
EPB49 erythrocyte membrane protein band 4.9 (dematin) 1.7 
EPS15 epidermal growth factor receptor pathway substrate 15 1.4 
ETHE1 ethylmalonic encephalopathy 1 5.6 
EXOC1 exocyst complex component 1 1.5 
EXOC6B exocyst complex component 6B 3.3 
EXPH5 exophilin 5 1.5 
FAM127A family with sequence similarity 127, member A 1.7 
FAM13A1 family with sequence similarity 13, member A1 1.7 
FAM38A family with sequence similarity 38, member A 1.6 
FAM84B family with sequence similarity 84, member B 1.4 
FAT FAT tumor suppressor homolog 1 (Drosophila) 1.5 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) 1.6 
FBLIM1 filamin binding LIM protein 1 1.6 
FBXL2 F-box and leucine-rich repeat protein 2 1.7 
FCHO2 FCH domain only 2 1.6 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 1.4 
FER1L3 fer-1-like 3, myoferlin (C. elegans) 1.5 
FEZ2 fasciculation and elongation protein zeta 2 (zygin II) 1.5 
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FGF1 fibroblast growth factor 1 (acidic) 1.5 
FGF13 fibroblast growth factor 13 2.3 
FGL1 fibrinogen-like 1 1.4 
FHL1 four and a half LIM domains 1 1.4 
FHOD3 formin homology 2 domain containing 3 1.5 
FIBIN fin bud initiation factor 1.5 
FIG4 FIG4 homolog (S. cerevisiae) 1.6 
FILIP1L filamin A interacting protein 1-like 1.9 
FKBP1B FK506 binding protein 1B, 12.6 kDa 1.8 
FLJ22536 hypothetical locus LOC401237 2.4 
FLNB filamin B, beta (actin binding protein 278) 2.9 
FLOT1 flotillin 1 1.5 
FMNL2 formin-like 2 1.7 
FN1 fibronectin 1 7.7 
FNBP1L formin binding protein 1-like 1.9 
FNDC4 fibronectin type III domain containing 4 1.6 
FNDC5 fibronectin type III domain containing 5 2.6 
FOXC1 forkhead box C1 2.0 
FOXN3 forkhead box N3 1.4 
FOXO1 forkhead box O1 1.8 
FOXO3 forkhead box O3 2.0 
FREM1 FRAS1 related extracellular matrix 1 2.2 
FRS3 fibroblast growth factor receptor substrate 3 1.4 
FSTL1 follistatin-like 1 8.8 
FSTL3 follistatin-like 3 (secreted glycoprotein) 1.4 
FUCA1 fucosidase, alpha-L- 1, tissue 1.6 
FZD5 frizzled homolog 5 (Drosophila) 1.5 
G0S2 G0/G1switch 2 1.6 
GAB2 GRB2-associated binding protein 2 2.3 
GABARAPL1 GABA(A) receptor-associated protein like 1 1.5 
GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 1.9 
GAL galanin prepropeptide 2.9 
GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7 (GalNAc-T7) 
1.4 
GALR1 galanin receptor 1 2.2 
GAS2 growth arrest-specific 2 1.8 
GATS opposite strand transcription unit to STAG3 1.8 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 1.4 
GDAP1 ganglioside-induced differentiation-associated protein 1 1.5 
GDAP1L1 ganglioside-induced differentiation-associated protein 1-like 1 1.7 
GDF1 growth differentiation factor 1 2.1 
GDF10 growth differentiation factor 10 1.8 
GDF15 growth differentiation factor 15 2.9 
GDI1 GDP dissociation inhibitor 1 1.5 
GFRA2 GDNF family receptor alpha 2 1.6 
GJA5 gap junction protein, alpha 5, 40kDa 1.7 
GKAP1 G kinase anchoring protein 1 1.6 
GLIPR1 GLI pathogenesis-related 1 (glioma) 1.6 
GLIS2 GLIS family zinc finger 2 1.5 
GLS glutaminase 1.6 
GNAO1 guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide O 
2.4 
GNAQ guanine nucleotide binding protein (G protein), q polypeptide 1.5 
GNB5 guanine nucleotide binding protein (G protein), beta 5 1.5 
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GNG2 guanine nucleotide binding protein (G protein), gamma 2 2.3 
GNG3 guanine nucleotide binding protein (G protein), gamma 3 3.3 
GNG4 guanine nucleotide binding protein (G protein), gamma 4 1.5 
GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and beta 
subunits 
1.4 
GNS glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) 1.4 
GPC2 glypican 2 2.0 
GPM6B glycoprotein M6B 1.9 
GPNMB glycoprotein (transmembrane) nmb 2.0 
GPR124 G protein-coupled receptor 124 1.5 
GPR137B G protein-coupled receptor 137B 2.0 
GPR160 G protein-coupled receptor 160 1.4 
GPR161 G protein-coupled receptor 161 1.5 
GPR176 G protein-coupled receptor 176 1.5 
GPR22 G protein-coupled receptor 22 1.8 
GPR56 G protein-coupled receptor 56 1.5 
GPR64 G protein-coupled receptor 64 1.9 
GPR68 G protein-coupled receptor 68 1.5 
GPR83 G protein-coupled receptor 83 1.6 
GPR85 G protein-coupled receptor 85 1.6 
GPRC5A G protein-coupled receptor, family C, group 5, member A 1.5 
GRB10 growth factor receptor-bound protein 10 1.5 
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 1.7 
GRIA1 glutamate receptor, ionotropic, AMPA 1 1.5 
GRIA2 glutamate receptor, ionotropic, AMPA 2 2.0 
GRK4 G protein-coupled receptor kinase 4 1.5 
GRK5 G protein-coupled receptor kinase 5 1.9 
H2AFY2 H2A histone family, member Y2 1.5 
HBEGF heparin-binding EGF-like growth factor 1.9 
HBP1 HMG-box transcription factor 1 1.5 
HEBP2 heme binding protein 2 3.4 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 1.4 
HERV-FRD HERV-FRD provirus ancestral Env polyprotein 1.8 
HEY1 hairy/enhancer-of-split related with YRPW motif 1 1.5 
HIC1 hypermethylated in cancer 1 1.7 
HIST2H2BE histone cluster 2, H2be 1.7 
HIVEP2 human immunodeficiency virus type I enhancer binding protein 2 1.4 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 1.7 
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 2.2 
HMGCL 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
(hydroxymethylglutaricaciduria) 
1.4 
HOMER3 homer homolog 3 (Drosophila) 1.5 
HOXA5 homeobox A5 2.0 
HOXC4 homeobox C4 1.5 
HOXD1 homeobox D1 1.9 
HOXD10 homeobox D10 2.5 
HOXD11 homeobox D11 1.5 
HOXD4 homeobox D4 1.8 
HOXD9 homeobox D9 1.8 
HPCAL1 hippocalcin-like 1 1.6 
HRASLS3 HRAS-like suppressor 3 1.7 
HRH1 histamine receptor H1 1.6 
HS6ST3 heparan sulfate 6-O-sulfotransferase 3 1.7 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 2.4 
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HSPB8 heat shock 22kDa protein 8 1.4 
HTN1 histatin 1 2.0 
HTN3 histatin 3 1.8 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 3.2 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 2.0 
IDS iduronate 2-sulfatase (Hunter syndrome) 1.5 
IER3 immediate early response 3 1.7 
IFI16 interferon, gamma-inducible protein 16 1.7 
IFNAR2 interferon (alpha, beta and omega) receptor 2 1.5 
IGF2 insulin-like growth factor 2 (somatomedin A) 2.0 
IGF2R insulin-like growth factor 2 receptor 1.4 
IGFBP3 insulin-like growth factor binding protein 3 2.6 
IGFBP5 insulin-like growth factor binding protein 5 1.9 
IGFBP6 insulin-like growth factor binding protein 6 1.9 
IGH immunoglobulin heavy locus 2.1 
IGSF11 immunoglobulin superfamily, member 11 1.8 
IL13RA1 interleukin 13 receptor, alpha 1 1.5 
IL17D interleukin 17D 1.8 
INHBA inhibin, beta A 2.5 
INSC inscuteable homolog (Drosophila) 1.5 
INSM1 insulinoma-associated 1 1.6 
IRF9 interferon regulatory factor 9 1.7 
ISYNA1 myo-inositol 1-phosphate synthase A1 1.6 
ITGA1 integrin, alpha 1 5.7 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.5 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 
receptor) 
2.2 
JAG1 jagged 1 (Alagille syndrome) 1.5 
JARID1B jumonji, AT rich interactive domain 1B 2.9 
JARID2 jumonji, AT rich interactive domain 2 1.8 
JMJD1A jumonji domain containing 1A 1.6 
JMJD2B jumonji domain containing 2B 1.5 
JMJD2C jumonji domain containing 2C 1.5 
JMJD3 jumonji domain containing 3, histone lysine demethylase 1.5 
JPH3 junctophilin 3 1.8 
JUB jub, ajuba homolog (Xenopus laevis) 1.7 
JUND jun D proto-oncogene 1.4 
JUP junction plakoglobin 1.7 
KALRN kalirin, RhoGEF kinase 1.6 
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 1.4 
KCNA3 potassium voltage-gated channel, shaker-related subfamily, 
member 3 
1.7 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 
3.0 
KCNIP4 Kv channel interacting protein 4 1.6 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 2.2 
KCNMA1 potassium large conductance calcium-activated channel, subfamily 
M, alpha member 1 
1.9 
KCNMB4 potassium large conductance calcium-activated channel, subfamily 
M, beta member 4 
1.7 
KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member 2 1.5 
KCNT2 potassium channel, subfamily T, member 2 1.5 
KCTD13 potassium channel tetramerisation domain containing 13 1.7 
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 1.7 
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KIAA0513 KIAA0513 1.5 
KIAA0746 KIAA0746 protein 1.7 
KIAA1109 KIAA1109 1.4 
KIAA1199 KIAA1199 1.5 
KIDINS220 kinase D-interacting substrate of 220 kDa 1.6 
KIF13B kinesin family member 13B 1.5 
KIF1A kinesin family member 1A 1.5 
KIF1B kinesin family member 1B 2.2 
KIF3A kinesin family member 3A 1.5 
KIF3C kinesin family member 3C 1.9 
KIF5A kinesin family member 5A 1.7 
KIF5C kinesin family member 5C 2.2 
KIFAP3 kinesin-associated protein 3 2.1 
KIRREL kin of IRRE like (Drosophila) 1.4 
KLC1 kinesin light chain 1 2.2 
KLF5 Kruppel-like factor 5 (intestinal) 1.5 
KLF7 Kruppel-like factor 7 (ubiquitous) 1.5 
KLHDC9 kelch domain containing 9 1.5 
KLHL13 kelch-like 13 (Drosophila) 1.6 
KLHL24 kelch-like 24 (Drosophila) 1.4 
KLHL7 kelch-like 7 (Drosophila) 2.0 
KRT18 keratin 18 6.5 
KRT7 keratin 7 1.6 
KRT86 keratin 86 1.5 
LAMP2 lysosomal-associated membrane protein 2 1.4 
LAPTM4A lysosomal-associated protein transmembrane 4 alpha 1.4 
LARP6 La ribonucleoprotein domain family, member 6 1.9 
LASP1 LIM and SH3 protein 1 1.8 
LASS5 LAG1 homolog, ceramide synthase 5 1.5 
LATS2 LATS, large tumor suppressor, homolog 2 (Drosophila) 1.6 
LBH limb bud and heart development homolog (mouse) 2.5 
LCOR ligand dependent nuclear receptor corepressor 1.7 
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 1.9 
LEF1 lymphoid enhancer-binding factor 1 1.6 
LGALS3 lectin, galactoside-binding, soluble, 3 2.0 
LHFPL2 lipoma HMGIC fusion partner-like 2 2.2 
LIN7B lin-7 homolog B (C. elegans) 1.4 
LMBRD1 LMBR1 domain containing 1 1.9 
LMO3 LIM domain only 3 (rhombotin-like 2) 2.1 
LOC57228 small trans-membrane and glycosylated protein 1.8 
LONRF2 LON peptidase N-terminal domain and ring finger 2 2.2 
LOXL2 lysyl oxidase-like 2 1.6 
LPHN1 latrophilin 1 1.4 
LRP12 low density lipoprotein-related protein 12 1.5 
LRRC15 leucine rich repeat containing 15 1.4 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 1.9 
LRRN3 leucine rich repeat neuronal 3 1.6 
LTB4DH leukotriene B4 12-hydroxydehydrogenase 1.7 
LTBP1 latent transforming growth factor beta binding protein 1 2.2 
LTBP3 latent transforming growth factor beta binding protein 3 2.1 
LTK leukocyte receptor tyrosine kinase 1.4 
LYST lysosomal trafficking regulator 1.7 
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MAB21L1 mab-21-like 1 (C. elegans) 1.4 
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) 
1.4 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
(avian) 
1.5 
MAFK v-maf musculoaponeurotic fibrosarcoma oncogene homolog K 
(avian) 
2.6 
MAGED2 melanoma antigen family D, 2 1.7 
MAGEH1 melanoma antigen family H, 1 1.4 
MAML3 mastermind-like 3 (Drosophila) 1.5 
MAOA monoamine oxidase A 1.8 
MAP1B microtubule-associated protein 1B 1.8 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha 1.4 
MAP1LC3B microtubule-associated protein 1 light chain 3 beta 2.4 
MAP3K13 mitogen-activated protein kinase kinase kinase 13 1.7 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 1.6 
MAP3K9 mitogen-activated protein kinase kinase kinase 9 2.0 
MAP4 microtubule-associated protein 4 2.1 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 1.4 
MAP6 microtubule-associated protein 6 1.5 
MAPK10 mitogen-activated protein kinase 10 1.5 
MAPK8 mitogen-activated protein kinase 8 1.6 
MAPKAPK3 mitogen-activated protein kinase-activated protein kinase 3 1.8 
MAPRE2 microtubule-associated protein, RP/EB family, member 2 1.4 
MAPRE3 microtubule-associated protein, RP/EB family, member 3 1.5 
MAPT microtubule-associated protein tau 2.3 
MARCH6 membrane-associated ring finger (C3HC4) 6 1.4 
MARCKSL1 MARCKS-like 1 1.6 
MAST1 microtubule associated serine/threonine kinase 1 1.5 
MAST4 microtubule associated serine/threonine kinase family member 4 1.8 
MATN2 matrilin 2 1.5 
MBNL3 muscleblind-like 3 (Drosophila) 1.7 
MCC mutated in colorectal cancers 1.8 
MCF2L MCF.2 cell line derived transforming sequence-like 1.8 
MDK midkine (neurite growth-promoting factor 2) 2.3 
MEIS1 Meis homeobox 1 2.3 
MEIS3 Meis homeobox 3 2.0 
MEST mesoderm specific transcript homolog (mouse) 14.2 
MGAT3 mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase 
1.5 
MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 
1.6 
MGP matrix Gla protein 7.8 
MGST3 microsomal glutathione S-transferase 3 1.9 
MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 homolog 
(zebrafish)) 
1.4 
MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 11 
1.8 
MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4 
1.4 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.0 
MMP11 matrix metallopeptidase 11 (stromelysin 3) 1.5 
MMP15 matrix metallopeptidase 15 (membrane-inserted) 1.5 
MOAP1 modulator of apoptosis 1 1.5 
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MOXD1 monooxygenase, DBH-like 1 2.2 
MRAS muscle RAS oncogene homolog 1.4 
MSRB3 methionine sulfoxide reductase B3 1.4 
MTA3 metastasis associated 1 family, member 3 1.6 
MUC12 mucin 12, cell surface associated 1.7 
MYADM myeloid-associated differentiation marker 2.4 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 2.3 
MYLK myosin light chain kinase 1.9 
MYO5A myosin VA (heavy chain 12, myoxin) 2.1 
MYO6 myosin VI 1.6 
MYPN myopalladin 1.7 
MYRIP myosin VIIA and Rab interacting protein 1.9 
MYST4 MYST histone acetyltransferase (monocytic leukemia) 4 1.5 
N4BP2L2 NEDD4 binding protein 2-like 2 1.4 
NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 1.6 
NANOS1 nanos homolog 1 (Drosophila) 1.6 
NAP1L2 nucleosome assembly protein 1-like 2 2.0 
NAP1L5 nucleosome assembly protein 1-like 5 1.4 
NAV2 neuron navigator 2 1.4 
NBEA neurobeachin 1.8 
NCAM1 neural cell adhesion molecule 1 1.6 
NCAM2 neural cell adhesion molecule 2 2.4 
NCOA3 nuclear receptor coactivator 3 1.5 
NCOA7 nuclear receptor coactivator 7 1.6 
NDN necdin homolog (mouse) 1.7 
NDRG4 NDRG family member 4 2.2 
NEBL nebulette 1.6 
NEDD9 neural precursor cell expressed, developmentally down-regulated 9 1.6 
NEIL2 nei like 2 (E. coli) 1.5 
NELL2 NEL-like 2 (chicken) 3.5 
NEO1 neogenin homolog 1 (chicken) 1.4 
NEURL2 neuralized homolog 2 (Drosophila) 1.4 
NFASC neurofascin homolog (chicken) 1.5 
NFIB nuclear factor I/B 1.5 
NFIL3 nuclear factor, interleukin 3 regulated 2.2 
NGB neuroglobin 1.5 
NGFR nerve growth factor receptor (TNFR superfamily, member 16) 2.0 
NID1 nidogen 1 1.9 
NIPSNAP3A nipsnap homolog 3A (C. elegans) 1.5 
NLRP1 NLR family, pyrin domain containing 1 2.1 
NNMT nicotinamide N-methyltransferase 1.9 
NOTCH2 Notch homolog 2 (Drosophila) 2.3 
NOVA1 neuro-oncological ventral antigen 1 1.6 
NPC2 Niemann-Pick disease, type C2 3.2 
NPPA natriuretic peptide precursor A 1.5 
NPPB natriuretic peptide precursor B 3.5 
NPR1 natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic 
peptide receptor A) 
1.5 
NPTX1 neuronal pentraxin I 1.4 
NPTX2 neuronal pentraxin II 2.5 
NR0B1 nuclear receptor subfamily 0, group B, member 1 5.5 
NR0B2 nuclear receptor subfamily 0, group B, member 2 1.4 
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor) 
1.5 
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NRG1 neuregulin 1 1.5 
NRG3 neuregulin 3 1.9 
NRXN2 neurexin 2 1.4 
NT5E 5'-nucleotidase, ecto (CD73) 2.2 
NTNG2 netrin G2 1.5 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 1.4 
NUAK1 NUAK family, SNF1-like kinase, 1 3.0 
OLFM3 olfactomedin 3 1.6 
OLFML3 olfactomedin-like 3 2.0 
ONECUT2 one cut homeobox 2 1.5 
OPTN optineurin 1.8 
OSBPL8 oxysterol binding protein-like 8 1.4 
OSTF1 osteoclast stimulating factor 1 2.9 
P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide II 
1.4 
PACSIN2 protein kinase C and casein kinase substrate in neurons 2 1.5 
PAK3 p21 (CDKN1A)-activated kinase 3 1.5 
PAK7 p21(CDKN1A)-activated kinase 7 1.5 
PALM paralemmin 1.9 
PANX1 pannexin 1 1.5 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 1.6 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.5 
PART1 prostate androgen-regulated transcript 1 1.5 
PBX3 pre-B-cell leukemia homeobox 3 1.9 
PBXIP1 pre-B-cell leukemia homeobox interacting protein 1 1.4 
PCBP4 poly(rC) binding protein 4 1.7 
PCDH7 protocadherin 7 1.7 
PCDHA9 protocadherin alpha 9 1.8 
PCDHB9 protocadherin beta 9 1.5 
PCNXL2 pecanex-like 2 (Drosophila) 1.4 
PCSK1N proprotein convertase subtilisin/kexin type 1 inhibitor 2.8 
PCSK5 proprotein convertase subtilisin/kexin type 5 1.5 
PDE11A phosphodiesterase 11A 1.5 
PDE4DIP phosphodiesterase 4D interacting protein (myomegalin) 1.5 
PDE5A phosphodiesterase 5A, cGMP-specific 1.4 
PDLIM5 PDZ and LIM domain 5 1.8 
PDLIM7 PDZ and LIM domain 7 (enigma) 1.5 
PDZD2 PDZ domain containing 2 1.7 
PDZK1 PDZ domain containing 1 2.4 
PECI peroxisomal D3,D2-enoyl-CoA isomerase 1.6 
PELI1 pellino homolog 1 (Drosophila) 1.5 
PGAM2 phosphoglycerate mutase 2 (muscle) 1.9 
PGM2L1 phosphoglucomutase 2-like 1 2.5 
PGPEP1 pyroglutamyl-peptidase I 1.5 
PHLDA2 pleckstrin homology-like domain, family A, member 2 1.9 
PHLDB2 pleckstrin homology-like domain, family B, member 2 1.7 
PHOX2A paired-like homeobox 2a 1.6 
PHOX2B paired-like homeobox 2b 1.7 
PI15 peptidase inhibitor 15 2.5 
PID1 phosphotyrosine interaction domain containing 1 1.4 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 2.3 
PIPOX pipecolic acid oxidase 1.7 
PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 1.8 
PITPNM1 phosphatidylinositol transfer protein, membrane-associated 1 1.5 
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PKIA protein kinase (cAMP-dependent, catalytic) inhibitor alpha 1.6 
PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma 1.5 
PLAT plasminogen activator, tissue 3.3 
PLAUR plasminogen activator, urokinase receptor 1.4 
PLB1 phospholipase B1 1.4 
PLD3 phospholipase D family, member 3 2.1 
PLEKHA5 pleckstrin homology domain containing, family A member 5 1.4 
PLEKHA6 pleckstrin homology domain containing, family A member 6 4.2 
PLK2 polo-like kinase 2 (Drosophila) 8.3 
PLSCR3 phospholipid scramblase 3 1.6 
PLXNA2 plexin A2 3.0 
PLXNA3 plexin A3 1.5 
PLXNB1 plexin B1 1.5 
PNMAL1 PNMA-like 1 1.5 
PNOC prepronociceptin 1.5 
PNRC1 proline-rich nuclear receptor coactivator 1 1.7 
PPAP2A phosphatidic acid phosphatase type 2A 1.6 
PPAP2B phosphatidic acid phosphatase type 2B 1.6 
PPAPDC1A phosphatidic acid phosphatase type 2 domain containing 1A 3.3 
PPARG peroxisome proliferator-activated receptor gamma 1.8 
PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) 1.4 
PPIC peptidylprolyl isomerase C (cyclophilin C) 1.6 
PPM2C protein phosphatase 2C, magnesium-dependent, catalytic subunit 1.6 
PPP1R14A protein phosphatase 1, regulatory (inhibitor) subunit 14A 1.4 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A 1.4 
PPP2R2B protein phosphatase 2 (formerly 2A), regulatory subunit B, beta 
isoform 
1.5 
PPP2R2C protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma 
isoform 
1.7 
PPP2R5B protein phosphatase 2, regulatory subunit B', beta isoform 1.6 
PRAF2 PRA1 domain family, member 2 1.6 
PRCP prolylcarboxypeptidase (angiotensinase C) 1.6 
PRDM1 PR domain containing 1, with ZNF domain 2.1 
PREP prolyl endopeptidase 1.6 
PRG2 plasticity-related gene 2 1.7 
PRICKLE1 prickle homolog 1 (Drosophila) 2.6 
PRKACB protein kinase, cAMP-dependent, catalytic, beta 1.4 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 2.2 
PRKCE protein kinase C, epsilon 1.6 
PRKCH protein kinase C, eta 3.3 
PRKCZ protein kinase C, zeta 2.0 
PRNP prion protein (p27-30) (Creutzfeldt-Jakob disease, Gerstmann-
Strausler-Scheinker syndrome, fatal familial insomnia) 
1.5 
PROK2 prokineticin 2 1.5 
PROM1 prominin 1 1.4 
PRSS12 protease, serine, 12 (neurotrypsin, motopsin) 2.2 
PRSS23 protease, serine, 23 3.6 
PSAP prosaposin (variant Gaucher disease and variant metachromatic 
leukodystrophy) 
1.5 
PSCD3 pleckstrin homology, Sec7 and coiled-coil domains 3 1.5 
PSEN1 presenilin 1 (Alzheimer disease 3) 1.5 
PSEN2 presenilin 2 (Alzheimer disease 4) 1.5 
PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 1.9 
PTPN18 protein tyrosine phosphatase, non-receptor type 18 (brain-derived) 1.5 
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PTPN21 protein tyrosine phosphatase, non-receptor type 21 1.5 
PTPRE protein tyrosine phosphatase, receptor type, E 1.8 
PTPRF protein tyrosine phosphatase, receptor type, F 1.5 
PTPRH protein tyrosine phosphatase, receptor type, H 3.1 
PTPRM protein tyrosine phosphatase, receptor type, M 1.6 
PTPRN2 protein tyrosine phosphatase, receptor type, N polypeptide 2 1.8 
PTPRR protein tyrosine phosphatase, receptor type, R 1.6 
PTRF polymerase I and transcript release factor 1.5 
PTTG1IP pituitary tumor-transforming 1 interacting protein 1.5 
PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 9.0 
PURG purine-rich element binding protein G 1.8 
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) 1.5 
QPCT glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 1.4 
QPRT quinolinate phosphoribosyltransferase (nicotinate-nucleotide 
pyrophosphorylase (carboxylating)) 
1.6 
QSOX1 quiescin Q6 sulfhydryl oxidase 1 1.4 
RAB20 RAB20, member RAS oncogene family 3.5 
RAB27B RAB27B, member RAS oncogene family 1.5 
RAB2B RAB2B, member RAS oncogene family 2.0 
RAB38 RAB38, member RAS oncogene family 12.1 
RAB39B RAB39B, member RAS oncogene family 1.7 
RAB3A RAB3A, member RAS oncogene family 1.8 
RAB4B RAB4B, member RAS oncogene family 1.4 
RAB5B RAB5B, member RAS oncogene family 1.5 
RAB6B RAB6B, member RAS oncogene family 2.2 
RABAC1 Rab acceptor 1 (prenylated) 1.4 
RAI14 retinoic acid induced 14 2.5 
RALB v-ral simian leukemia viral oncogene homolog B (ras related; GTP 
binding protein) 
1.6 
RAMP1 receptor (G protein-coupled) activity modifying protein 1 1.7 
RARA retinoic acid receptor, alpha 1.6 
RARB retinoic acid receptor, beta 2.4 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 2.7 
RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 1.7 
RBM9 RNA binding motif protein 9 1.6 
RBP1 retinol binding protein 1, cellular 3.4 
RBPMS RNA binding protein with multiple splicing 1.4 
RCAN2 regulator of calcineurin 2 2.0 
RDH10 retinol dehydrogenase 10 (all-trans) 1.7 
REC8 REC8 homolog (yeast) 1.8 
REEP1 receptor accessory protein 1 3.2 
REEP2 receptor accessory protein 2 1.5 
REG3G regenerating islet-derived 3 gamma 2.5 
RET ret proto-oncogene 2.4 
RFTN1 raftlin, lipid raft linker 1 1.5 
RGS16 regulator of G-protein signaling 16 1.6 
RGS4 regulator of G-protein signaling 4 2.5 
RHBDD2 rhomboid domain containing 2 1.4 
RHOBTB3 Rho-related BTB domain containing 3 1.4 
RHOC ras homolog gene family, member C 1.7 
RIT2 Ras-like without CAAX 2 1.8 
RNASEL ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 1.5 
RND3 Rho family GTPase 3 2.7 
RNF103 ring finger protein 103 1.4 
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RNF11 ring finger protein 11 1.7 
RNF146 ring finger protein 146 1.5 
RNF19A ring finger protein 19A 1.5 
RNF24 ring finger protein 24 1.5 
ROR1 receptor tyrosine kinase-like orphan receptor 1 1.5 
RP1-21O18.1 kazrin 1.5 
RP4-691N24.1 ninein-like 1.7 
RSL1D1 ribosomal L1 domain containing 1 1.5 
RTN1 reticulon 1 2.1 
RTN2 reticulon 2 1.5 
RUFY2 RUN and FYVE domain containing 2 1.5 
RUFY3 RUN and FYVE domain containing 3 2.3 
RUSC2 RUN and SH3 domain containing 2 1.5 
RYBP RING1 and YY1 binding protein 1.6 
S100A10 S100 calcium binding protein A10 2.0 
S100A13 S100 calcium binding protein A13 1.8 
S100A16 S100 calcium binding protein A16 2.0 
SALL2 sal-like 2 (Drosophila) 1.4 
SAMD9 sterile alpha motif domain containing 9 1.5 
SAMD9L sterile alpha motif domain containing 9-like 1.7 
SBK1 SH3-binding domain kinase 1 2.4 
SCARB2 scavenger receptor class B, member 2 1.6 
SCG2 secretogranin II (chromogranin C) 1.7 
SCG5 secretogranin V (7B2 protein) 3.6 
SCN2A sodium channel, voltage-gated, type II, alpha subunit 1.6 
SCN3A sodium channel, voltage-gated, type III, alpha subunit 2.6 
SCOC short coiled-coil protein 1.7 
SCRG1 scrapie responsive protein 1 2.4 
SDC3 syndecan 3 1.4 
SDC4 syndecan 4 1.7 
SDCBP syndecan binding protein (syntenin) 1.8 
SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
1.5 
SEMA4F sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4F 
1.5 
SEPT3 septin 3 2.3 
SEPT6 septin 6 1.7 
SEPT8 septin 8 1.8 
SERINC1 serine incorporator 1 1.9 
SERINC3 serine incorporator 3 1.7 
SERP2 stress-associated endoplasmic reticulum protein family member 2 1.8 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 1.6 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
1.9 
SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 2 
1.4 
SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 1.6 
SFXN3 sideroflexin 3 1.5 
SGCB sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 1.4 
SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 2.2 
SH2D3C SH2 domain containing 3C 1.5 
SH3BGRL SH3 domain binding glutamic acid-rich protein like 1.9 
SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 2 1.6 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 2.3 
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SH3D19 SH3 domain containing 19 1.4 
SH3KBP1 SH3-domain kinase binding protein 1 1.5 
SH3PXD2A SH3 and PX domains 2A 1.5 
SHANK3 SH3 and multiple ankyrin repeat domains 3 1.9 
SHC1 SHC (Src homology 2 domain containing) transforming protein 1 1.6 
SHC2 SHC (Src homology 2 domain containing) transforming protein 2 1.9 
SIGIRR single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 2.1 
SKAP2 src kinase associated phosphoprotein 2 1.4 
SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 
6 
1.4 
SLC16A2 solute carrier family 16, member 2 (monocarboxylic acid transporter 
8) 
1.4 
SLC17A5 solute carrier family 17 (anion/sugar transporter), member 5 1.6 
SLC18A3 solute carrier family 18 (vesicular acetylcholine), member 3 1.5 
SLC22A17 solute carrier family 22, member 17 1.7 
SLC23A2 solute carrier family 23 (nucleobase transporters), member 2 1.4 
SLC25A24 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 24 
1.6 
SLC27A6 solute carrier family 27 (fatty acid transporter), member 6 1.6 
SLC30A3 solute carrier family 30 (zinc transporter), member 3 1.5 
SLC35D2 solute carrier family 35, member D2 1.4 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 1.7 
SLC44A2 solute carrier family 44, member 2 1.4 
SLC47A1 solute carrier family 47, member 1 1.5 
SLC6A17 solute carrier family 6, member 17 2.0 
SLIT2 slit homolog 2 (Drosophila) 4.2 
SLITRK6 SLIT and NTRK-like family, member 6 1.6 
SMAD1 SMAD family member 1 1.6 
SMAD3 SMAD family member 3 1.5 
SMARCA1 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1 
1.4 
SMARCD3 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 3 
1.5 
SMOX spermine oxidase 1.4 
SMPD3 sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 
1.5 
SMURF2 SMAD specific E3 ubiquitin protein ligase 2 1.5 
SMYD3 SET and MYND domain containing 3 1.5 
SNAI2 snail homolog 2 (Drosophila) 1.4 
SNAP25 synaptosomal-associated protein, 25kDa 2.1 
SNCG synuclein, gamma (breast cancer-specific protein 1) 1.4 
SNIP SNAP25-interacting protein 1.5 
SNN stannin 1.8 
SNRPN small nuclear ribonucleoprotein polypeptide N 1.4 
SOCS2 suppressor of cytokine signaling 2 2.9 
SOCS5 suppressor of cytokine signaling 5 1.5 
SOCS6 suppressor of cytokine signaling 6 1.8 
SOHLH2 spermatogenesis and oogenesis specific basic helix-loop-helix 2 1.4 
SORCS2 sortilin-related VPS10 domain containing receptor 2 2.6 
SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 2.7 
SOX11 SRY (sex determining region Y)-box 11 1.6 
SOX4 SRY (sex determining region Y)-box 4 1.8 
SOX9 SRY (sex determining region Y)-box 9 (campomelic dysplasia, 
autosomal sex-reversal) 
1.4 
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SPARC secreted protein, acidic, cysteine-rich (osteonectin) 2.5 
SPARCL1 SPARC-like 1 (mast9, hevin) 1.4 
SPG3A spastic paraplegia 3A (autosomal dominant) 1.5 
SPIN1 spindlin 1 1.5 
SPINK5 serine peptidase inhibitor, Kazal type 5 1.5 
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 1 
1.7 
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 2 
1.6 
SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early 
T-lymphocyte activation 1) 
1.7 
SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 1.6 
SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 1.6 
SRA1 steroid receptor RNA activator 1 1.6 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian) 
1.4 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 1.4 
SRPX sushi-repeat-containing protein, X-linked 1.5 
SRrp35 serine-arginine repressor protein (35 kDa) 1.6 
SST somatostatin 6.0 
SSTR2 somatostatin receptor 2 1.5 
ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 3 
1.8 
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 1.9 
STAU2 staufen, RNA binding protein, homolog 2 (Drosophila) 1.6 
STC1 stanniocalcin 1 1.7 
STK17A serine/threonine kinase 17a 1.6 
STK32B serine/threonine kinase 32B 2.5 
STMN2 stathmin-like 2 1.8 
STMN4 stathmin-like 4 5.5 
STX12 syntaxin 12 1.7 
STX7 syntaxin 7 1.5 
STX8 syntaxin 8 1.5 
STXBP1 syntaxin binding protein 1 1.6 
SUCNR1 succinate receptor 1 5.0 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 1.9 
SULT4A1 sulfotransferase family 4A, member 1 1.9 
SYN1 synapsin I 1.5 
SYNGR1 synaptogyrin 1 1.7 
SYNGR3 synaptogyrin 3 3.1 
SYNJ2 synaptojanin 2 1.5 
SYNPO synaptopodin 1.4 
SYNPO2 synaptopodin 2 1.9 
SYT1 synaptotagmin I 1.6 
SYT11 synaptotagmin XI 2.4 
SYT4 synaptotagmin IV 2.2 
SYT5 synaptotagmin V 1.7 
TAGLN transgelin 7.3 
TAGLN3 transgelin 3 5.0 
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 1.7 
TBX2 T-box 2 1.4 
TBX3 T-box 3 (ulnar mammary syndrome) 1.7 
TCEA2 transcription elongation factor A (SII), 2 1.5 
TCEAL7 transcription elongation factor A (SII)-like 7 1.9 
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TDRD7 tudor domain containing 7 1.6 
TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 
beta) 
1.4 
TFDP2 transcription factor Dp-2 (E2F dimerization partner 2) 1.7 
TGFB1 transforming growth factor, beta 1 2.5 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 1.8 
TGFBR1 transforming growth factor, beta receptor I (activin A receptor type 
II-like kinase, 53kDa) 
1.5 
TGIF1 TGFB-induced factor homeobox 1 1.6 
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
2.5 
THBS1 thrombospondin 1 2.2 
THBS2 thrombospondin 2 2.3 
TIMP2 TIMP metallopeptidase inhibitor 2 1.7 
TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) 1.5 
TLR4 toll-like receptor 4 1.4 
TM4SF1 transmembrane 4 L six family member 1 1.7 
TM4SF4 transmembrane 4 L six family member 4 1.8 
TM7SF2 transmembrane 7 superfamily member 2 1.8 
TMEFF1 transmembrane protein with EGF-like and two follistatin-like 
domains 1 
1.6 
TMEM130 transmembrane protein 130 1.7 
TMEM2 transmembrane protein 2 1.9 
TMEM35 transmembrane protein 35 2.6 
TMEM45A transmembrane protein 45A 1.6 
TMEM59L transmembrane protein 59-like 1.6 
TMEPAI transmembrane, prostate androgen induced RNA 1.6 
TMSB10 thymosin beta 10 1.9 
TMSB4Y thymosin beta 4, Y-linked 1.6 
TMSL8 thymosin-like 8 3.3 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 1.5 
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 1.9 
TNIK TRAF2 and NCK interacting kinase 1.7 
TNRC4 trinucleotide repeat containing 4 1.8 
TNS3 tensin 3 12.4 
TOM1L2 target of myb1-like 2 (chicken) 1.5 
TOX2 TOX high mobility group box family member 2 2.4 
TP53BP1 tumor protein p53 binding protein 1 1.4 
TP53I3 tumor protein p53 inducible protein 3 1.6 
TP53INP1 tumor protein p53 inducible nuclear protein 1 2.6 
TP53INP2 tumor protein p53 inducible nuclear protein 2 3.0 
TPPP3 tubulin polymerization-promoting protein family member 3 2.1 
TPST1 tyrosylprotein sulfotransferase 1 2.0 
TRAF3IP2 TRAF3 interacting protein 2 1.5 
TRAK1 trafficking protein, kinesin binding 1 1.5 
TRIB2 tribbles homolog 2 (Drosophila) 1.7 
TRIM2 tripartite motif-containing 2 1.4 
TRIM36 tripartite motif-containing 36 1.7 
TRIM5 tripartite motif-containing 5 1.4 
TSC22D3 TSC22 domain family, member 3 1.5 
TSHZ1 teashirt zinc finger homeobox 1 1.6 
TSPAN13 tetraspanin 13 2.2 
TSPAN18 tetraspanin 18 1.4 
TSPAN31 tetraspanin 31 1.6 
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TSPAN5 tetraspanin 5 1.8 
TSPAN7 tetraspanin 7 1.5 
TSPAN8 tetraspanin 8 1.6 
TSPYL2 TSPY-like 2 1.8 
TTC3 tetratricopeptide repeat domain 3 1.5 
TTC8 tetratricopeptide repeat domain 8 1.6 
TUBB2B tubulin, beta 2B 1.7 
TUBB3 tubulin, beta 3 1.8 
TUSC3 tumor suppressor candidate 3 1.4 
UBE2H ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 1.5 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 1.5 
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 1.5 
UGCG UDP-glucose ceramide glucosyltransferase 1.4 
USP11 ubiquitin specific peptidase 11 1.6 
USP20 ubiquitin specific peptidase 20 1.4 
VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) 1.5 
VANGL2 vang-like 2 (van gogh, Drosophila) 1.6 
VASH1 vasohibin 1 1.4 
VAT1 vesicle amine transport protein 1 homolog (T. californica) 2.2 
VCAN versican 1.6 
VEZT vezatin, adherens junctions transmembrane protein 1.5 
VIM vimentin 1.6 
VLDLR very low density lipoprotein receptor 2.1 
VTN vitronectin 1.6 
WARS tryptophanyl-tRNA synthetase 1.7 
WDR44 WD repeat domain 44 1.4 
WSB1 WD repeat and SOCS box-containing 1 1.5 
WSCD2 WSC domain containing 2 1.5 
WWTR1 WW domain containing transcription regulator 1 1.6 
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 1.5 
XYLT1 xylosyltransferase I 2.1 
YAP1 Yes-associated protein 1, 65kDa 1.5 
YIPF5 Yip1 domain family, member 5 1.5 
YPEL1 yippee-like 1 (Drosophila) 1.5 
YPEL5 yippee-like 5 (Drosophila) 2.2 
ZBTB20 zinc finger and BTB domain containing 20 1.8 
ZBTB38 zinc finger and BTB domain containing 38 1.5 
ZDHHC2 zinc finger, DHHC-type containing 2 1.5 
ZFHX3 zinc finger homeobox 3 1.5 
ZFP90 zinc finger protein 90 homolog (mouse) 1.5 
ZFPM1 zinc finger protein, multitype 1 2.0 
ZKSCAN1 zinc finger with KRAB and SCAN domains 1 1.4 
ZNF10 zinc finger protein 10 1.4 
ZNF135 zinc finger protein 135 1.8 
ZNF177 zinc finger protein 177 1.4 
ZNF193 zinc finger protein 193 1.5 
ZNF238 zinc finger protein 238 1.7 
ZNF25 zinc finger protein 25 1.5 
ZNF587 zinc finger protein 587 1.4 
ZNF627 zinc finger protein 627 1.7 
ZNF711 zinc finger protein 711 1.5 
ZYX zyxin 1.4 
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Genes Decreased with Neuronal Differentiation 
Gene Symbol Gene Name Fold 
Change 
AATF apoptosis antagonizing transcription factor -1.6 
ABCB10 ATP-binding cassette, sub-family B (MDR/TAP), member 10 -1.9 
ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 -1.5 
ABCB9 ATP-binding cassette, sub-family B (MDR/TAP), member 9 -1.4 
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 -1.5 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -1.5 
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 -1.5 
ADAMTS17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 -1.6 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 -1.8 
ADAT2 adenosine deaminase, tRNA-specific 2, TAD2 homolog (S. 
cerevisiae) 
-1.4 
ADRA2C adrenergic, alpha-2C-, receptor -2.0 
AEBP2 AE binding protein 2 -1.5 
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic 
acid acyltransferase, beta) 
-1.6 
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic 
acid acyltransferase, epsilon) 
-1.4 
AHCTF1 AT hook containing transcription factor 1 -1.5 
AK1 adenylate kinase 1 -1.4 
AK2 adenylate kinase 2 -1.5 
ALDH18A1 aldehyde dehydrogenase 18 family, member A1 -1.4 
AMD1 adenosylmethionine decarboxylase 1 -1.4 
ANLN anillin, actin binding protein -1.7 
ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 family, member B -1.6 
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E -1.5 
ARF6 ADP-ribosylation factor 6 -1.4 
ARHGAP10 Rho GTPase activating protein 10 -1.8 
ARL5A ADP-ribosylation factor-like 5A -1.4 
ARS2 arsenate resistance protein 2 -1.5 
ASAM adipocyte-specific adhesion molecule -1.7 
ASPH aspartate beta-hydroxylase -1.5 
ASPM asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila) 
-1.7 
ASXL1 additional sex combs like 1 (Drosophila) -1.6 
ATAD2 ATPase family, AAA domain containing 2 -1.8 
ATAD3A ATPase family, AAA domain containing 3A -1.6 
ATAD5 ATPase family, AAA domain containing 5 -1.6 
ATF1 activating transcription factor 1 -1.5 
ATG3 ATG3 autophagy related 3 homolog (S. cerevisiae) -1.6 
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
-1.7 
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta 
subunit 
-1.4 
ATP5G1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
C1 (subunit 9) 
-1.5 
ATPBD4 ATP binding domain 4 -1.8 
ATR ataxia telangiectasia and Rad3 related -1.5 
ATXN7 ataxin 7 -1.4 
AURKA aurora kinase A -1.8 
AURKAIP1 aurora kinase A interacting protein 1 -1.5 
AURKB aurora kinase B -1.9 
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B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 -1.5 
BAALC brain and acute leukemia, cytoplasmic -1.6 
BAG3 BCL2-associated athanogene 3 -1.5 
BARD1 BRCA1 associated RING domain 1 -1.7 
BAZ1A bromodomain adjacent to zinc finger domain, 1A -1.5 
BCCIP BRCA2 and CDKN1A interacting protein -1.5 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) -1.6 
BDH1 3-hydroxybutyrate dehydrogenase, type 1 -1.5 
BIRC5 baculoviral IAP repeat-containing 5 (survivin) -1.7 
BLM Bloom syndrome -1.4 
BRCA1 breast cancer 1, early onset -1.6 
BRCA2 breast cancer 2, early onset -1.5 
BRMS1 breast cancer metastasis suppressor 1 -1.5 
BRP44L brain protein 44-like -1.5 
BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta 
(yeast) 
-1.6 
BXDC2 brix domain containing 2 -1.5 
BZW2 basic leucine zipper and W2 domains 2 -1.5 
C10orf119 chromosome 10 open reading frame 119 -1.5 
C10orf2 chromosome 10 open reading frame 2 -1.4 
C13orf34 chromosome 13 open reading frame 34 -1.6 
C17orf79 chromosome 17 open reading frame 79 -1.5 
C17orf81 chromosome 17 open reading frame 81 -1.8 
C19orf48 chromosome 19 open reading frame 48 -1.5 
C1orf107 chromosome 1 open reading frame 107 -1.4 
C1orf43 chromosome 1 open reading frame 43 -1.9 
C1QBP complement component 1, q subcomponent binding protein -1.7 
C20orf20 chromosome 20 open reading frame 20 -1.6 
C21orf45 chromosome 21 open reading frame 45 -1.6 
C6orf153 chromosome 6 open reading frame 153 -1.4 
C6orf159 chromosome 6 open reading frame 159 -1.6 
C6orf173 chromosome 6 open reading frame 173 -1.8 
C6orf66 chromosome 6 open reading frame 66 -1.7 
C7orf23 chromosome 7 open reading frame 23 -1.5 
CABC1 chaperone, ABC1 activity of bc1 complex homolog (S. pombe) -1.6 
CABLES1 Cdk5 and Abl enzyme substrate 1 -1.5 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 -1.8 
CACNG4 calcium channel, voltage-dependent, gamma subunit 4 -1.6 
CACYBP calcyclin binding protein -1.5 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
-1.6 
CALML4 calmodulin-like 4 -1.6 
CAMK4 calcium/calmodulin-dependent protein kinase IV -1.5 
CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha -1.5 
CARD9 caspase recruitment domain family, member 9 -1.6 
CASC5 cancer susceptibility candidate 5 -1.5 
CASP3 caspase 3, apoptosis-related cysteine peptidase -1.7 
CASP7 caspase 7, apoptosis-related cysteine peptidase -1.5 
CBLB Cas-Br-M (murine) ecotropic retroviral transforming sequence b -1.4 
CBX3 chromobox homolog 3 (HP1 gamma homolog, Drosophila) -1.4 
CBX5 chromobox homolog 5 (HP1 alpha homolog, Drosophila) -1.4 
CCDC59 coiled-coil domain containing 59 -1.5 
CCDC85B coiled-coil domain containing 85B -1.5 
CCNA2 cyclin A2 -1.5 
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CCNB1 cyclin B1 -1.7 
CCNB2 cyclin B2 -1.6 
CCNC cyclin C -1.6 
CCNE2 cyclin E2 -1.7 
CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) -1.5 
CD320 CD320 molecule -1.4 
CD3EAP CD3e molecule, epsilon associated protein -1.7 
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) -1.5 
CDC2 cell division cycle 2, G1 to S and G2 to M -1.5 
CDC20 cell division cycle 20 homolog (S. cerevisiae) -1.9 
CDC25A cell division cycle 25 homolog A (S. pombe) -1.6 
CDC45L CDC45 cell division cycle 45-like (S. cerevisiae) -1.5 
CDC6 cell division cycle 6 homolog (S. cerevisiae) -1.7 
CDC7 cell division cycle 7 homolog (S. cerevisiae) -1.4 
CDCA2 cell division cycle associated 2 -1.5 
CDCA3 cell division cycle associated 3 -1.6 
CDCA4 cell division cycle associated 4 -1.5 
CDCA7 cell division cycle associated 7 -1.8 
CDCA7L cell division cycle associated 7-like -2.3 
CDCA8 cell division cycle associated 8 -1.5 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) -1.5 
CDK2 cyclin-dependent kinase 2 -1.4 
CDKAL1 CDK5 regulatory subunit associated protein 1-like 1 -1.6 
CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) 
-1.7 
CDON Cdon homolog (mouse) -1.8 
CDT1 chromatin licensing and DNA replication factor 1 -1.6 
CENPA centromere protein A -1.6 
CENPB centromere protein B, 80kDa -1.4 
CENPE centromere protein E, 312kDa -1.6 
CENPF centromere protein F, 350/400ka (mitosin) -1.5 
CENPK centromere protein K -1.8 
CENPM centromere protein M -1.9 
CENPN centromere protein N -1.6 
CEP55 centrosomal protein 55kDa -1.5 
CHAF1A chromatin assembly factor 1, subunit A (p150) -1.4 
CHAF1B chromatin assembly factor 1, subunit B (p60) -1.5 
CHCHD3 coiled-coil-helix-coiled-coil-helix domain containing 3 -1.6 
CHCHD4 coiled-coil-helix-coiled-coil-helix domain containing 4 -1.4 
CHD1L chromodomain helicase DNA binding protein 1-like -1.4 
CHEK1 CHK1 checkpoint homolog (S. pombe) -1.4 
CHEK2 CHK2 checkpoint homolog (S. pombe) -1.6 
CHERP calcium homeostasis endoplasmic reticulum protein -1.4 
CHORDC1 cysteine and histidine-rich domain (CHORD)-containing 1 -1.6 
CHPT1 choline phosphotransferase 1 -1.5 
CHRAC1 chromatin accessibility complex 1 -1.5 
CHTF18 CTF18, chromosome transmission fidelity factor 18 homolog (S. 
cerevisiae) 
-1.6 
CINP cyclin-dependent kinase 2-interacting protein -1.5 
CKS2 CDC28 protein kinase regulatory subunit 2 -1.7 
CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant -1.8 
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1, cytosolic -1.5 
CMTM7 CKLF-like MARVEL transmembrane domain containing 7 -1.8 
CNBP CCHC-type zinc finger, nucleic acid binding protein -1.5 
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CNDP2 CNDP dipeptidase 2 (metallopeptidase M20 family) -1.4 
CNTNAP2 contactin associated protein-like 2 -1.4 
COASY Coenzyme A synthase -1.6 
COQ2 coenzyme Q2 homolog, prenyltransferase (yeast) -1.5 
COQ3 coenzyme Q3 homolog, methyltransferase (S. cerevisiae) -1.6 
CPLX2 complexin 2 -1.7 
CPNE2 copine II -1.4 
CPNE8 copine VIII -1.8 
CPOX coproporphyrinogen oxidase -1.5 
CREB3L2 cAMP responsive element binding protein 3-like 2 -1.5 
CRIP1 cysteine-rich protein 1 (intestinal) -2.5 
CRTAP cartilage associated protein -1.5 
CRY1 cryptochrome 1 (photolyase-like) -1.4 
CSE1L CSE1 chromosome segregation 1-like (yeast) -1.5 
CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase-like 
-1.5 
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 -2.0 
CTNNBL1 catenin, beta like 1 -1.5 
CTPS CTP synthase -1.5 
CWF19L2 CWF19-like 2, cell cycle control (S. pombe) -1.4 
CYC1 cytochrome c-1 -1.6 
CYGB cytoglobin -2.1 
DARS aspartyl-tRNA synthetase -1.4 
DAXX death-associated protein 6 -1.4 
DAZAP1 DAZ associated protein 1 -1.5 
DBF4 DBF4 homolog (S. cerevisiae) -1.5 
DBR1 debranching enzyme homolog 1 (S. cerevisiae) -1.5 
DDN dendrin -1.6 
DDT D-dopachrome tautomerase -1.5 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like 
helicase homolog, S. cerevisiae) 
-1.7 
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 -1.5 
DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 -1.5 
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 -1.6 
DEK DEK oncogene (DNA binding) -1.6 
DEPDC1 DEP domain containing 1 -1.5 
DEPDC1B DEP domain containing 1B -1.5 
DIAPH3 diaphanous homolog 3 (Drosophila) -1.4 
DKC1 dyskeratosis congenita 1, dyskerin -1.5 
DLEU1 deleted in lymphocytic leukemia, 1 -1.4 
DLG7 discs, large homolog 7 (Drosophila) -1.6 
DLK1 delta-like 1 homolog (Drosophila) -2.2 
DNA2 DNA replication helicase 2 homolog (yeast) -1.5 
DNPEP aspartyl aminopeptidase -1.5 
DOK4 docking protein 4 -1.9 
DPP9 dipeptidyl-peptidase 9 -1.5 
DRD2 dopamine receptor D2 -1.5 
DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) -1.7 
DSN1 DSN1, MIND kinetochore complex component, homolog (S. 
cerevisiae) 
-1.4 
DTL denticleless homolog (Drosophila) -1.5 
DTYMK deoxythymidylate kinase (thymidylate kinase) -1.7 
DUSP7 dual specificity phosphatase 7 -1.5 
DUT deoxyuridine triphosphatase -1.5 
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E2F1 E2F transcription factor 1 -1.5 
E2F2 E2F transcription factor 2 -1.4 
E2F8 E2F transcription factor 8 -1.7 
EBF3 early B-cell factor 3 -2.5 
EBNA1BP2 EBNA1 binding protein 2 -1.6 
ECE2 endothelin converting enzyme 2 -1.5 
ECSIT ECSIT homolog (Drosophila) -1.4 
ECT2 epithelial cell transforming sequence 2 oncogene -1.6 
EDIL3 EGF-like repeats and discoidin I-like domains 3 -2.1 
EED embryonic ectoderm development -1.4 
EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 -1.5 
EFNB1 ephrin-B1 -1.4 
EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian) 
-1.4 
EI24 etoposide induced 2.4 mRNA -1.4 
EIF2B5 eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa -1.4 
EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa -1.5 
EIF3B eukaryotic translation initiation factor 3, subunit B -1.5 
EIF3J eukaryotic translation initiation factor 3, subunit J -1.4 
EIF3M eukaryotic translation initiation factor 3, subunit M -1.6 
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 -1.4 
EIF5B eukaryotic translation initiation factor 5B -1.5 
ELMO1 engulfment and cell motility 1 -1.4 
EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) -1.7 
EMILIN1 elastin microfibril interfacer 1 -1.7 
ENDOD1 endonuclease domain containing 1 -1.5 
ENDOG endonuclease G -2.0 
ENOSF1 enolase superfamily member 1 -1.5 
ERCC6L excision repair cross-complementing rodent repair deficiency, 
complementation group 6-like 
-1.5 
ERLIN1 ER lipid raft associated 1 -1.6 
ERO1L ERO1-like (S. cerevisiae) -1.4 
ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) -1.4 
ESF1 ESF1, nucleolar pre-rRNA processing protein, homolog (S. 
cerevisiae) 
-1.6 
ESPL1 extra spindle pole bodies homolog 1 (S. cerevisiae) -1.4 
ETF1 eukaryotic translation termination factor 1 -1.4 
ETFA electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria 
II) 
-1.5 
ETFB electron-transfer-flavoprotein, beta polypeptide -1.5 
EXO1 exonuclease 1 -1.8 
EXOSC2 exosome component 2 -1.6 
EXOSC3 exosome component 3 -1.4 
EXOSC5 exosome component 5 -1.7 
EXOSC8 exosome component 8 -1.6 
EXOSC9 exosome component 9 -1.5 
EZH2 enhancer of zeste homolog 2 (Drosophila) -1.4 
FAIM Fas apoptotic inhibitory molecule -1.7 
FAM105A family with sequence similarity 105, member A -1.5 
FAM120A family with sequence similarity 120A -1.5 
FAM26B family with sequence similarity 26, member B -1.4 
FAM82C family with sequence similarity 82, member C -1.5 
FAM83D family with sequence similarity 83, member D -1.8 
FANCG Fanconi anemia, complementation group G -1.4 
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FANCI Fanconi anemia, complementation group I -1.6 
FBL fibrillarin -1.7 
FBXO5 F-box protein 5 -1.6 
FDX1 ferredoxin 1 -1.4 
FEN1 flap structure-specific endonuclease 1 -1.7 
FGFR1OP2 FGFR1 oncogene partner 2 -1.4 
FHL2 four and a half LIM domains 2 -1.4 
FIGNL1 fidgetin-like 1 -1.6 
FKBP4 FK506 binding protein 4, 59kDa -1.5 
FKBP5 FK506 binding protein 5 -1.5 
FLJ45983 FLJ45983 protein -1.7 
FOXM1 forkhead box M1 -1.9 
FOXP4 forkhead box P4 -1.5 
FRAS1 Fraser syndrome 1 -1.7 
FRMD3 FERM domain containing 3 -1.7 
FRMD4B FERM domain containing 4B -1.5 
FTSJ2 FtsJ homolog 2 (E. coli) -1.5 
FUBP3 far upstream element (FUSE) binding protein 3 -1.5 
FUSIP1 FUS interacting protein (serine/arginine-rich) 1 -1.4 
FUT9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase) -1.5 
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 -1.4 
GABRA4 gamma-aminobutyric acid (GABA) A receptor, alpha 4 -1.5 
GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 -1.5 
GALM galactose mutarotase (aldose 1-epimerase) -1.5 
GALNAC4S-
6ST 
B cell RAG associated protein -2.5 
GALNT14 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 
-2.3 
GART phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
-1.6 
GATA3 GATA binding protein 3 -5.3 
GEMIN5 gem (nuclear organelle) associated protein 5 -1.7 
GEMIN6 gem (nuclear organelle) associated protein 6 -1.4 
GINS1 GINS complex subunit 1 (Psf1 homolog) -1.9 
GLE1 GLE1 RNA export mediator homolog (yeast) -1.5 
GLO1 glyoxalase I -1.8 
GLRX2 glutaredoxin 2 -1.5 
GLRX5 glutaredoxin 5 -1.6 
GMNN geminin, DNA replication inhibitor -1.9 
GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 -1.7 
GNL2 guanine nucleotide binding protein-like 2 (nucleolar) -1.5 
GPAM glycerol-3-phosphate acyltransferase, mitochondrial -1.5 
GPATCH4 G patch domain containing 4 -1.8 
GPBAR1 G protein-coupled bile acid receptor 1 -1.5 
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) -1.5 
GPR107 G protein-coupled receptor 107 -1.4 
GPR125 G protein-coupled receptor 125 -1.4 
GRIA4 glutamate receptor, ionotrophic, AMPA 4 -2.1 
GRID1 glutamate receptor, ionotropic, delta 1 -1.8 
GRM5 glutamate receptor, metabotropic 5 -1.5 
GSPT1 G1 to S phase transition 1 -1.4 
GTF3C4 general transcription factor IIIC, polypeptide 4, 90kDa -1.5 
GTPBP4 GTP binding protein 4 -1.4 
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GTSE1 G-2 and S-phase expressed 1 -1.5 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 -1.4 
GULP1 GULP, engulfment adaptor PTB domain containing 1 -1.5 
GYG1 glycogenin 1 -1.5 
H2AFX H2A histone family, member X -1.7 
HAND1 heart and neural crest derivatives expressed 1 -1.7 
HAT1 histone acetyltransferase 1 -1.6 
HDAC1 histone deacetylase 1 -1.6 
HDAC9 histone deacetylase 9 -1.9 
HDGF hepatoma-derived growth factor (high-mobility group protein 1-like) -1.4 
HELLS helicase, lymphoid-specific -1.7 
HES1 hairy and enhancer of split 1, (Drosophila) -1.4 
HHEX hematopoietically expressed homeobox -1.5 
HK2 hexokinase 2 -2.0 
HMGN3 high mobility group nucleosomal binding domain 3 -1.5 
HMMR hyaluronan-mediated motility receptor (RHAMM) -1.7 
HNRPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA 
binding protein 1, 37kDa) 
-1.5 
HRSP12 heat-responsive protein 12 -1.7 
HS3ST5 heparan sulfate (glucosamine) 3-O-sulfotransferase 5 -1.9 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 -1.6 
HSCB HscB iron-sulfur cluster co-chaperone homolog (E. coli) -1.5 
HSPA14 heat shock 70kDa protein 14 -1.6 
HSPA9 heat shock 70kDa protein 9 (mortalin) -1.4 
HSPC111 hypothetical protein HSPC111 -1.7 
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) -1.5 
ICAM3 intercellular adhesion molecule 3 -1.5 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
-1.4 
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein 
-1.4 
IFRD2 interferon-related developmental regulator 2 -1.6 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa -1.8 
IGFBP4 insulin-like growth factor binding protein 4 -3.0 
IL11RA interleukin 11 receptor, alpha -1.8 
ILKAP integrin-linked kinase-associated serine/threonine phosphatase 2C -1.5 
IMPDH1 IMP (inosine monophosphate) dehydrogenase 1 -2.4 
IMPDH2 IMP (inosine monophosphate) dehydrogenase 2 -1.5 
INF2 inverted formin, FH2 and WH2 domain containing -1.6 
INSM2 insulinoma-associated 2 -1.9 
IPO4 importin 4 -1.5 
IRAK1 interleukin-1 receptor-associated kinase 1 -1.5 
ISG20L1 interferon stimulated exonuclease gene 20kDa-like 1 -1.6 
ITGA9 integrin, alpha 9 -2.4 
ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen 
CD51) 
-1.4 
ITGB1BP1 integrin beta 1 binding protein 1 -1.4 
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) -1.7 
ITGB5 integrin, beta 5 -1.6 
ITM2C integral membrane protein 2C -1.4 
ITPA inosine triphosphatase (nucleoside triphosphate pyrophosphatase) -1.4 
JOSD3 Josephin domain containing 3 -1.4 
JUNDM2 Jun dimerization protein 2 -1.5 
KANK2 KN motif and ankyrin repeat domains 2 -1.4 
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KAZALD1 Kazal-type serine peptidase inhibitor domain 1 -1.4 
KCNG1 potassium voltage-gated channel, subfamily G, member 1 -1.5 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 -1.5 
KCNK3 potassium channel, subfamily K, member 3 -1.5 
KCTD3 potassium channel tetramerisation domain containing 3 -1.5 
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 
3 
-1.6 
KHSRP KH-type splicing regulatory protein -1.4 
KIAA0020 KIAA0020 -1.5 
KIAA0101 KIAA0101 -1.7 
KIAA0586 KIAA0586 -1.4 
KIF11 kinesin family member 11 -1.8 
KIF14 kinesin family member 14 -1.8 
KIF15 kinesin family member 15 -1.4 
KIF20A kinesin family member 20A -1.4 
KIF22 kinesin family member 22 -1.5 
KIF23 kinesin family member 23 -1.6 
KIF2C kinesin family member 2C -1.4 
KIF4A kinesin family member 4A -1.5 
KLF15 Kruppel-like factor 15 -1.9 
KPNB1 karyopherin (importin) beta 1 -1.5 
KRIT1 KRIT1, ankyrin repeat containing -1.5 
KRR1 KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
-1.4 
LARP7 La ribonucleoprotein domain family, member 7 -1.5 
LBR lamin B receptor -1.5 
LDB2 LIM domain binding 2 -1.9 
LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 -2.0 
LHX9 LIM homeobox 9 -2.3 
LIMD1 LIM domains containing 1 -1.8 
LMNA lamin A/C -1.6 
LMNB1 lamin B1 -1.6 
LMNB2 lamin B2 -1.4 
LMO4 LIM domain only 4 -1.7 
LPGAT1 lysophosphatidylglycerol acyltransferase 1 -1.5 
LPHN2 latrophilin 2 -1.5 
LPPR4 plasticity related gene 1 -3.7 
LRRC4C leucine rich repeat containing 4C -1.5 
LSM2 LSM2 homolog, U6 small nuclear RNA associated (S. cerevisiae) -1.5 
LSM3 LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) -1.5 
LSM5 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) -1.6 
LSM8 LSM8 homolog, U6 small nuclear RNA associated (S. cerevisiae) -1.4 
LUM lumican -2.3 
LYAR Ly1 antibody reactive homolog (mouse) -1.7 
LYPLA1 lysophospholipase I -1.5 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) -1.6 
MAGOH mago-nashi homolog, proliferation-associated (Drosophila) -1.5 
MAGOHB mago-nashi homolog B (Drosophila) -1.5 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 -1.5 
MAP3K4 mitogen-activated protein kinase kinase kinase 4 -1.5 
MAP7 microtubule-associated protein 7 -1.6 
MASTL microtubule associated serine/threonine kinase-like -1.4 
MAT2A methionine adenosyltransferase II, alpha -1.4 
MBD2 methyl-CpG binding domain protein 2 -1.8 
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MBNL1 muscleblind-like (Drosophila) -1.5 
MCM10 minichromosome maintenance complex component 10 -1.8 
MCM2 minichromosome maintenance complex component 2 -1.6 
MCM3 minichromosome maintenance complex component 3 -1.7 
MCM4 minichromosome maintenance complex component 4 -1.4 
MCM5 minichromosome maintenance complex component 5 -1.6 
MCM6 minichromosome maintenance complex component 6 -1.6 
MCM7 minichromosome maintenance complex component 7 -1.6 
MCM8 minichromosome maintenance complex component 8 -1.7 
MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 -1.5 
MEG3 maternally expressed 3 -1.7 
MELK maternal embryonic leucine zipper kinase -1.7 
MEPCE methylphosphate capping enzyme -1.5 
METTL7A methyltransferase like 7A -1.5 
MFHAS1 malignant fibrous histiocytoma amplified sequence 1 -1.4 
MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, isozyme B 
-1.8 
MID1 midline 1 (Opitz/BBB syndrome) -1.6 
MIHG1 microRNA host gene (non-protein coding) 1 -1.5 
MINA MYC induced nuclear antigen -1.5 
MITF microphthalmia-associated transcription factor -1.5 
MKI67 antigen identified by monoclonal antibody Ki-67 -1.6 
MLF1IP MLF1 interacting protein -1.5 
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) -1.5 
MPHOSPH1 M-phase phosphoprotein 1 -1.7 
MPHOSPH9 M-phase phosphoprotein 9 -1.5 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) -1.6 
MRPL11 mitochondrial ribosomal protein L11 -1.8 
MRPL12 mitochondrial ribosomal protein L12 -1.7 
MRPL13 mitochondrial ribosomal protein L13 -1.6 
MRPL23 mitochondrial ribosomal protein L23 -1.6 
MRPL39 mitochondrial ribosomal protein L39 -1.5 
MRPL43 mitochondrial ribosomal protein L43 -1.4 
MRPS12 mitochondrial ribosomal protein S12 -1.4 
MRPS18B mitochondrial ribosomal protein S18B -1.6 
MRPS24 mitochondrial ribosomal protein S24 -1.5 
MRPS7 mitochondrial ribosomal protein S7 -1.4 
MSX2 msh homeobox 2 -1.5 
MT2A metallothionein 2A -1.8 
MTDH metadherin -1.5 
MTHFD1 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthetase 
-1.8 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like 
-1.6 
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
-1.4 
MTHFS 5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate 
cyclo-ligase) 
-1.5 
MTIF2 mitochondrial translational initiation factor 2 -1.4 
MTR 5-methyltetrahydrofolate-homocysteine methyltransferase -1.5 
MYBBP1A MYB binding protein (P160) 1a -1.5 
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 -1.6 
MYCBP c-myc binding protein -1.4 
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NAF1 nuclear assembly factor 1 homolog (S. cerevisiae) -1.5 
NASP nuclear autoantigenic sperm protein (histone-binding) -1.4 
NAT13 N-acetyltransferase 13 -1.5 
NBN nibrin -1.4 
NCAPD2 non-SMC condensin I complex, subunit D2 -1.8 
NCAPD3 non-SMC condensin II complex, subunit D3 -1.6 
NCAPG non-SMC condensin I complex, subunit G -1.8 
NCAPG2 non-SMC condensin II complex, subunit G2 -1.5 
NCAPH non-SMC condensin I complex, subunit H -1.6 
NCL nucleolin -1.5 
NDC80 NDC80 homolog, kinetochore complex component (S. cerevisiae) -1.5 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -1.4 
NEFH neurofilament, heavy polypeptide 200kDa -3.6 
NEIL3 nei endonuclease VIII-like 3 (E. coli) -1.6 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 -1.6 
NELL1 NEL-like 1 (chicken) -1.9 
NF2 neurofibromin 2 (merlin) -1.4 
NFATC3 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3 
-1.4 
NFATC4 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 4 
-1.5 
NHS Nance-Horan syndrome (congenital cataracts and dental 
anomalies) 
-1.4 
NID2 nidogen 2 (osteonidogen) -2.2 
NIP7 nuclear import 7 homolog (S. cerevisiae) -1.6 
NLE1 notchless homolog 1 (Drosophila) -1.6 
NMB neuromedin B -1.4 
NMT1 N-myristoyltransferase 1 -1.4 
NOC2L nucleolar complex associated 2 homolog (S. cerevisiae) -1.4 
NOC3L nucleolar complex associated 3 homolog (S. cerevisiae) -1.8 
NOL1 nucleolar protein 1, 120kDa -1.5 
NOL14 nucleolar protein 14 -1.5 
NOL5A nucleolar protein 5A (56kDa with KKE/D repeat) -1.5 
NOL7 nucleolar protein 7, 27kDa -1.4 
NOL8 nucleolar protein 8 -1.4 
NOLA1 nucleolar protein family A, member 1 (H/ACA small nucleolar 
RNPs) 
-1.4 
NOLC1 nucleolar and coiled-body phosphoprotein 1 -1.4 
NOX3 NADPH oxidase 3 -1.4 
NP nucleoside phosphorylase -2.7 
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) -1.9 
NPM3 nucleophosmin/nucleoplasmin, 3 -1.7 
NR2C2AP nuclear receptor 2C2-associated protein -1.4 
NR2F2 nuclear receptor subfamily 2, group F, member 2 -1.6 
NRCAM neuronal cell adhesion molecule -1.8 
NRM nurim (nuclear envelope membrane protein) -1.5 
NRP1 neuropilin 1 -1.8 
NSBP1 nucleosomal binding protein 1 -1.8 
NSMAF neutral sphingomyelinase (N-SMase) activation associated factor -1.5 
NTHL1 nth endonuclease III-like 1 (E. coli) -1.6 
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 -1.7 
NUDT1 nudix (nucleoside diphosphate linked moiety X)-type motif 1 -1.5 
NUF2 NUF2, NDC80 kinetochore complex component, homolog (S. 
cerevisiae) 
-1.8 
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NUP107 nucleoporin 107kDa -1.4 
NUP153 nucleoporin 153kDa -1.5 
NUP155 nucleoporin 155kDa -1.5 
NUP205 nucleoporin 205kDa -1.5 
NUP37 nucleoporin 37kDa -1.7 
NUP43 nucleoporin 43kDa -1.7 
NUP85 nucleoporin 85kDa -1.5 
NUP88 nucleoporin 88kDa -1.5 
NUSAP1 nucleolar and spindle associated protein 1 -1.6 
OAF OAF homolog (Drosophila) -1.8 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa -1.5 
ODC1 ornithine decarboxylase 1 -1.4 
OIP5 Opa interacting protein 5 -1.7 
OLFM1 olfactomedin 1 -3.4 
OPRM1 opioid receptor, mu 1 -1.5 
OPRS1 opioid receptor, sigma 1 -1.6 
ORAI1 ORAI calcium release-activated calcium modulator 1 -1.6 
ORC6L origin recognition complex, subunit 6 like (yeast) -1.5 
P2RY11 purinergic receptor P2Y, G-protein coupled, 11 -1.5 
PA2G4 proliferation-associated 2G4, 38kDa -1.6 
PAICS phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide synthetase 
-1.4 
PAK1IP1 PAK1 interacting protein 1 -1.5 
PAP2D phosphatidic acid phosphatase type 2 -1.8 
PAPD5 PAP associated domain containing 5 -1.5 
PARVA parvin, alpha -1.5 
PAXIP1 PAX interacting (with transcription-activation domain) protein 1 -2.0 
PBK PDZ binding kinase -1.8 
PC pyruvate carboxylase -1.5 
PCDH9 protocadherin 9 -1.9 
PCNA proliferating cell nuclear antigen -1.5 
PCOLCE procollagen C-endopeptidase enhancer -1.7 
PCOLCE2 procollagen C-endopeptidase enhancer 2 -1.9 
PDCD2 programmed cell death 2 -1.6 
PDE2A phosphodiesterase 2A, cGMP-stimulated -1.9 
PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 
dunce homolog, Drosophila) 
-1.4 
PDE9A phosphodiesterase 9A -1.5 
PDGFRB platelet-derived growth factor receptor, beta polypeptide -1.5 
PEG10 paternally expressed 10 -1.6 
PER2 period homolog 2 (Drosophila) -1.4 
PES1 pescadillo homolog 1, containing BRCT domain (zebrafish) -1.5 
PEX3 peroxisomal biogenesis factor 3 -1.4 
PFAS phosphoribosylformylglycinamidine synthase (FGAR 
amidotransferase) 
-1.6 
PGM2 phosphoglucomutase 2 -1.6 
PHB prohibitin -1.5 
PHF17 PHD finger protein 17 -1.5 
PHF5A PHD finger protein 5A -1.5 
PHIP pleckstrin homology domain interacting protein -1.5 
PIF1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) -1.4 
PINX1 PIN2-interacting protein 1 -1.5 
PLK1 polo-like kinase 1 (Drosophila) -1.6 
PLK4 polo-like kinase 4 (Drosophila) -1.5 
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PLXND1 plexin D1 -1.9 
PMM2 phosphomannomutase 2 -1.5 
PMP22 peripheral myelin protein 22 -1.5 
PMPCA peptidase (mitochondrial processing) alpha -1.5 
PNPT1 polyribonucleotide nucleotidyltransferase 1 -1.5 
POLA1 polymerase (DNA directed), alpha 1 -1.6 
POLA2 polymerase (DNA directed), alpha 2 (70kD subunit) -1.6 
POLD2 polymerase (DNA directed), delta 2, regulatory subunit 50kDa -1.5 
POLD3 polymerase (DNA-directed), delta 3, accessory subunit -1.5 
POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) -1.8 
POLE3 polymerase (DNA directed), epsilon 3 (p17 subunit) -1.8 
POLQ polymerase (DNA directed), theta -1.6 
POLR2C polymerase (RNA) II (DNA directed) polypeptide C, 33kDa -1.5 
POLR2H polymerase (RNA) II (DNA directed) polypeptide H -1.5 
POLR3C polymerase (RNA) III (DNA directed) polypeptide C (62kD) -1.4 
POLR3G polymerase (RNA) III (DNA directed) polypeptide G (32kD) -1.6 
POLR3K polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa -1.5 
POLRMT polymerase (RNA) mitochondrial (DNA directed) -1.4 
POP5 processing of precursor 5, ribonuclease P/MRP subunit (S. 
cerevisiae) 
-1.4 
POP7 processing of precursor 7, ribonuclease P/MRP subunit (S. 
cerevisiae) 
-1.5 
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 
beta 
-1.5 
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1) -1.5 
PPIF peptidylprolyl isomerase F (cyclophilin F) -1.7 
PPIH peptidylprolyl isomerase H (cyclophilin H) -1.6 
PPIL1 peptidylprolyl isomerase (cyclophilin)-like 1 -1.6 
PPIL5 peptidylprolyl isomerase (cyclophilin)-like 5 -1.6 
PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform -1.4 
PPP2R1B protein phosphatase 2 (formerly 2A), regulatory subunit A, beta 
isoform 
-1.6 
PPRC1 peroxisome proliferator-activated receptor gamma, coactivator-
related 1 
-1.6 
PRC1 protein regulator of cytokinesis 1 -1.5 
PRELID1 PRELI domain containing 1 -1.5 
PRICKLE4 prickle homolog 4 (Drosophila) -1.5 
PRIM1 primase, DNA, polypeptide 1 (49kDa) -1.4 
PRIM2 primase, DNA, polypeptide 2 (58kDa) -1.5 
PRKCA protein kinase C, alpha -2.3 
PRKD3 protein kinase D3 -1.5 
PRMT3 protein arginine methyltransferase 3 -1.5 
PRPF3 PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) -1.5 
PRPF4 PRP4 pre-mRNA processing factor 4 homolog (yeast) -1.4 
PRPH peripherin -2.0 
PSAT1 phosphoserine aminotransferase 1 -1.6 
PSD3 pleckstrin and Sec7 domain containing 3 -1.5 
PSMC3IP PSMC3 interacting protein -1.5 
PSMG1 proteasome (prosome, macropain) assembly chaperone 1 -1.7 
PSMG3 proteasome (prosome, macropain) assembly chaperone 3 -1.4 
PSMG4 proteasome (prosome, macropain) assembly chaperone 4 -1.6 
PSRC1 proline/serine-rich coiled-coil 1 -1.7 
PTBP1 polypyrimidine tract binding protein 1 -1.4 
PTDSS1 phosphatidylserine synthase 1 -1.6 
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PTGER3 prostaglandin E receptor 3 (subtype EP3) -1.5 
PTGES2 prostaglandin E synthase 2 -1.4 
PTN pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1) 
-1.8 
PTPLA protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member A 
-1.4 
PTPLB protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member b 
-1.4 
PTPN13 protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 
(Fas)-associated phosphatase) 
-1.5 
PTPRK protein tyrosine phosphatase, receptor type, K -1.6 
PTPRU protein tyrosine phosphatase, receptor type, U -1.7 
PTTG1 pituitary tumor-transforming 1 -1.5 
PUNC putative neuronal cell adhesion molecule -1.6 
PUS1 pseudouridylate synthase 1 -1.7 
PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C) -1.6 
PWP2 PWP2 periodic tryptophan protein homolog (yeast) -1.4 
PXMP2 peroxisomal membrane protein 2, 22kDa -1.4 
QKI quaking homolog, KH domain RNA binding (mouse) -1.5 
RAB27A RAB27A, member RAS oncogene family -1.7 
RABGGTB Rab geranylgeranyltransferase, beta subunit -1.5 
RAD18 RAD18 homolog (S. cerevisiae) -1.4 
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) -1.5 
RAD51AP1 RAD51 associated protein 1 -1.6 
RAD54L RAD54-like (S. cerevisiae) -1.4 
RANBP1 RAN binding protein 1 -1.6 
RANBP5 RAN binding protein 5 -1.5 
RASA3 RAS p21 protein activator 3 -1.5 
RASEF RAS and EF-hand domain containing -2.2 
RASL11B RAS-like, family 11, member B -1.4 
RBBP8 retinoblastoma binding protein 8 -1.5 
RBL1 retinoblastoma-like 1 (p107) -1.6 
RBM14 RNA binding motif protein 14 -1.4 
RCC1 regulator of chromosome condensation 1 -1.6 
RCOR1 REST corepressor 1 -1.5 
RDX radixin -2.0 
RELN reelin -3.7 
RERG RAS-like, estrogen-regulated, growth inhibitor -2.1 
REXO4 REX4, RNA exonuclease 4 homolog (S. cerevisiae) -1.5 
RFC2 replication factor C (activator 1) 2, 40kDa -1.5 
RFC3 replication factor C (activator 1) 3, 38kDa -1.5 
RFC4 replication factor C (activator 1) 4, 37kDa -1.5 
RFC5 replication factor C (activator 1) 5, 36.5kDa -1.5 
RFXAP regulatory factor X-associated protein -1.5 
RGS10 regulator of G-protein signaling 10 -1.5 
RGS19 regulator of G-protein signaling 19 -1.8 
RHOB ras homolog gene family, member B -1.4 
RHOU ras homolog gene family, member U -1.6 
RIMS2 regulating synaptic membrane exocytosis 2 -2.2 
RIN2 Ras and Rab interactor 2 -1.5 
RIOK1 RIO kinase 1 (yeast) -1.6 
RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. 
cerevisiae) 
-1.5 
RNASEH2A ribonuclease H2, subunit A -1.5 
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RNF138 ring finger protein 138 -1.5 
RPA1 replication protein A1, 70kDa -1.5 
RPA3 replication protein A3, 14kDa -1.5 
RPL39L ribosomal protein L39-like -1.7 
RPP25 ribonuclease P/MRP 25kDa subunit -2.4 
RPS19BP1 ribosomal protein S19 binding protein 1 -1.4 
RPS24 ribosomal protein S24 -1.7 
RRM1 ribonucleotide reductase M1 -1.6 
RRM2 ribonucleotide reductase M2 polypeptide -1.6 
RRP1 ribosomal RNA processing 1 homolog (S. cerevisiae) -1.4 
RRP1B ribosomal RNA processing 1 homolog B (S. cerevisiae) -1.5 
RRP9 ribosomal RNA processing 9, small subunit (SSU) processome 
component, homolog (yeast) 
-1.6 
RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) -1.5 
RUVBL1 RuvB-like 1 (E. coli) -1.7 
RWDD1 RWD domain containing 1 -1.5 
RXRA retinoid X receptor, alpha -1.5 
S100A4 S100 calcium binding protein A4 -2.0 
SAC3D1 SAC3 domain containing 1 -1.5 
SACM1L SAC1 suppressor of actin mutations 1-like (yeast) -1.5 
SAP30 Sin3A-associated protein, 30kDa -1.4 
SASS6 spindle assembly 6 homolog (C. elegans) -1.4 
SC65 synaptonemal complex protein SC65 -1.5 
SCARB1 scavenger receptor class B, member 1 -1.8 
SCLY selenocysteine lyase -1.9 
SCYE1 small inducible cytokine subfamily E, member 1 (endothelial 
monocyte-activating) 
-1.4 
SDC1 syndecan 1 -1.7 
SDHD succinate dehydrogenase complex, subunit D, integral membrane 
protein 
-1.5 
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A 
-2.0 
SEP15 15 kDa selenoprotein -1.4 
SEPT10 septin 10 -1.7 
SERBP1 SERPINE1 mRNA binding protein 1 -1.4 
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
-1.5 
SERTAD4 SERTA domain containing 4 -1.6 
SF3A1 splicing factor 3a, subunit 1, 120kDa -1.4 
SF3A3 splicing factor 3a, subunit 3, 60kDa -1.5 
SF3B3 splicing factor 3b, subunit 3, 130kDa -1.4 
SFRS1 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate 
splicing factor) 
-1.5 
SFRS2 splicing factor, arginine/serine-rich 2 -1.4 
SFXN2 sideroflexin 2 -1.5 
SGOL2 shugoshin-like 2 (S. pombe) -1.7 
SHCBP1 SHC SH2-domain binding protein 1 -2.0 
SHF Src homology 2 domain containing F -1.6 
SHOX2 short stature homeobox 2 -2.6 
SIVA1 SIVA1, apoptosis-inducing factor -1.6 
SIX3 SIX homeobox 3 -1.6 
SLC10A4 solute carrier family 10 (sodium/bile acid cotransporter family), 
member 4 
-1.9 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member -1.6 
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SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 
8 
-1.6 
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 
1) 
-1.4 
SLC16A7 solute carrier family 16, member 7 (monocarboxylic acid transporter 
2) 
-1.5 
SLC18A1 solute carrier family 18 (vesicular monoamine), member 1 -1.4 
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 -1.5 
SLC25A33 solute carrier family 25, member 33 -1.6 
SLC25A37 solute carrier family 25, member 37 -1.4 
SLC25A39 solute carrier family 25, member 39 -1.6 
SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 -1.5 
SLC2A4RG SLC2A4 regulator -1.4 
SLC30A5 solute carrier family 30 (zinc transporter), member 5 -1.5 
SLC31A1 solute carrier family 31 (copper transporters), member 1 -1.6 
SLC35A3 solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) 
transporter), member A3 
-1.4 
SLC35F2 solute carrier family 35, member F2 -1.8 
SLC39A14 solute carrier family 39 (zinc transporter), member 14 -1.6 
SLC39A8 solute carrier family 39 (zinc transporter), member 8 -1.5 
SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), 
member 6 
-1.6 
SLCO4A1 solute carrier organic anion transporter family, member 4A1 -2.0 
SLITRK5 SLIT and NTRK-like family, member 5 -1.5 
SMAD6 SMAD family member 6 -1.7 
SMARCD2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 2 
-1.6 
SMC2 structural maintenance of chromosomes 2 -1.7 
SMC4 structural maintenance of chromosomes 4 -1.5 
SNF1LK2 SNF1-like kinase 2 -1.5 
SNHG5 small nucleolar RNA host gene (non-protein coding) 5 -1.5 
SNRPA small nuclear ribonucleoprotein polypeptide A -1.5 
SNRPB small nuclear ribonucleoprotein polypeptides B and B1 -1.5 
SNRPD1 small nuclear ribonucleoprotein D1 polypeptide 16kDa -1.4 
SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa -1.4 
SNX3 sorting nexin 3 -1.4 
SNX5 sorting nexin 5 -1.5 
SOAT1 sterol O-acyltransferase (acyl-Coenzyme A: cholesterol 
acyltransferase) 1 
-1.4 
SOLH small optic lobes homolog (Drosophila) -1.5 
SORBS2 sorbin and SH3 domain containing 2 -2.6 
SOX2 SRY (sex determining region Y)-box 2 -1.5 
SOX7 SRY (sex determining region Y)-box 7 -1.5 
SPAG5 sperm associated antigen 5 -1.7 
SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. 
cerevisiae) 
-1.5 
SPC25 SPC25, NDC80 kinetochore complex component, homolog (S. 
cerevisiae) 
-1.7 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 3 
-2.6 
SPTBN1 spectrin, beta, non-erythrocytic 1 -1.5 
SRFBP1 serum response factor binding protein 1 -1.4 
SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 -1.5 
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SRM spermidine synthase -1.4 
SS18L2 synovial sarcoma translocation gene on chromosome 18-like 2 -1.4 
SSB Sjogren syndrome antigen B (autoantigen La) -1.5 
SSFA2 sperm specific antigen 2 -1.6 
SSRP1 structure specific recognition protein 1 -1.5 
SSU72 SSU72 RNA polymerase II CTD phosphatase homolog (S. 
cerevisiae) 
-1.5 
ST3GAL4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 -1.4 
STC2 stanniocalcin 2 -1.6 
STEAP3 STEAP family member 3 -1.7 
STIL SCL/TAL1 interrupting locus -1.6 
STOM stomatin -1.5 
STOML2 stomatin (EPB72)-like 2 -1.5 
SUCLG2 succinate-CoA ligase, GDP-forming, beta subunit -1.5 
SULF2 sulfatase 2 -3.4 
SUV39H1 suppressor of variegation 3-9 homolog 1 (Drosophila) -1.5 
SUV39H2 suppressor of variegation 3-9 homolog 2 (Drosophila) -1.5 
SUZ12 suppressor of zeste 12 homolog (Drosophila) -1.5 
SVIL supervillin -1.8 
SYCP3 synaptonemal complex protein 3 -1.4 
SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein -1.6 
SYPL1 synaptophysin-like 1 -1.4 
TACC3 transforming, acidic coiled-coil containing protein 3 -1.6 
TAF4B TAF4b RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 105kDa 
-1.6 
TAF5 TAF5 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 100kDa 
-1.5 
TARBP2 TAR (HIV-1) RNA binding protein 2 -1.5 
TATDN2 TatD DNase domain containing 2 -1.4 
TBC1D2B TBC1 domain family, member 2B -1.6 
TBC1D4 TBC1 domain family, member 4 -1.6 
TBRG4 transforming growth factor beta regulator 4 -1.5 
TCF12 transcription factor 12 (HTF4, helix-loop-helix transcription factors 
4) 
-1.5 
TCF19 transcription factor 19 (SC1) -1.6 
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) -1.8 
TCHP trichoplein, keratin filament binding -1.5 
TFAM transcription factor A, mitochondrial -1.6 
TFB2M transcription factor B2, mitochondrial -1.5 
TFEB transcription factor EB -1.5 
TGS1 trimethylguanosine synthase homolog (S. cerevisiae) -1.5 
THAP11 THAP domain containing 11 -1.4 
THOC4 THO complex 4 -1.4 
THOC7 THO complex 7 homolog (Drosophila) -1.5 
THOP1 thimet oligopeptidase 1 -1.6 
THRAP3 thyroid hormone receptor associated protein 3 -1.5 
TIAM1 T-cell lymphoma invasion and metastasis 1 -1.5 
TIFA TRAF-interacting protein with forkhead-associated domain -1.5 
TIMELESS timeless homolog (Drosophila) -1.6 
TIMM10 translocase of inner mitochondrial membrane 10 homolog (yeast) -1.4 
TIMM13 translocase of inner mitochondrial membrane 13 homolog (yeast) -1.9 
TIMM8A translocase of inner mitochondrial membrane 8 homolog A (yeast) -1.4 
TIPIN TIMELESS interacting protein -1.8 
TJAP1 tight junction associated protein 1 (peripheral) -1.4 
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TLE1 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) -2.9 
TLE2 transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila) -1.5 
TMEM106C transmembrane protein 106C -1.4 
TMEM115 transmembrane protein 115 -1.5 
TMEM48 transmembrane protein 48 -1.6 
TMEM97 transmembrane protein 97 -1.5 
TMTC1 transmembrane and tetratricopeptide repeat containing 1 -1.9 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 -1.5 
TOB1 transducer of ERBB2, 1 -1.6 
TOM1L1 target of myb1 (chicken)-like 1 -1.6 
TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) -1.4 
TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) -1.5 
TOP1MT topoisomerase (DNA) I, mitochondrial -1.8 
TOP2A topoisomerase (DNA) II alpha 170kDa -1.6 
TOPBP1 topoisomerase (DNA) II binding protein 1 -1.5 
TP53 tumor protein p53 -1.5 
TPCN1 two pore segment channel 1 -1.5 
TPD52 tumor protein D52 -1.5 
TPST2 tyrosylprotein sulfotransferase 2 -2.4 
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) -1.6 
TRA T cell receptor alpha locus -1.7 
TRAF5 TNF receptor-associated factor 5 -1.8 
TRIM14 tripartite motif-containing 14 -1.5 
TRIM24 tripartite motif-containing 24 -1.5 
TRIM25 tripartite motif-containing 25 -1.5 
TRIM59 tripartite motif-containing 59 -1.4 
TRIM9 tripartite motif-containing 9 -2.0 
TRIP13 thyroid hormone receptor interactor 13 -1.7 
TROAP trophinin associated protein (tastin) -1.6 
TRPA1 transient receptor potential cation channel, subfamily A, member 1 -3.2 
TRPM7 transient receptor potential cation channel, subfamily M, member 7 -1.5 
TSPO translocator protein (18kDa) -1.9 
TSR1 TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) -1.6 
TTF2 transcription termination factor, RNA polymerase II -1.6 
TTK TTK protein kinase -1.8 
TUBD1 tubulin, delta 1 -1.4 
TUBGCP3 tubulin, gamma complex associated protein 3 -1.5 
TUSC4 tumor suppressor candidate 4 -1.5 
TXN2 thioredoxin 2 -1.5 
TXNDC1 thioredoxin domain containing 1 -1.8 
TYMS thymidylate synthetase -1.7 
UBAP2L ubiquitin associated protein 2-like -1.5 
UBE2C ubiquitin-conjugating enzyme E2C -1.4 
UBE2CBP ubiquitin-conjugating enzyme E2C binding protein -1.6 
UBE2G2 ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) -1.5 
UCHL5 ubiquitin carboxyl-terminal hydrolase L5 -1.5 
UCHL5IP UCHL5 interacting protein -2.0 
UMPS uridine monophosphate synthetase -1.6 
UNG uracil-DNA glycosylase -1.9 
USP1 ubiquitin specific peptidase 1 -1.6 
UTRN utrophin -2.0 
VRK1 vaccinia related kinase 1 -1.5 
WASF3 WAS protein family, member 3 -1.5 
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WDR4 WD repeat domain 4 -1.6 
WDR5 WD repeat domain 5 -1.4 
WDR61 WD repeat domain 61 -1.4 
WDR77 WD repeat domain 77 -1.5 
WDSOF1 WD repeats and SOF1 domain containing -1.5 
WFS1 Wolfram syndrome 1 (wolframin) -1.4 
WHSC1 Wolf-Hirschhorn syndrome candidate 1 -1.4 
WIPF1 WAS/WASL interacting protein family, member 1 -1.8 
WT1 Wilms tumor 1 -2.0 
XPO1 exportin 1 (CRM1 homolog, yeast) -1.4 
XTP3TPA XTP3-transactivated protein A -1.7 
ZAK sterile alpha motif and leucine zipper containing kinase AZK -1.4 
ZBTB24 zinc finger and BTB domain containing 24 -1.5 
ZFPM2 zinc finger protein, multitype 2 -3.3 
ZFYVE16 zinc finger, FYVE domain containing 16 -1.6 
ZMYND19 zinc finger, MYND-type containing 19 -1.4 
ZNF367 zinc finger protein 367 -1.9 
ZNF423 zinc finger protein 423 -1.5 
ZNF503 zinc finger protein 503 -1.6 
ZNF536 zinc finger protein 536 -1.6 
ZNF804A zinc finger protein 804A -1.4 
ZRF1 zuotin related factor 1 -1.8 
ZWINT ZW10 interactor -1.5 
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Supplemental Table S2.2.  Quantitative RT-PCR Validation of Microarray 
Results. 
Superarray PI3K-Akt qRT-PCR Array 
-Data normalized to average Ct for 5 control housekeeping genes; genes with maximal Ct = 35 in       
either trial not analyzed (italics) 
-Averages calculated from two individual experiments, fold-change calculated from log2 
transformed data 
-Statistical analysis: two-tailed Student's t-test assuming unequal variance, significant 
upregulated genes in bold 
-Microarray results using both Genomatix and Bioconductor software are shown for comparison; 
"-", not significant) 
pRT-PCR array validation results  Microarray results (fold-change) 
Gene Fold change p-value   Genomatix Bioconductor 
AKT1 3.3 0.232   - - 
AKT2 1.4 0.488   - - 
AKT3 2.3 0.007   - - 
APC 7.1 0.006   1.6 1.9 
BAD 1.9 0.091   - - 
CASP9 3.7 0.087   - - 
CCND1 3.7 0.114   - - 
CD14 27.9 0.000   1.9 4.6 
CDC42 2.6 0.113   1.5 2.1 
CHUK 1.0 0.873   - - 
CSNK2A1 1.8 0.070   - - 
CTNNB1 1.8 0.017   - - 
EIF2AK2 1.5 0.430   - - 
EIF4B 1.7 0.165   - - 
EIF4E 1.3 0.513   1.7 2.0 
EIF4EBP1 1.2 0.549   -1.4 - 
EIF4G1 2.9 0.088   - - 
ELK1 1.5 0.143   - - 
FKBP1A 5.1 0.095   - - 
FOXO1 86.3 0.011   1.8 8.3 
FOXO3 4.6 0.004   2.0 2.0 
FRAP1 1.3 0.020   - - 
GRB10 NA NA   - 4.1 
GRB2 2.5 0.076   - - 
GSK3B 3.0 0.036   - - 
HRAS 1.6 0.505   - - 
HSPB1 1.6 0.364   - - 
IGF1R 3.7 0.071   - - 
IRAK1 2.2 0.166   -1.5 - 
IRS1 1.2 0.095   - - 
ITGB1 2.6 0.001   - 2.1 
JUN 1.7 0.037   - - 
MAP2K1 2.4 0.085   - - 
MAPK1 1.9 0.072   - - 
MAPK14 1.9 0.474   - -2.0 
MAPK3 3.2 0.148   - - 
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MAPK8 4.0 0.021   1.6 2.0 
MTCP1 0.9 0.553   - - 
MYD88 2.6 0.111   - - 
PABPC1 1.2 0.300   - - 
PAK1 3.9 0.011   - 1.7 
PDGFRA NA NA   - - 
PDK1 2.1 0.087   - - 
PDPK1 2.0 0.019   - - 
PIK3CA 3.0 0.004   - - 
PIK3CG NA NA   - - 
PIK3R1 5.7 0.040   2.3 2.6 
PIK3R2 2.0 0.210   - - 
PRKCA 0.4 0.276   - -2.6 
PRKCZ 3.1 0.124   2.0 - 
PTEN 1.0 1.000   - - 
PTK2 1.6 0.088   - - 
PTPN11 0.9 0.684   - - 
RAC1 1.6 0.408   - - 
RAF1 1.4 0.689   - - 
RASA1 4.5 0.003   2.7 2.5 
RBL2 1.2 0.198   - - 
RHEB 1.7 0.108   - - 
RHOA 0.9 0.572   - - 
RPS6KA1 0.8 0.776   - - 
RPS6KB1 1.1 0.804   - - 
SHC1 3.1 0.070   1.6 1.8 
SOS1 1.1 0.423   - - 
SRF 2.1 0.150   - - 
TIRAP 1.1 0.860   - - 
TLR4 40.3 0.019   1.4 31.0 
TOLLIP 1.4 0.255   - - 
TSC1 1.4 0.304   - - 
TSC2 2.2 0.017   - - 
WASL 1.5 0.353   - - 
YWHAH 2.2 0.050   - - 
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Supplemental Table S2.3.  Effects of Kinase Inhibitors on Poly(I-C)-
Stimulated BE(2)-C/m-ISRE Cells.  
-Values represent averages from two replicates - ranges are given due to limited titrations 
-IC50 = concentrations producing 50% maximal inhibition 
-CC50 = concentrations producing 50% cytotoxicity 
-Active inhibitors, defined as IC50 values for either extracellular or transfected poly(I-C) <20, 
CC50 values >20, and no overlap in ranges, are indicated in bold italic type 
Kinase inhibitor name Target(s) Extracellular 
poly(I-C) 
IC50 
Transfected-
poly(I-C) 
IC50 
CC50 
BML-257 Akt 0.8-4 4-20 >100 
Triciribine Akt  0.8-4 0.8 100 
Perifosine Akt, JNK, 
MAPK 
100 20 100 
Imatinib BCL/ABL 0.8 0.8 20 
Terreic acid BTK 4 100 >100 
LFM-A13 BTK >100 100 >100 
KN-93 CaMK II <0.8 <0.8 <0.8 
KN-62 CaMK II 100 100 >100 
Olomoucine CDK 20-100 4 0.8 
N9-Isopropyl-olomoucine CDK >100 >100 100 
Roscovitine CDK 20 20-100 >100 
Flavopiridol CDK 1,2,4 0.8-4 0.8-4 20-
100 
BML-259 CDK5/p25 100 >100 >100 
DRB (5,6-Dichloro-1-b-D-
ribofuranosylbenzimidazole) 
CK II 100 >100 >100 
Apigenin CK-II 100 4-20 100 
GW 5074 cRAF 20-100 20-100 20 
ZM 336372 cRAF >100 100 >100 
PI-103 DNA-PK, PI3K 
p110 , mTOR 
<0.8 <0.8 >100 
Tyrphostin 25 EGFRK 20-100 4 >100 
Tyrphostin 51 EGFRK 20-100 0.8-4 >100 
BML-265 (Erlotinib analog) EGFRK 4-20 0.8 100 
Tyrphostin 47 EGFRK 20-100 0.8-4 0.8 
Lavendustin A EGFRK 100 >100 >100 
Tyrphostin 23 EGFRK 100 >100 >100 
Tyrphostin AG 1478 EGFRK >100 100 >100 
RG-14620 EGFRK 20-100 100 >100 
Erbstatin analog EGFRK 20-100 20-100 20-
100 
Tyrphostin 46 EGFRK,  
PDGFRK 
20-100 20 20-
100 
HDBA (2-Hydroxy-5-(2,5-
dihydroxybenzylamino)benzoic acid) 
EGFRK, CaMK 
II 
4 <0.8 20 
AG-494 EGFRK, 
PDGFRK 
4-20 0.8-4 20 
5-Iodotubercidin ERK2, 
Adenosine 
kinase, CK1, 
CK2,  
4 20 100 
SU 4312 FLK1 100 4 0.8 
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SU1498 FLK1 20-100 100 >100 
FLT3 Inhibitor FLT3 >100 20-100 >100 
PK412  FLT3, SRC, 
ABL 
0.8 <0.8 >100 
GSK3 Inhibitor XIII GSK3  0.8-4 0.8-4 100 
GSK3 Inhibitor VI GSK3  0.8-4 0.8-4 4 
SB-415286 GSK3  100 100 100 
SB-216763 GSK3- 100 20 100 
Purvalanol A  GSK3-, 
CDK's 
4-20 4-20 100 
Kenpaullone GSK3 4-20 0.8-4 20 
Indirubin-3'-monoxime GSK3 4-20 0.8-4 20 
Indirubin-3'-monoxime GSK3 100 4 20 
Indirubin  GSK3, CDK5 0.8 0.8 20 
AG-825 HER1-2  100 100 >100 
AG1024 IGF-IR IGF-IR 100 20-100 >100 
BAY 11-7082 IKK pathway 100 100 >100 
SC-514 IKK2 100 20-100 >100 
AG-126 IRAK 100 100 >100 
HNMPA (Hydroxy-2-
naphthalenylmethylphosphonic acid) 
IRK  4-20 4-20 20-
100 
AG-490 JAK-2 20-100 20-100 100 
ZM 449829 JAK-3 100 4-20 100 
SP 600125 JNK >100 100 >100 
PD-98059 MEK  >100 >100 >100 
U-0126 MEK  100 20-100 >100 
ML-7 MLCK 20-100 20-100 >100 
ML-9 MLCK 20-100 20-100 >100 
Rapamycin mTOR 20 <0.8 20-
100 
Daidzein Negative 
control for 
genistein 
20-100 20-100 100 
iso-Olomoucine Negative 
control for 
olomoucine 
100 100 100 
Tyrphostin 1 Negative 
control for TK 
inhibitors 
20-100 4-20 20 
AG-879 NGFRK 20-100 20-100 100 
SB-203580 p38 MAPK  >100 >100 >100 
SB-202190 p38 MAPK  20-100 20-100 >100 
Damnacanthal p56 LCK 4-20 0.8-4 20 
2-Aminopurine p58 PITSLRE-
b1 
20-100 4-20 100 
Staurosporine Pan-specific 0.8 <0.8 4 
AG-370 PDGFRK 100 >100 >100 
AG-1296 PDGFRK 100 100 >100 
Tyrphostin 9 PDGFRK 4-20 0.8-4 4-20 
LY 294002 PI3K 4-20 4-20 >100 
Quercetin dihydrate PI3K 20-100 4 100 
Wortmannin PI3K 4-20 4-20 20 
PI3K Inhibitor 2 PI3K p110 0.8-4 0.8-4 100 
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TGX-221 PI3K p110 20-100 20-100 100 
AS-252424 PI3K p110 20-100 20-100 100 
AS-605240 PI3K p110 100 20-100 100 
PIM1 Inhibitor II PIMI  100 100 >100 
Quercetagetin PIMI 100 100 >100 
H-89 PKA 100 100 >100 
HA-1077 PKA, PKG 100 20-100 0.8 
HA-1004 PKA, PKG 20-100 20-100 100 
H-8  PKA, PKG 4 4-20 20-
100 
H-7 PKA, PKG, 
MLCK, and 
PKC. 
20 4-20 20 
H-9 PKA, PKG, 
MLCK, and 
PKC. 
20-100 20-100 100 
Hypericin PKC <0.8 <0.8 20 
GF 109203X PKC 100 100 100 
Ro 31-8220 PKC 20-100 20-100 >100 
Sphingosine PKC 100 20-100 >100 
Palmitoyl-DL-carnitine Cl PKC 4 20-100 20-
100 
HBDDE (2,2',3,3',4,4'-
Hexahydroxy-1,1'-biphenyl-6,6'-
dimethanol dimethyl ether) 
PKC, PKC 4-20 4-20 100 
Rottlerin PKC 4-20 4 20-
100 
Sunitinib Receptor 
tyrosine 
kinases 
<0.8 <0.8 4 
Y-27632 ROCK 100 >100 >100 
PP2 Src family >100 >100 >100 
PP1 Src family 4-20 4-20 20-
100 
Piceatannol Syk 20-100 20-100 >100 
Tyrphostin AG 1295 Tyrosine 
kinases 
100 20-100 >100 
Genistein Tyrosine 
Kinases 
20-100 20-100 >100 
Tyrphostin AG 1288 Tyrosine 
kinases (TK) 
4 0.8 >100 
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Chapter III 
 
IRF3 Mediates an Interferon-Independent Cytoprotective Response                       
Against Neurotropic Arboviruses in Neurons 
 
Early cellular innate immune responses are often vital for effective 
pathogen control, and an effective neuronal innate immune response may be 
crucial to prevent the essentially irreversible loss of critical central nervous 
system neurons by neurotropic arboviruses.  To test this hypothesis, we used 
targeted, genetic approaches and a variety of neuronal culture models to study 
the influence of neuronal PRR pathway signaling on neurotropic arbovirus 
pathogenesis mainly using western equine encephalitis virus (WEEV) as a model 
neurotropic arbovirus.  We found that WEEV activates neuronal PRR pathways 
in a replication dependent manner that requires IRF3, and abrogation of IRF3 
enhanced virus-mediated neuronal cytopathogenicity for distinct neurotropic 
arboviruses including WEEV.  Interestingly, IRF3-dependent protection of 
neurons from neurotropic arbovirus mediated cytopathology was independent of 
autocrine/paracrine type-I IFN activity and was likely due to direct IRF3-mediated 
induction of cell-intrinsic factors with cytoprotective properties.  Importantly 
WEEV, and other neurotropic arboviruses, were found to potently and specifically 
block induction of neuronal antiviral PRR pathways at early times post infection.  
The antiviral PRR pathway inhibitory capacity of WEEV was mapped to the 
capsid gene, which blocked antiviral PRR signaling downstream of IRF3 
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activation.  In addition, we determined that a WEEV structural gene, likely capsid, 
inhibited IRF3 nuclear translocation and host gene expression providing a 
potential dual mechanism for capsid-mediated inhibition of neuronal antiviral 
PRR signaling.  Altogether, these data indicated that neuronal PRR pathways 
may be important determinants in neurotropic arbovirus pathogenesis.     
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Introduction 
Viruses within several families preferentially infect CNS neurons, 
especially the neurotropic arboviruses which include but are not limited to West 
Nile virus (Flaviviridae), St. Louis encephalitis virus (Flaviviridae), La Crosse 
virus (Bunyaviridae), and the equine encephalitic alphaviruses (Togaviridae).  
Neurotropic arboviruses are transmitted via insect vectors and are responsible 
for sporadic epidemics of viral encephalitis (29) in which the extent of virus-
mediated destruction of CNS neurons is often an important determinant in the 
severity and clinical outcome after infection.  Unfortunately, there are very few 
effective treatments or vaccines for these viral infections, which contributes to 
their classification as potential bioterrorism agents (54).   
Early cellular innate immune responses are often vital for effective 
pathogen control (15-17, 19, 21, 28), and an effective neuronal innate immune 
response may be crucial to prevent the essentially irreversible loss of critical 
central nervous system neurons by neurotropic arboviruses.  Innate immune 
responses are activated by pattern recognition receptors (PRRs) that bind 
ligands containing pathogen-associated molecular patterns, such as modified 
carbohydrate or nucleic acid structures (37, 47).  Ligation of these receptors 
induces a signal transduction cascade resulting in the production of antiviral type-
I IFNs, other proinflammatory cytokines, and cell-intrinsic factors important for the 
generation of an antiviral cellular microenvironment (47).  In addition, PRR 
signaling is important for activating an appropriate adaptive immune response 
(1), which is required for the eventual clearance of most viral infections (9).  
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Thus, PRR-mediated innate immune pathway signaling serves a pivotal role in 
controlling viral infections and may protect neurons from neurotropic arbovirus 
mediated destruction.   
 There are three general steps in innate antiviral immune responses: 
activation, amplification, and effector production.  Antiviral PRR signaling is 
initiated by a variety of receptors, including the transmembrane Toll-like receptor 
(TLR) proteins and the cytoplasmic retinoic acid inducible gene I (RIG-I)-like 
receptors (RLRs) RIG-I and melanoma differentiated-associated gene 5 (MDA5) 
(34).  Due to differential expression, ligand specificity, and pathogen-mediated 
interference, PRRs respond to viral infections in both a pathogen and cell type-
specific manner (34, 61).  After PRR ligation, PRR signal transduction is 
mediated by several adaptor proteins, including MyD88, TIR-domain-containing 
adapter-inducing IFN-β (TRIF), and IFN- promoter stimulator protein 1 (IPS-1) 
(also referred to as Cardif, MAVS, and VISA) (34, 61).  These adaptor protein 
complexes mediate the downstream activation of kinases such as TANK-binding 
kinase 1 (TBK1), several IB kinases, and PI3K, which subsequently activate the 
transcription factors NFB and IFN regulatory factor 3 (IRF3) (5, 8, 10, 11).  
Activated NFB and IRF3 upregulate the expression of many genes important for 
mounting a robust antiviral response, including type-I IFNs, which function in 
either a paracrine or autocrine manner to induce IFN-stimulated genes (ISGs) 
(52).  There are several ISGs that act directly as antiviral effectors, but many are 
also components of antiviral PRR pathways, which provides a mechanism for 
positive feedback regulation and amplification (8). 
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 Viral PRR pathways protect host cells and tissues against viral infections, 
yet many viruses including neurotropic arboviruses possess PRR pathway 
countermeasures (61).  For instance, the NS2A and NS1 proteins of the 
neurotropic arbovirus West Nile virus (WNV) inhibit the activation of antiviral PRR 
pathways (18, 22, 38, 59) resulting in higher viral replication and enhanced 
virulence in a manner that may be both viral strain and cell type-dependent.  In a 
similar fashion, the NSs protein of La Crosse virus (LACV) potently inhibits type-I 
IFN induction, and in its absence, mutant virus robustly induces type-I IFNs 
resulting in reduced virulence (7).        
We and others have demonstrated that neurons possess active antiviral 
PRR pathways mediated by the receptors TLR3, RIG-I, and MDA5 which activate 
NFB and require IRF3 for the induction of type-I interferons (11, 30, 35, 41, 42, 
44, 49).  However, relatively little is known about how neuronal PRR pathways 
influence neurotropic arbovirus pathogenesis, but important observations have 
been made.  For instance, it is known that infection of neurons with several 
neurotropic arboviruses induces the expression of type-I interferons (15, 17, 20, 
49, 51, 53) and West Nile virus replication is enhanced in cortical neurons 
isolated from IPS-1-/-, TLR3-/-, IRF7-/, and IRF7/3-/- mice (15-17, 19, 57).  
Additionally, WNV is known to be recognized by both RIGI and MDA5 in non-
neuronal cell types (19), and evidence exists for the recognition of old world 
alphaviruses, which are not naturally encephalitic, via RIGI or MDA5 depending 
on the cell type and virus (10, 48).  
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In this report, we used targeted, genetic approaches to study the influence 
of neuronal PRR pathway signaling on neurotropic arbovirus pathogenesis using 
western equine encephalitis virus (WEEV) as a model neurotropic arbovirus due 
to its natural neurotropism.  We found that IRF3 mediates a cytoprotective 
response against WEEV that was likely due to IRF3-mediated induction of cell-
intrinsic factors with cytoprotective properties and independent of 
autocrine/paracrine type-I IFN activity.  Viral countermeasures to neuronal PRR 
pathways were also observed, where WEEV, and other neurotropic arboviruses, 
were found to potently and specifically block induction of neuronal antiviral PRR 
pathways at early times post infection.  The antiviral PRR pathway inhibitory 
capacity of WEEV was mapped to the capsid gene, which inhibited neuronal 
antiviral PRR signaling in part by early inhibition of IRF3 nuclear translocation 
and late inhibition of host macromolecular synthesis.  These data indicated that 
neuronal PRR pathways may be important determinants in neurotropic arbovirus 
pathogenesis and that neuronal PRR pathways and viral countermeasures to 
them may be exploited to develop more efficacious vaccines and anti-neurotropic 
arboviral treatments.  
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Materials and Methods 
Plasmids and Cytokines 
The dominant negative overexpression plasmids pDN-TLR3, pDN-TRIF(TIR), 
pDN-RIG-I(N), and pDN-IRF3(N), as well as the short-hairpin RNA 
overexpression plasmids pshRNA-MDA5, pGIPZ-shCD14, and pGIPZ-
shPI3K110 are described elsewhere (44).  The construction of the HA-tagged -
galactosidase in a pCMV-TnT (Promega, Madison, WI) backbone (pIVT-LacZ) 
has been previously described (55).  The shRNA overexpression plasmid pGIPZ-
shOASL was purchased from Open Biosystems (Huntsville, AL).  The 
overexpression plasmids pUNO-IRF3, pUNO-saIRF3, pUNO-MDA5, pUNO-
TLR3, and pUNO-saTRIF as well as the promoter-reporter constructs pISRE-
SEAP and pNFB-SEAP were purchased from InvivoGen (San Diego, CA).  The 
WEEV and WNV gene expression constructs were generated by PCR-amplifying 
individual WEEV genes from the full length WEEV cDNA clone pWEE2000 (12) 
or the WNV cDNA non-structural protein clone pc-WNV (provided by Richard 
Kinney, CDC, Atlanta, GA) and inserting them into the expression vector pCMV-
TnT.  V5-tagged viral gene expression constructs were generated for the 
indicated genes by first subcloning viral gene PCR products into pMT/V5-HisA 
(31) prior to inserting them into pCMV-TnT.  Recombinant human IFN-A/D and 
poly(I-C) are described elsewhere (44).  Murine IFN (NR-3082) human 
IFN (NR-3078), and human IFN (NR-3080) were obtained from the BEI 
repository (Manassas, VA).  Cells pre-treated with type-I IFNs were washed twice 
with HBSS (Life Technologies) prior to viral infection unless otherwise noted.          
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Cell Culture 
BE(2)-C and Vero cells were cultured as previously described (44).  BHK21 and 
BHK21 cells stably overexpressing bacteriophage T7 RNA polymerase (BHK21-
T7/C3) were cultured as for the Vero cells except cells were supplemented with 
non-essential amino acids (Life Technologies), and 10% fetal calf serum was 
used instead of bovine growth serum.  To avoid potential confounding effects of 
cell differentiation on transfection efficiency, stable cell lines were generated prior 
to differentiation as previously described (44) using Lipofectamine 2000.  Primary 
rat cortical neurons were isolated and cultured as previously described (44).  
Primary mouse cortical neurons were isolated from wild-type, IRF3-/- (15),    
MDA5-/- (27), and IFNAR-/- (19) C57BL/6 mice or IPS-I-/- (C57Bl/6 x 129Sv/Ev) 
(57) and wild-type litter mate control mice.  Freshly dissected cortices were 
stored in Hibernate E, 2% B27, 0.5 mM L-Gln and shipped overnight on ice.  
Mouse cortical neurons were disassociated and cultured as described for rat 
cortical neurons except they were plated at a density of 5 x 105 cells per cm2 on 
poly-D-lysine and laminin coated plates (15), washed once three hours after 
plating, and fed every 1-2 days until use at 10-12 days in culture at which point 
they were highly susceptible to glutamate excitotoxicity, a characteristic of 
differentiated cortical neurons.  
 Populations of human neurons were derived from the human embryonic 
stem cell line H7 (WiCell, University of Wisconsin Madison, Madison, WI)  over 
the course of four weeks through the sequential development of embryoid 
bodies, neuroepithelial rosettes, and neuroprogenitor cell cultures based on 
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previously established techniques (39, 43, 62).  Fully differentiated cultures were 
screened by immunuflourescence for the expression of neurofilament 200 and 
synaptophysin and analyzed by flow cytometry to assess culture purity.  Our 
hESC-derived human neurons were routinely positive for the neuronal surface 
markers CD90 (94.52 + 3.58), PSA-NCAM (97.76 + 0.17), and NGFR (72.61 + 
2.40).   
 Cell viability was determined by an MTT assay (44) or a luminescent ATP 
assay (ATPlite, PerkinElmer, Waltham, MA) according to manufacturer 
instruction.  Lipofection of BE(2)-C/m cells was accomplished using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer 
instructions except one-fourth the amount of total DNA by weight was used to 
transfect 60-75% confluent monolayers.  For cotransfections involving 3 or more 
plasmids, 25% of the total DNA weight was the transfection control pIVT-LacZ, 
and the remaining 75% of total DNA weight was divided equally among the 
remaining plasmids. Transfection complexes were removed after 6-20 hours of 
incubation.  Transfection of BHK cells was described previously (45). 
 
Viruses 
The Cba 87 WEEV strain generated from the cDNA WEEV clone, pWE2000, was 
used for all WEEV infections as previously described (12), except reconstitution 
of infectious virus was accomplished by transfecting BSR-T7/5 cells (45) and 
harvesting tissue culture supernatants 36 hours post transfection at which point 
most of the cells had rounded up and detached.  Infectious tissue culture 
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supernatants were cleared by centrifuging at 1500 x g for 10 minutes and 
contained 1-10 x 106 pfu/ml when quantitated by plaque assay on Vero cell 
monolayers.  Stocks were further expanded by passing them once in Vero cells 
for 48 hours at a low multiplicity of infection (MOI).  This typically yielded a final 
stock of 1-10 x 106 pfu/ml that was stored at -80o C in single use aliquots and 
used for all infections unless otherwise noted.   
 Generation of sucrose gradient purified WEEV was accomplished using 
infectious WEEV 2000 tissue culture supernatants generated previously (12).  
Supernatants containing infectious virions were precipitated overnight at 4o C 
with stirring in sterile 7% polyethylene glycol (Fisher, Fair Lawn, NJ) and 2.3 % 
sodium chloride (Fisher, Fair Lawn, NJ).  Virions were recovered by centrifuging 
at 3500 x g for 20 minutes, resuspended in HBSS (Life Technologies), loaded 
onto 15-45% linear sucrose gradients, and centrifuged at 35,000 x g for 60 
minutes.  Virion bands were readily visible at approximate 15-30% and 30-45% 
sucrose levels and were collected separately and diluted in HBSS.  Virions were 
pelleted at 35,000 x g for 60 minutes, resuspended in HBSS, titered (typically 
107-109 pfu/ml), and stored at -80o C in single use aliquots. 
 St. Louis encephalitis virus (SLEV) strain TBH-23 was obtained from 
Robert Tesh (University of Texas at Galveston) and propagated once in BHK21 
cells followed by propagation in Vero cells to generate viral stocks.  LaCrosse 
virus (LACV) strain LACV/human/1960 was also provided by Robert Tesh and 
propagated in Vero cells.  The GFP-tagged Sendai virus (SeV) is described 
elsewhere (44).  Viral titers were determined via plaque formation on Vero cell 
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monolayers as previously described (44), except SLEV was titered using BHK21 
monolayers.  To inactivate virus, supernatants were treated with ultraviolet light 
for 15 minutes on ice using a Spectrolinker crosslinker (Spectronics Corporation, 
Westbury, NY), which reproducibly blocked the propagation of WEEV in Vero 
cells and failed to produce detectable levels of WEEV transcripts in neuronal 
cells infected for 20 hours.  Viral attachment was carried out in complete culture 
media for 90 minutes followed by two washes and application of neutralizing 
antisera where indicated.  Primary cortical neuronal cultures were exclusively 
infected with sucrose-gradient purified WEEV to avoid non-specific neurotoxicity 
of unpurified viral preparations observed at high MOIs in preliminary experiments 
and to control for potential virus-independent activation of PRR pathways in 
unpurified viral preparations. 
 
Conditioned Supernatants  
Supernants from BE(2)-C/m cells or media treated with IFN-A/D were UV-
inactivated as described above, spun at 100,000 x g for 1 hour at 40 C, sterile 
filtered, and stored at -80o C.   
 
Immunoblotting, Immunofluorescence, Antibodies, SEAP Assay, and RT-
PCR Analysis 
Immunoblotting, RT-PCR, and immunofluorescence analysis were carried out as 
previously described (44).  All antibodies have been previously described (44) 
except V5, WEEV, and Oct-1 which were purchased from Sigma-Aldrich (St. 
172 
 
Louis, MO), ATCC (Manassas, VA), and BioVision (Mountain View, CA), 
respectively. Neutralizing antisera against IFN and IFN were purchased from 
PBL Biomedical Laboratories (Piscataway, NJ) and used at 500 neutralizing units 
per mL.  RT-PCR primer sequences are available upon request.  Secreted 
alkaline phosphatase activity was measured by a Quanti-Blue assay as 
previously described (12).   
 
Subcellular Fractionation and Protein Radiolabeling 
Nuclear and cytoplasmic extracts were generated as previously described (36) 
with several modifications.  Namely, aprotinin was not used, the first spin was at 
1500 x g, and the nuclei were washed twice with PBS and centrifuged at 1500 x 
g for 5 minutes at 4o C after each wash.   
To measure total protein synthesis, we used metabolic incorporation of 
35S-labeled methionine and cysteine.  Control and WEEV-infected cells were 
incubated with 50 μCi per ml PRO-MIX 35S-cell labeling mix (Amersham) for 30 
min, washed with TBS containing 100 μg cycloheximide per ml, and lysed in 
SDS-PAGE sample buffer (12).  After electrophoresis, gels were fixed, 
impregnated with sodium salicylate, dried, exposed, and digitized images of 
radioactive protein bands were quantitated as described previously (13).  
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Results 
WEEV Replication Induces IFN Transcription in Neurons 
To begin studying the influence of neuronal PRR pathways on neurotropic 
arbovirus pathogenesis, we first asked if WEEV could induce IFN transcription, 
a hallmark of PRR pathway activation, in a variety neuronal culture models (Fig 
3.1).  The first model employed was the previously characterized BE(2)-C 
neuronal culture model (46).  This neuroblastoma cell line can be differentiated 
into mature human neurons, designated BE(2)-C/m, using retinoic acid, and it 
has been used to demonstrate differentiation-dependent responses of human 
neuronal cells to type-I IFN stimulation and neurotropic virus infection (12).  
Infection of differentiated BE(2)-C/m neuronal cells with WEEV, or the positive 
control Sendai virus (SeV) (44), robustly induced IFN transcripts (Fig 3.1.A).   
However, treatment of BE(2)-C/m neuronal cells with UV-inactivated WEEV (see 
materials and methods) largely failed to induce IFN transcription (115 fold 
induction versus 4-fold induction respectively, p < 0.003), suggesting that viral 
replication was required and that mere cell surface exposure of virus was largely 
insufficient to induce IFN transcription in human neuronal cells (Fig 3.1.A).  
Similarly, human embryonic stem cell-derived neurons induced IFN transcripts 
in response to both SeV and WEEV infection (Fig 3.1.B).  Finally, rat primary 
cortical neurons induced IFN transcripts independent of the WEEV inoculating 
dose (Fig 3.1.C).  These data suggest that human neuronal PRR pathways  
respond to WEEV. 
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Figure 3.1.  WEEV induction of IFN transcription in neurons.  A.  BE(2)-C/m 
cells were infected with SeV MOI 5.0 for 30 hours, WEEV MOI 1.0 for 20 hours, 
or UV-treated WEEV MOI 1.0 for 20 hours, and IFN transcript levels were 
assessed via qRT-PCR.  B.  Human embryonic stem cell-derived neurons were 
infected with SeV MOI 0.1 for 72 hours or WEEV MOI 0.1 for 24 hours, and IFN 
transcript levels were assessed.  C.  Rat primary cortical neurons were infected 
with WEEV at the indicated MOI, and IFN transcript levels were assessed 20 
hours later.  Data represent averages and SEMs from three independent trials for 
A and B and two independent trials for C.  *p-value < 0.05.  
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IRF3 mediates a neuronal cytoprotective response against WEEV 
To further characterize the neuronal innate immune response to WEEV, we 
tested the functional impact of known PRR pathway signaling components on 
neuronal responses to WEEV.  PRR pathway signaling components were 
genetically disrupted by stably overexpressing specific dominant negative 
mutants to the central PRR pathway transcription factor IRF3, the cytoplasmic 
PRR RIG-I, and the required TLR3 adaptor TRIF in BE(2)-C/m cells (see (44) for 
validation and pertinent controls).  The IRF3 mutant lacks a DNA binding domain 
such that it competes for activation signals but does not induce transcription; the 
RIG-I mutant lacks the N-terminal CARD domains required for signal 
transduction; and the dominant negative TRIF mutant contains only a TIR 
domain and blocks downstream signal transduction.  Overexpression of the  
dominant negative IRF3 and RIG-I mutants in BE(2)-C/m cells reduced WEEV-
mediated induction of IFN transcripts (Fig 3.2.A); whereas no reduction was 
observed when the dominant negative TRIF mutant was overexpressed.  These 
results indicated that RIG-I and IRF3 mediated a neuronal transcriptional 
response to WEEV and that a TLR3-TRIF-mediated pathway was largely 
dispensible.  In further support of this, BE(2)-C/m cells stably expressing an 
shRNA targeting PI3K p110, which we previously demonstrated influences 
TLR3 signaling in neuronal cells (44), showed no reduction in IFN transcripts 
following WEEV infection (Supplemental Fig S3.1.A). 
 Next, we tested the significance of PRR pathway signaling components on 
cell viability and viral titers following WEEV infection.  Genetic disruption of IRF3  
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Figure 3.2.  Neuronal PRR pathway component-dependent responses to WEEV.  A.  
BE(2)-C/m cells stably overexpressing dominant negative forms of IRF3, RIG-I, or TRIF 
were mock infected or infected with WEEV MOI 1.0 for 20 hours, and IFN mRNA levels 
were measured by qRT-PCR.  Results are expressed as the fold-change compared to 
similarly treated cells stably transfected with an empty vector.  B.  Control and dominant 
negative IRF3 overexpressing BE(2)-C/m cells were infected with WEEV at the indicated 
MOI and percent viability relative to mock infected controls was assessed via a MTT 
assay 48 hours post infection (HPI: left panel), or titers (MOI 1.0) were measured via 
plaque assay from supernatants harvested at the indicated times (right panel).  Similar 
titers were observed for MOI 0.01 infections (data not shown).  C.  Control and dominant 
negative RIG-I overexpressing BE(2)-C/m cells were infected and analyzed as in B.  
Data represent averages and SEMs from at least three independent trials.  *p-value < 
0.05. 
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rendered BE(2)-C/m neuronal cells more susceptible to WEEV-mediated 
cytopathic effect (CPE) and resulted in modestly higher WEEV titers independent 
of MOI (Fig 3.2.B).  Expression of dominant negative RIG-I only impaired 
neuronal viability in response to a high WEEV inoculum and had no impact on 
viral titers (Fig 3.2.C).  These results indicated that in neuronal cells IRF3 
mediated a cytoprotective and potentially antiviral response to WEEV; however, 
RIG-I only mediated a cytoprotective response when the initial viral burden was 
high, suggesting that there may be redundancy for cytosolic detection of WEEV 
at the receptor level in neuronal cells or that the level of dominant negative RIG-I 
expression was insufficient to effect cell viability or viral replication following 
WEEV infection.  Consistent with the dispensable role of a TLR3-TRIF pathway 
for transcriptional responses to WEEV in neuronal cells, no change in viability or 
WEEV titers was observed in cells stably overexpressing dominant negative 
TRIF (Supplemental Fig S3.2.A).  Furthermore, transient overexpression of 
wild-type TLR3 or a dominant negative TLR3 mutant lacking a TIR domain failed 
to modulate neuronal viability following WEEV infection (Supplemental Fig 
S3.2.B and C).  To demonstrate the functionality of transiently overexpressed 
wild-type and dominant negative TLR3, we verified the appropriate modulation of 
an ISRE promoter in neuronal cells when presented with the TLR3 ligand poly(I-
C) (Supplemental Fig S2.5).  
 Since genetic disruption of RIG-I suggested that multiple cytoplasmic 
receptors may respond to WEEV in neurons, we examined the role of MDA5 in   
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Figure 3.3.  Neuronal cell MDA5-dependent response to WEEV.  A.  BE(2)-
C/m cells stably overexpressing a control or MDA5-targeted shRNA were either 
mock-pretreated or pretreated with 1000 U/ml of IFN-A/D for six hours, washed 
twice, and mock-infected or infected with WEEV MOI 1.0 for 20 hours.  Samples 
were analyzed by RT-PCR for IFN and rRNA transcripts.  Adjacent lanes for 
individual samples represent results using 10-fold dilutions of cDNA.  B.  Control 
BE(2)-C/m cells or cells stably overexpressing a MDA5-targeted shRNA were 
either mock-pretreated or pretreated with 1000 U/ml of IFN-A/D for six hours, 
washed twice, and then mock-infected or infected with WEEV MOI 1.0.  Cell 
viability relative to mock-infected controls was assessed 48 hours after infection 
via a MTT assay.  C.  Supernatants from WEEV-infected, IFN-A/D-pretreated 
control or MDA5-depleted BE(2)-C/m cells were titered via plaque assay at the 
indicated times post infection.  Data are representative of three independent trials 
for A.  Averages and SEMs are displayed from three independent trials for B and 
two trials for C.  *p-value < 0.05. 
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neuronal responses to WEEV (Fig 3.3).  To achieve this we generated stable 
BE(2)-C/m cells expressing a shRNA targeting MDA5.  In these neuronal cells, 
MDA5 expression was reduced by approximately 50% (Fig 2.4.B) (44), but when 
pretreated with type-I IFNs, the difference in MDA5 expression between control 
cells and cells with an MDA5-targeted shRNA greatly increased (Fig 2.4.B) (44).  
We observed no difference in the IFN transcriptional response to WEEV in 
control neuronal cells versus cells expressing an shRNA targeting MDA5 (Fig 
3.3.A) (compare lane 5 to 13), but when the difference in MDA5 expression was 
accentuated by pretreating with type-I IFNs, WEEV activated IFN transcription 
in control neuronal cells to a greater extent than in MDA5-depleted neuronal 
cells, which trended towards a significant difference (average density of lane 8 
versus 16, p-value 0.15) (Fig 3.3.A).  Targeting MDA5 expression in mock 
pretreated cells had no impact on neuronal cell viability following WEEV infection 
(Fig 3.3.B), but pretreating control versus MDA5-depleted neuronal cells with 
type-I IFNs significantly rendered the MDA5-depleted neuronal cells more 
susceptible to a WEEV-mediated CPE (Fig 3.3.B) and trended towards higher 
WEEV titers at 20 hours post infection (Fig 3.3.C) when the difference in MDA5 
expression was still greatly accentuated by the type-I IFN pretreatment 
(Supplemental Fig S3.3).  Pretreating the neuronal cells with type-I IFNs could 
have given them the capacity to produce functional amounts of 
autocrine/paracrine antiviral type-I IFN protein following WEEV infection, a 
finding that would be in contrast with our previous observations in mock 
pretreated neuronal cells (44).  To assess this possibility, we tested the ability of 
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type-I IFN neutralizing antibodies to modulate neuronal viability following WEEV 
infection. To accomplish this, we incubated IFN-pretreated BE(2)-C/m cells with 
type-I IFN neutralizing antibodies following WEEV attachment, and observed no 
difference in WEEV-mediated CPE compared to matched cells in which no 
neutralizing antibody was given (see the far right bar of Fig 3.3.B for reference).  
Altogether, these data indicated that MDA5 may detect WEEV in neuronal cells 
and mediate a cytoprotective and potentially antiviral response independent of 
antiviral autocrine/paracrine type-I IFN signaling. 
 In addition to the loss-of-function studies described above, we also 
attempted gain-of-function studies for neuronal PRR pathway signaling 
components, but we were unable to isolate neuronal cells stably overexpressing 
wild-type IRF3, RIG-I, or MDA5.  However, transient overexpression of IRF3 or 
RIG-I did protect neuronal cells from WEEV-mediated CPE, and transient 
overexpression of IRF3 or, as a positive control, a constitutively active IRF3 
mutant reduced viral titers (Supplemental Fig S3.4.A and B).  However, 
subsequent analysis revealed that transient overexpression of wild-type RIG-I or 
IRF3 constitutively induced type-I IFNs (Supplemental Fig S3.4.C and D), which 
we have previously shown decreases WEEV titers and enhances WEEV-infected 
neuronal cell viability (12).  Therefore, we could not confidently interpret the role 
these over expression constructs played in neuronal responses to WEEV given 
the confounding ability of the constructs to constitutively activate neuronal 
antiviral PRR pathways. 
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IRF3 Mediates a Cytoprotective Response to WEEV in Primary Cortical 
Neurons 
PRR pathway responses can be both cell type- and species-specific (34).  To 
determine if our observations were unique to neuroblastoma-derived human 
neurons, we examined neuronal responses to WEEV in primary cortical neurons 
derived from wild-type, IRF3-/-, MDA5-/-, and IPS-1-/- mice.  Consistent with results 
from neuroblastoma-derived human neurons, IRF3-/- and MDA5-/- cortical 
neurons were deficient in transcriptional induction of IFN when infected with 
WEEV (Fig 3.4.A and B).  In addition, IRF3-/- cortical neurons were significantly 
more susceptible to WEEV-mediated CPE independent of MOI but showed no 
difference in WEEV titers (Fig 3.4.C and D).  In contrast to the differentiated 
neuronal BE(2)-C/m cells, MDA5-/- and IPS-1-/- primary cortical neurons were as 
susceptible to WEEV-mediated CPE as wild-type cortical neurons (Fig 3.4.C), 
and WEEV titers from MDA5-/- primary neurons were no different than controls 
(Fig 3.4.D).  These results suggested that neuronal IRF3 mediated a 
cytoprotective response to WEEV and that the influence of individual PRRs on 
this neuron-protective response may be complex, redundant, unique to 
immortalized human neuronal cells, or a combination of these factors.  
Accordingly, we focused further studies on the role of IRF3 in neuronal 
responses to neurotropic arboviruses.         
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Figure 3.4.  PRR pathway component-dependent responses to WEEV in 
primary neurons.  A and B.  Wild-type, IRF3-/- (A), or MDA5-/- (B) primary 
neurons were mock infected or infected with WEEV MOI 1.0 for 20 hours, and 
transcript expression was assessed via RT-PCR for the indicated genes.  C.  
Primary cortical neurons derived from C57BL/6 wild-type, IRF3-/-, MDA5-/-, and 
IPS-1-/- mice were infected with WEEV MOI 1.0, and cell viability relative to mock 
infected controls was analyzed via a luminescent ATP assay 48 hours later.  
Neurons infected at an MOI of 0.01 demonstrated a similar phenotype (data not 
shown).  D.  WEEV titers from supernatants harvested from C were determined 
via plaque assay.  Neurons infected at an MOI of 0.01 demonstrated a similar 
phenotype (data not shown).  Data are representative of two independent trials 
for A and one trial for B.  Data represent averages and SEMs from three 
independent trials for C and two for D.  *p-value < 0.05. 
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Neuronal Cell PRR Responses to Diverse Neurotropic Arboviruses 
Pattern recognition receptor pathway responses are often both pathogen- and 
cell type-specific.  To determine if neuronal PRR pathways broadly respond to 
neurotropic viral infection, we examined neuronal cell responses to the 
neurotropic arboviruses St. Louis encephalitis virus (SLEV) and La Crosse virus 
(LACV).  Both SLEV and LACV induced IFN transcription in neuronal cells, 
albeit SLEV did so to a greater extent than LACV 20 hours post infection.  In 
addition, dominant negative IRF3 overexpression reproducibly reduced neuronal 
IFN transcription induced by SLEV and may have had a minor effect on LACV-
induced IFN transcription, but the ability of dominant negative IRF3 to inhibit 
LACV-mediated induction of IFN was not reproducible (Fig 3.5.A).  Next we 
assessed the effect of genetic disruption of the central PRR pathway 
transcription factor IRF3 on neuronal responses to SLEV and LACV, and we 
observed that neuronal cells overexpressing dominant negative IRF3 were 
significantly more susceptible to SLEV-mediated CPE independent of MOI (Fig 
3.5.B).  These data indicated that IRF3, like in the case of a WEEV infection, 
may influence neuronal survival following a SLEV infection.  In contrast, 
overexpression of dominant negative IRF3 had no effect on LACV-mediated 
CPE, indicating that IRF3 may be dispensable for neuronal survival following 
LACV infection or that the extent of dominant negative IRF3 overexpression was 
insufficient to affect LACV-mediated CPE (Fig 3.5.C) (note that end points for 
each viral infection were adjusted to give viabilities within typical linear death 
curves for BE(2)-C/m cells).  The differing influence of IRF3 in neuronal  
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Figure 3.5.  IRF3-dependent neuronal cell response to St. Louis and La 
Crosse viruses.  A.  BE(2)-C/m cells stably overexpressing a dominant negative 
IRF3 or a vector control were mock infected, infected with SLEV MOI 1.0, or 
infected with LACV MOI 1.0 for 20 hours followed by IFN and rRNA RT-PCR.  B 
and C.  Control or dominant negative IRF3 overexpressing BE(2)-C/m cells were 
infected with SLEV (B) or LACV (C) MOI 1.0, and cell viability relative to mock 
infected controls was assessed 48 (B) and 24 (C) hours later via a MTT assay.  
Neuronal cells infected at an MOI of 0.01 with either SLEV (B) or LACV (C) 
demonstrated similar phenotypes (data not shown).  Data are representative of 
two independent trials for A.  Averages and SEMs are displayed from three 
independent trials for B and C.  *p-value < 0.05. 
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responses to WEEV, SLEV, and LACV suggests that neuronal PRR responses 
are indeed complex and pathogen-dependent, but not without some level of 
overlap. 
 
Neuronal IRF3-Dependent Cytoprotective Response to WEEV is 
Independent of Type-I IFN Autocrine/Paracrine Signaling  
The observation that a dominant negative IRF3 mutant lacking a DNA binding 
domain accentuated WEEV-mediated CPE in neuronal cells suggested that IRF3 
transcriptional activity was involved in the IRF3-dependent cytoprotective 
response to WEEV.  To begin to understand what factors downstream of IRF3 
were required for this response, we first assessed whether induction of antiviral 
type-I IFNs might mediate the IRF3-dependent cytoprotective response.  
Previous attempts to identify type-I IFNs in supernatants of WEEV-infected 
neuronal cells via ELISAs failed to detect any measurable amount of type-I IFNs, 
and treatment of WEEV-infected neuronal cells with type-I IFN neutralizing 
antibodies failed to increase WEEV-mediated CPE (12).  In addition, WEEV 
failed to activate IFN-dependent ISRE reporter neuronal cells (data not shown).  
However, these assays may not have been sensitive enough to detect low levels 
of biologically relevant autocrine IFN signaling.  Therefore, we developed an 
alternative assay that measured accumulation of the interferon-stimulated gene, 
RIG-I, following viral infection.  When neuronal cells were infected with the 
positive control SeV, RIG-I protein accumulated (Fig 3.6.A, compare lane 1 and 
lane 6) in a manner dependent on autocrine IFN signaling because an IFN  
186 
 
 
Figure 3.6.  Neuronal response to WEEV is independent of type-I IFN 
autocrine/paracrine signaling.  A.  BE(2)-C/m cells were mock infected or 
infected with SeV MOI 5.0 and then incubated with 500 neutralizing units of 
control, IFN, IFN, or IFN and IFN neutralizing antibodies.  As positive 
controls for IFN neutralization, indicated mock-infected, neutralizing antibody-
treated cells were stimulated with 20 U/ml IFN or 10 U/ml IFN 28 hours post 
infection.  Whole cell lysates were collected 48 hours post infection and analyzed 
by western blot for RIG-I and GAPDH.  B.  BE(2)-C/m cells were mock-infected 
or infected with SeV MOI 5.0 for 48 hours, or  mock infected or infected with 
WEEV MOI 1.0 for 24 hours.  Lysates were analyzed by western blot for RIG-I 
and GAPDH.  C.  C57Bl/6 wild-type or IFNAR-/- cortical neurons were mock-
pretreated or pretreated with 100 U/ml of mouse IFN for 24 hours followed 
by WEEV MOI 1.0.  Cell viability relative to mock infected controls was assessed 
48 hours post infection via a luminescent ATP assay.  Similar results were 
observed with WEEV MOI 0.01 (data not shown).  D.  WEEV titers from 
supernatants collected from neurons infected for 20 hours described in C were 
determined via plaque assay.  Similar results were observed with WEEV MOI 
0.01 (data not shown).  No difference in titers was observed between wild-type or 
IFNAR-/- neurons at 8 or 48 hours post infection (data not shown).  Data are 
representative of three independent trials for A and B.  Averages and SEMs are 
displayed from three independent trials for C and one for D.  *p-value < 0.05. 
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neutralizing antibody blocked the SeV-mediated induction of RIG-I (compare lane 
6 to lane 8).  Treatment with an IFN neutralizing antibody had no effect on SeV-
mediated induction of RIG-I (compare lane 6 to lane 7).  Activity of the 
neutralizing antibodies was verified by demonstrating the specific ability of each 
antibody to potently and selectively block IFN- or IFN-mediated induction of 
RIG-I (see lanes 1-5).  To assess the neutralizing capacity of the type-I IFN 
antibodies throughout the experiment, exogenous IFN delivered to the antibody 
specificity control samples was added 28 hours after addition of neutralizing 
antibodies.  In addition, SeV increased global expression of IRF3 and expression 
of a slower migrating form of IRF3, often indicative of phosphorylated, 
transcriptionally-active IRF3 (Supplemental Fig S3.5).  Interestingly, WEEV 
failed to upregulate RIG-I expression in BE(2)-C/m cells (Fig 3.6.B) despite 
optimization of both MOI and assay end point.  As a further test for WEEV-
mediated induction of functional, antiviral type-I IFNs in neurons, we compared 
responses of primary cortical neurons derived from wild-type and interferon 
receptor (IFNAR) knock-out mice.  No difference in cell viability (Fig 3.6.C) or 
WEEV titer (Fig 3.6.D) from IFNAR-/- versus wild-type primary neurons was 
observed.  As a control for IFNAR function, primary neurons were pretreated with 
murine IFN which, as expected, protected neurons from WEEV-mediated 
CPE and decreased WEEV titers 20 hours after infection of wild-type neurons, 
while IFNAR-/- primary neurons were refractory to this treatment.  Altogether 
these data indicated that the IRF3-dependent, neuron-protective response to 
WEEV was independent of type-I IFN signaling.        
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 After ruling out type-I IFN signaling, we asked if the IRF3-dependent, 
cytoprotective response to WEEV was mediated by cell-intrinsic or -extrinsic 
factors other than type-I IFNs.  To accomplish this, we set up a bioassay to 
determine if conditioned supernatants from WEEV-infected BE(2)-C/m cells could 
transfer any modulatory capacity to a subsequent neuronal, WEEV-mediated 
cytopathic response.  Control conditioned supernatants, with exogenous IFN-
A/D added to them prior to conditioning, protected target neurons from a WEEV-
mediated CPE; however, conditioned supernatants from WEEV-infected 
producer neurons had no modulatory capacity on a subsequent WEEV-mediated 
CPE (Supplemental Fig S3.6).  These data suggested that the IRF3-dependent, 
cytoprotective response to WEEV may be independent of cytoprotective, soluble, 
secreted factors.  However, we could not rule out the possibility that our bioassay 
was insufficient to detect low levels of biologically relevant cell-extrinsic factors 
because we did observe a reduction in the protective capacity of type-I IFN-
treated conditioned media relative to that of media with fresh, unconditioned 
type-I IFN.  Therefore, we chose to directly test our alternate hypothesis that cell-
intrinsic factor(s) downstream of IRF3 were responsible for the IRF3-dependent, 
cytoprotective response to WEEV.     
 
WEEV-Induced, IRF3-Dependent Genes Which are Cytoprotective Against 
Neurotropic Arboviruses 
Many antiviral effector genes are directly induced by IRF3 (2, 58), some of which 
have known antiviral activity against alphaviruses, although most have not been 
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tested against WEEV (6, 63).  To test our hypothesis that the IRF3-dependent, 
cytoprotective response to WEEV in neuronal cells was mediated by cell-intrinsic 
factors, we searched for IRF3-dependent, WEEV-induced, antiviral effector 
genes.  We looked for the WEEV-mediated induction of several of these genes in 
BE(2)-C/m cells at both ten and twenty hours post infection via RT-PCR using 
IFN and rRNA as positive and loading controls, respectively (Fig 3.7).  The 
antiviral effectors oligoadenylate synthetase-like protein (OASL), myxoma 
resistance gene-B (MxB), MxA, and interferon inducible transcript-2 (IFIT2) were 
all reproducibly induced by WEEV, albeit to differing extents.  In contrast, the 
expression of the IRF3-inducible antiviral effectors IFIT1, viperin, ISG20, ISG15, 
and zinc finger antiviral protein (ZAP) were unresponsive to WEEV infection.  We 
verified that the two most responsive putative effectors, OASL and MxB (Mx2 is 
the mouse homologue), were dependent on not only IRF3, but also MDA5 in 
primary cortical neurons (Fig 3.4.A and B).  WEEV envelope protein-1 
transcripts were similar under each condition indicating that viral RNA burden 
between samples was equal.  These data demonstrated that WEEV induces cell-
intrinsic, IRF3-dependent, antiviral effector genes that may mediate an IRF3-
dependent, cytoprotective response.   
 To determine if IRF3-dependent antiviral effector genes might mediate the 
neuronal-protective response to neurotropic arboviruses, we assessed whether 
shRNA-mediated depletion of the most responsive putative effector, OASL, 
rendered neuronal cells more susceptible to neurotropic arbovirus-mediated  
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Figure 3.7.  WEEV-induced genes in neuronal cells.  BE(2)-C/m cells were 
mock infected or infected with WEEV MOI 1.0 for 10 or 20 hours, and 
transcription of the indicated genes was analyzed by RT-PCR.  Data are 
representative of three independent trials.   
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CPE.  For this purpose, we generated stable neuronal cell lines expressing 
control- or OASL-targeting shRNAs.  Targeted depletion of OASL was verified by 
RT-PCR from mock-, WEEV-, and LACV-infected BE(2)-C/m cells in relation to 
cells stably expressing a control shRNA (Fig 3.8.A).  Figure 3.8.A also 
demonstrates that LACV induces OASL mRNA.  Decreased expression of OASL 
had no effect on a neuronal WEEV- (Fig 3.8.B) or SLEV-mediated CPE (Fig 
3.8.D), but did modestly enhance a LACV-mediated cytopathic response (Fig 
3.8.C).  This finding indicated that OASL may mediate a neuronal response to 
LACV that could potentially be independent of IRF3, as cells stably 
overexpressing a dominant negative mutant of IRF3 responded normally to 
LACV (Fig 3.5.C).  Given that depletion of OASL had no effect on a neuronal 
response to WEEV, but did affect the response to LACV, we concluded that 
OASL was not likely to be involved in the IRF3-dependent, cytoprotective 
response to WEEV.  However, OASL depletion may have been insufficient to 
affect a neuronal response to WEEV.  Nevertheless, these results suggested that 
cell-intrinsic factor(s) downstream of IRF3 may be responsible for the IRF3-
dependent, cytoprotective response to WEEV, and that further study of other 
IRF3-dependent, putative cytoprotective genes, such as MxB, may identify genes 
which are protective against WEEV and possibly SLEV.  In addition, non-biased 
methods, such as transcriptional arrays, may identify alternative WEEV-induced, 
IRF3-dependent cytoprotective genes in neuronal cells. 
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Figure 3.8.  OASL protects neuronal cells from a LACV-mediated cytopathic 
effect.  A.  BE(2)-C/m cells stably overexpressing a control shRNA or a shRNA 
directed against OASL were mock-infected or infected at a MOI of 1.0 with 
WEEV or LACV for 20 hours and analyzed by RT-PCR for the transcription of 
OASL and rRNA.  B-G.  Cells described in A were infected with WEEV (B and E), 
LACV (C and F), or SLEV (D and G) at a MOI 0.01 (B-D) or 1.0 (E-F), and 
viability relative to mock-infected controls was assessed via a MTT assay at 24 
(F), 48 (B, C, E, and G), or 72 (D) hours post infection.  Data are representative 
of one trial for A.  Averages and SEMs are displayed from four independent trials 
for B-G.  *p-value < 0.05.  
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WEEV Impairs Poly(I-C)-Induced activation of ISRE and NFB Reporter 
Neuronal Cells                 
Time course studies in neuronal cells revealed that IFN transcription was not 
robustly activated until ten or more hours post WEEV infection (Supplemental 
Fig S3.7) despite measurable amounts of viral RNA, protein, and viral particles at 
times as early as six hours post infection (12).  Furthermore, WEEV induced 
IFN transcription, but we failed to observe any antiviral type-IFN protein 
production (Fig 3.6).  Together, these observations suggested that WEEV may 
impair antiviral PRR pathway signaling at early times post infection, which is a 
hypothesis that others have formed and subsequently confirmed based on similar 
observations of West Nile virus (WNV) (23).  To test this hypothesis, we 
determined if WEEV could inhibit poly(I-C)-mediated induction of neuronal 
antiviral PRR signaling.  We either pre-infected (Fig 3.9.A and Supplemental 
Fig S3.8.A) or pre-stimulated (Fig 3.9.B and Supplemental Fig S3.8.B) IFN-
dependent ISRE or NFB reporter neuronal cells (44) with the TLR3 ligand, 
poly(I-C) (pIC); the MDA5 ligand, transfected-poly(I-C) (T-pIC); IFN-A/D; or 
TNF and measured SEAP reporter production 20 hours later.  To control for 
non-specific effects of viral-mediated CPE, we monitored neuronal cell viability.  
WEEV impaired pIC- and T-pIC-mediated induction of ISRE and NFB reporter 
neuronal cells independent of order of infection (Fig 3.9.A and B), albeit the 
reduction in reporter signal was greater in pre-infected cells.  Under these 
conditions WEEV did not affect type-I IFN signaling, but when cells were pre-
infected for at least four hours prior to IFN  
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Figure 3.9.  WEEV inhibition of neuronal cell antiviral PRR pathways.  A.  
BE(2)-C/m ISRE (top panel) or NFB (bottom panel) reporter cells were mock 
pre-infected or pre-infected with WEEV MOI 1.0 for 90 minutes followed by 
mock-stimulation or stimulation with 100 U/ml IFN-A/D, TNF (25 ng/ml), 50 
g/ml poly(I-C) (pIC), or 500 ng/ml transfected-poly(I-C) (T-pIC) as indicated.  
Secreted alkaline phosphatase (SEAP) reporter activity and cell viability were 
measured 20.5 hours post infection and expressed as percents of mock-infected 
controls.  B.  Cells were treated as in A except they were pre-stimulated for 3 
hours and analyzed 16 hours post infection.  C.  BE(2)-C/m cells were pre-
infected with WEEV MOI 1.0 for 3 hours followed by a 4 hour mock, IFN-A/D, 
pIC, or T-pIC stimulation.  The indicated transcripts were analyzed by RT-PCR.  
Averages and SEMs are displayed from three independent trials for A and B.  
Data are representative of three independent trials for C.  *p-value < 0.05 
compared to either percent viability or matched mock-infected percent reporter 
activity.  
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stimulation, ISRE reporter levels decreased in parallel with cell viability, indicating 
that the impaired type-I IFN response by a well-established WEEV infection was 
likely due to a non-specific mechanism (Supplemental Fig S3.8.A).  WEEV also 
inhibited TNF-mediated activation of NFB reporter cells (Fig 3.9.A and B), 
suggesting that WEEV inhibits a common factor between PRR and TNF 
signaling pathways. 
 
WEEV Impairs Transcription of Poly(I-C)-Induced Endogenous Genes in 
Neuronal Cells 
To validate that WEEV specifically blocks neuronal PRR signaling at early times 
post infection, we examined whether WEEV could block poly(I-C)-mediated 
induction of endogenous transcripts.  As expected, pre-infection of BE(2)-C/m 
cells with WEEV decreased the induction of IFN transcripts by a four hour 
treatment of either pIC (compare group 3 to 7) or T-pIC (compare group 4 to 8) 
(Fig 3.9.C).  Importantly, WEEV was unable to block the IFN-mediated induction 
of ISG15 (compare group 2 to 6), but it did inhibit the poly(I-C)-mediated 
induction of ISG15 (compare group 3 to 7 and 4 to 8) (Fig 3.9.C).  A similar 
phenotype to that of ISG15 was observed for MxB, OASL, and Viperin and, 
which like ISG15, are responsive to both type-I IFN and PRR pathway signaling 
(Supplemental Fig S3.9).  WEEV envelope protein-1 transcripts were similar 
under each condition indicating that viral RNA burden between samples was 
equal.  These data demonstrated WEEV’s ability to specifically block neuronal 
antiviral PRR signaling at early times post infection.   
196 
 
Diverse Neurotropic Arboviruses Inhibit Poly(I-C)-Induced Activation of 
ISRE Reporter Neuronal Cells                         
 To determine if neuronal antiviral PRR pathway inhibition might be a general 
feature of neurotropic arboviruses, we assessed the ability of LACV and SLEV to 
inhibit poly(I-C)-mediated induction of ISRE reporter cells.  Both viruses, when 
co-administered with poly(I-C) or IFN-A/D, inhibited both exogenous poly(I-C) 
and transfected poly(I-C) stimulations, but had no effect an IFN-A/D stimulation 
(Fig 3.10.A and B).  Pre-infection for ten hours with LACV or SLEV did decrease 
type-I IFN-induced ISRE activity, but the reduction in ISRE activity was paralleled 
by a reduction in neuronal viability, indicating that the impaired type-I IFN 
response by a well-established LACV or SLEV infection was likely due to a non-
specific mechanism (Supplemental Fig S3.10).  Based on previous work (7), we 
expected LACV to block PRR signaling, but to our knowledge this is the first 
demonstration of SLEV inhibiting PRR signal transduction.  Given that WNV (22), 
WEEV, LACV, and SLEV inhibit antiviral PRR signal transduction, we postulate 
that this may be a common virulence mechanism of many neurotropic 
arboviruses. 
 
Exogenous Expression of WEEV Capsid Inhibits Neuronal Antiviral PRR 
Signaling  
To determine which WEEV gene was responsible for antiviral PRR pathway 
inhibition, we individually placed the WEEV genes non-structural protein-1 
(pnsP1), nsP2 (pnsP2), nsP3 (pnsP3), capsid (pCapsid), and the entire structural   
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Figure 3.10.  LACV and SLEV inhibit neuronal antiviral PRR pathways.  A 
and B.  BE(2)-C/m ISRE reporter neurons were infected with LACV MOI 1.0 (A) 
or SLEV MOI 1.0 (B) and co-stimulated with IFN-A/D (100 U/ml), pIC (50 
ug/ml), or T-pIC (700 ng/ml).  SEAP reporter activity and cell viability were 
measured 22 hours later and expressed as percents of mock infected controls.  
Averages and SEMs are displayed from three independent trials.  *p-value < 
0.05.       
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protein ORF (pStructural) under the control of a nuclear promoter.  Repeated 
attempts to clone full-length nsP4 under the control of a mammalian promoter 
failed as did attempts to express nsP4 in bacterial cells.  This was likely due to 
the short half-life observed for alphavirus nsP4 and is consistent with the 
relatively low amount of nsP4 expressed by cells infected with whole virus (56).  
A construct harboring the complete ORF for the nsP123 poly-protein did not 
express any detectable nsP123 in neuronal cells.  As positive controls for 
antiviral PRR pathway inhibition, WNV NS1 and NS2A were also cloned (pNS2A 
and pNS1) (18, 22, 38, 59).  Each viral gene was transfected into ISRE and 
NFB reporter neuronal cells and, 48 hours later, were mock-stimulated or 
stimulated with pIC, T-pIC, IFN-A/D, or TNF.  Neuronal viability was monitored 
following stimulation via an MTT assay to control for potential toxicity; none was 
observed.  Twenty-four hours after stimulation, SEAP reporter activity was 
assessed, and the results are shown in Figure 3.11.A and B.  Importantly, 
pCapsid and pStructural inhibited pIC and T-pIC-mediated ISRE activation 
without affecting an IFN-A/D stimulation.  pnsP1, pnsP2, and pnsP3 had no 
inhibitory activity, and the WNV genes pNS2A and pNS1 only inhibited a T-pIC 
stimulation.  TNF and pIC-mediated NFB activation were inhibited by both 
pCapsid and pStructural, whereas pnsP1, pnsP2, and pnsP3 had no NFB-
inhibitory capacity.  The WNV genes pNS2A and pNS1 only inhibited pIC-
mediated NFB activation.  T-pIC-mediated activation of NFB reporter cells 
previously transiently transfected with viral gene constructs was not assessed 
because we were unable to obtain sufficient T-pIC-mediated activation of  
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Figure 3.11.  WEEV capsid inhibits neuronal PRR signaling.  A and B.  
BE(2)-C/m ISRE (A) and NFB (B) reporter cells were transfected with a vector 
control or expression constructs containing the WNV genes pNS2A and pNS1, or 
the WEEV genes pCapsid, pStructural, pnsP1, pnsP2, or pnsP3.  48 hours post 
transfection cells were mock-stimulated or stimulated for 24 hours with IFN-A/D 
(100 U/ml) (A only), TNF (25 ng/ml) (B only), pIC (50 g/ml), or T-pIC (700 
ng/ml) (A only), and SEAP reporter activity was assessed and presented as 
percent of vector-transfected control cells.  Mock stimulations did not induce 
SEAP activity and were omitted from the figure.  Averages and SEMs are 
displayed from three independent trials.  *p-value < 0.05.  
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previously transiently-transfected NFB reporter cells.  The inability of WNV 
NS2A and NS1 to inhibit pIC-mediated induction of a neuronal ISRE, while still 
inhibiting a T-pIC stimulation and a pIC-mediated activation of neuronal NFB, is 
in contradiction with previous work.  One explanation for the ISRE phenotype 
may be that the dose of pIC given was too strong to observe NS1- or NS2A-
mediated inhibition.  This is consistent with the fact that the T-pIC stimulation is a 
much less efficacious activator of neuronal ISRE than the pIC stimulation (44), 
and may have been a weak enough stimulation to observe inhibition mediated by 
NS2A and NS1. In addition, the ability of NS1 to inhibit TLR3 signaling has 
recently come into question (5).  Since pCapsid and pStructural essentially 
mimicked the antiviral PRR pathway inhibitory capacity of live WEEV, we 
concluded that WEEV capsid was likely responsible for antiviral PRR pathway 
inhibition.           
Viral gene expression from the cloned constructs was verified in a variety 
of ways.  pNS1, pNS2A, pnsP1, pnsP2, and pnsP3 all contained a C-terminal V5 
epitope tag, and their expression in neuronal cells was verified via western 
blotting (Fig 3.12.A).  Transfection efficiency was monitored by co-transfection of 
a HA-tagged -galactosidase and western blotting for HA (Fig 3.12.A).  We were 
unable to find commercially-available antibodies sufficiently sensitive to detect 
any of the untagged WEEV structural genes in BE(2)-C/m cells at 24 or 48 hours 
post transfection, nor were we able to detect expression of a V5-tagged version 
of pCapsid in BE(2)-C/m cells.  Importantly, the V5-tagged version of pCapsid 
also inhibited neuronal PRR pathways (Supplemental Fig S3.11).  However, we   
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Figure 3.12.  Viral gene expression analysis.   A.  Lysates from cells 
transfected for 48 hours, as described in figure 11, were analyzed by western 
blot for HA-tagged B-galactosidase, V5-tagged viral gene expression constructs, 
and GAPDH.  B.  BE(2)-C/m cells were transfected for 24 hours with an empty 
vector or an expression construct containing WEEV capsid.  Samples were 
analyzed via RT-PCR for WEEV capsid or rRNA transcripts.  “-RT” denotes 
controls where reverse-transcriptase was omitted.  Data are representative of 
three independent trials for A and one for B. 
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did verify plasmid-mediated expression of WEEV capsid transcripts in BE(2)-C/m 
cells (Fig 3.12.B).  These data indicated that plasmid-mediated capsid 
expression in neuronal cells was poor, but, despite the poor expression of WEEV 
capsid protein, transfection of pCapsid was sufficient to inhibit PRR signaling. 
 
WEEV Capsid-Mediated Inhibition of Host Gene Expression  
It is well documented that the capsid protein of the new world alphavirus 
Venezuelan equine encephalitis virus (VEEV), a close relative to WEEV, inhibits 
host gene expression (25, 26).  Given our inability to visualize plasmid-mediated 
WEEV capsid protein expression in neuronal cells, we began to suspect that 
WEEV capsid may auto inhibit its own expression when under the control of a 
host-dependent promoter.  To test this, we asked if capsid expression from 
pCapsid, which also contains a T7 promoter, could be enhanced in cells 
expressing bacteriophage T7 RNA polymerase.  To accomplish this, BHK21 and 
BHK21 cells stably expressing a T7 bacteriophage RNA polymerase (BHK21-
T7/C3) were transfected with an empty vector, pCapsid, pStructural, or a   
T7-driven WEEV replicon with the N-terminal 27 residues of capsid fused to YFP 
(pWEErep-YFP) which served as a positive control for our capsid antibody and 
T7 function.  Whole cell lysates were collected 24 and 48 hours later and 
immunoblotted with a mouse ascites fluid generated from a WEEV-infected 
animal that we had previously determined recognized capsid.  Transfection 
efficiency was monitored by co-transfecting a HA-tagged -galactosidase and 
western blotting for HA.  Surprisingly, WEEV capsid (approximately 30 kDa) was 
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visualized in both BHK21 and BHK21-T7/C3 cells transfected with pCapsid or 
pStructural at 24 hours with slightly more capsid being expressed from pCapsid 
than pStructural, whereas replicon-driven expression of capsid was appropriately 
observed only in BHK21-T7/C3 cells (Fig 3.13.A).  However, by 48 hours post 
transfection, capsid expression was undetectable or extremely reduced in BHK21 
cells.  In contrast, capsid expression 48 hours post transfection in BHK21-T7/C3 
cells was maintained (Fig 3.13.A), suggesting that capsid undergoes 
autoinhibition when controlled by mammalian nuclear promoters.  In agreement 
with this, HA-tagged -galactosidase expression, which was controlled by the 
same hybrid promoter region as pCapsid and pStructural, was reduced by capsid 
expression, but -galactosidase expression was relatively even for matched 
transfections between BHK21 and BHK21-T7/C3 cells at 24 hours post 
transfection.  In comparison to the 24 hours time point, expression of -
galactosidase 48 hours post transfection in BHK21 cells co-transfected with 
pCapsid or pStructural was undetectable or extremely reduced, whereas in the 
BHK21-T7/C3 cells, levels of -galactosidase were significantly higher than in the 
identically transfected parental BHK21 cells 48 hours post transfection.  
Furthermore, sustained, high-level expression of capsid induced a cytopopathic 
effect observed 48 hours after pCapsid transfection of BHK21-T7/C3 cells 
(Supplemental Fig S3.12).  These data indicated that pCapsid is capable of 
producing WEEV capsid protein and that WEEV capsid is capable of inhibiting 
the expression of genes controlled by mammalian nuclear promoters.  These  
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Figure 3.13.  WEEV capsid-mediated inhibition of host gene expression.  A.  
Identical numbers of BHK21 or BHK21 cells stably expressing T7 RNA 
polymerase (BHK21-T7/C3)  were seeded overnight followed by transfection with 
a vector control, pCapsid, pStructural, or a T7-controlled WEEV replicon 
(pWEErep-YFP).  Whole cell lysates were collected 24 and 48 hours post 
transfection and subjected to western blot analysis.  Transfection efficiency was 
approximately 65% in both lines 24 hours post transfection with a GFP reporter 
(data not shown).  B.  BE(2)-C/m cells were infected with WEEV at an MOI of 10, 
labeled with 50 μCi per ml 35S-Met/Cys for 30 min prior to harvesting at 3, 6, 9, 
and 12 hpi, and lysates were analyzed by SDS-PAGE and fluorography.  
Translation of a cellular protein at approximately 45 kDa was quantitated by 
densitometry, and results are expressed as the percentage of uninfected 
controls.  Data are representative of two trials for A and four for B. 
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data, along with the fact that we could not detect capsid in BE(2)-C/m cells 
transfected with pCapsid, yet transfection with this construct inhibited neuronal 
PRR signaling, suggest that relatively little capsid expression was required to 
inhibit neuronal antiviral PRR signal transduction.  The ability of small amounts of 
WEEV capsid to inhibit PRR signaling is consistent with the early inhibition of 
antiviral PRR signaling in WEEV-infected neurons (Fig 3.9.C), a time when 
capsid expression is relatively low. 
The data in Figure 3.13.A suggested that WEEV capsid inhibits host gene 
expression.  To determine if this may contribute to WEEV-mediated inhibition of 
PRR signaling, we first assessed, in neuronal cells, the kinetics of WEEV-
mediated host translational shut down, which is often kinetically similar to 
alphavirus-mediated inhibition of host translation (14).  To achieve this, BE(2)-
C/m cells were labeled with 35S-Met/Cys at varying times post WEEV infection 
(MOI 10), and analyzed by SDS-PAGE and fluorography.  WEEV infection of 
neuronal cells suppressed host protein synthesis by just 25% compared to 
uninfected controls 9 hours post infection (Fig 3.13.B).  However, WEEV 
suppressed antiviral PRR signaling by approximately 65% (Fig 3.9.C 
densitometry of IFN RT-PCR) at 7 hours post infection with a ten-fold lower 
inoculum, suggesting that host translational shut off was not likely to be the sole 
mechanism for capsid-mediated inhibition of antiviral PRR signaling. 
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Capsid Inhibits Neuronal Antiviral PRR Signaling After IRF3 Activation 
To further characterize at what point WEEV capsid inhibits antiviral PRR signal 
transduction, we tested the ability of capsid to inhibit neuronal PRR pathways 
activated by expression of PRR pathway components that drive signaling from 
distinct points within the PRR pathway.  Specifically, ISRE reporter neuronal cells 
were stimulated by transfecting an empty vector (pEmpty), MDA5 (pMDA5), 
constitutively-active TRIF mutant (psa.TRIF), or a constitutively-active IRF3 
mutant (psa.IRF3) along with either a vector control (pVector), pnsP1, pDN.IRF3, 
pCapsid, or pStructural and an HA-tagged -galactosidase to monitor 
transfection efficiency (Fig 3.14.A).  As predicted, co-transfection of pDN.IRF3 
with psa.TRIF or pMDA5 inhibited ISRE activation, whereas co-transfection of 
pDN.IRF3 with psa.IRF3 was unable to inhibit ISRE induction.  Co-transfection of 
either pCapsid or pStructural with either psa.TRIF, pMDA5, or psa.IRF3 inhibited 
ISRE activation, where pCapsid had greater PRR pathway inhibitory activity than 
pStructural when co-transfected with psa.TRIF or psa.IRF3.  pNS1 and pnsP1 
had no inhibitory activity.  Expression of constitutively-active TRIF, MDA5, 
constitutively-active IRF3, and the transfection efficiency control -galactosidase 
was confirmed by western blot analysis (Fig 3.14.B).  Of note, transfection of 
psa.TRIF, pMDA5, or psa.IRF3 reduced expression of -galctosidase with 
psa.IRF3 and pMDA5 having the most and least dramatic effect respectively.  
Transfection of capsid reduced expression of constitutively-active TRIF, MDA5, 
and constitutively-active IRF3 by 80, 50, and 10%, respectively, relative to an 
empty vector (compare lane 2 to 8, lane 3 to 9, and lane 4 to 10).  In comparison,     
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Figure 3.14.  WEEV capsid inhibits neuronal antiviral PRR signaling after 
IRF3 activation.  A.  BE(2)-C/m ISRE reporter cells were co-transfected with a 
HA-tagged -galactosidase to monitor transfection efficiency as well as an empty 
vector (pEmpty) or the PRR pathway signaling components constitutively active 
MDA5 (pMDA5), TRIF (psa.TRIF), and constitutively active IRF3 (psa.IRF3).  To 
assess the ability of WEEV capsid to inhibit PRR signaling driven by the above 
PRR signaling components, cells were co-transfected with a negative vector 
control (pVector), pnsP1, the positive dominant negative IRF3 (pDN.IRF3) 
control, pCapsid, or pStructural.   SEAP reporter activity was measured 48 hours 
later and expressed as percent of pVector-transfected controls.  pEmpty-
transfected cells failed to induce SEAP activity and were omitted from the figure.  
B.  Lysates from the transfected cells described above were subject to western 
blot analysis for TRIF, MDA5, IRF3, HA, and GAPDH.  Densitometry (44) was 
used to quantitate relative expression of proteins indicated in the text.  Averages 
and SEMs are displayed from three independent trials for A.  Data are 
representative of two trials for B.  *p-value < 0.05.  
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transfection of pStructural reduced expression of constitutively-active TRIF, 
MDA5, and constitutively-active IRF3 by 45, 5, and 0%, respectively, relative to 
an empty vector (compare lane 2 to 11, lane 3 to 12, and lane 4 to 13).  
Therefore, we cannot rule out a role for capsid-mediated inhibition of host gene 
expression as a mechanism for inhibition of PRR signaling, especially when PRR 
signal transduction was activated by constitutively-active TRIF overexpression; 
however, capsid-mediated reduction of 0-10% for constitutively-active IRF3 
expression is unlikely to solely account for the capsid-dependent 80-90% 
inhibition of PRR signaling driven by constitutively-active IRF3 overexpression.  
These data further confirmed that WEEV capsid blocks antiviral PRR signaling 
and that it does so after IRF3 activation.  
          
A WEEV Structural Gene, Likely Capsid, Inhibits IRF3 Nuclear 
Translocation 
Venezuelan equine encephalitis virus capsid was recently shown to inhibit 
nuclear translocation by disrupting nuclear pore function (3, 4), and attenuated 
strains of VEEV blocked pores less efficiently (3).  In addition, strong VEEV 
capsid-mediated blockade of nuclear translocation was observed just 4 hours 
post infection, whereas strong inhibition of cellular transcription was delayed until 
10-24 hours post infection (3).  These data correlate nicely with our results 
regarding WEEV inhibition of antiviral PRR signaling and host gene shut off 
(Figures 3.9.C and 3.13.B).  To determine if disruption of nuclear translocation 
contributes to WEEV capsid-dependent inhibition of PRR signaling, we asked if 
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WEEV capsid inhibited nuclear translocation of IRF3 following a poly(I-C) 
stimulation.  To achieve this, BE(2)-C/m cells were transfected with an empty 
vector or pStructural.  pStructural was used as opposed to pCapsid because 
pStructural had a greater inhibitory capacity against a poly(I-C) stimulation and 
affected host gene expression less than pCapsid (Figures 3.11 and 3.14), which 
may be due to different dynamics for capsid expression and autoinhibition 
mediated by capsid expressed from pStructural versus pCapsid.  As before, cells 
were co-transfected with a HA-tagged -galactosidase to monitor transfection 
efficiency.  Forty-eight hours post transfection, BE(2)-C/m cells were mock 
stimulated or stimulated with pIC for 2.5 or 5 hours, separated into cytosolic and 
nuclear fractions, and analyzed by western blotting (Fig 3.15.A).  Immunoblotting 
for HA revealed uniform transfections and, as expected, a predominantly 
cytosolic localization of -galactosidase.  In contrast, the nuclear marker Oct-1 
was primarily present in the nuclear fractions, and -actin expression was 
present in both the cytosolic and nuclear fractions.  Throughout the time-course, 
IRF3 expression was predominantly cytosolic, but upon poly(I-C) stimulation, 
IRF3 accumulated in the nucleus of vector-transfected cells but not pStructural-
transfected cells.  These data suggested that a WEEV structural gene, possibly 
capsid, inhibits IRF3 nuclear translocation.   
To test if WEEV capsid, expressed in the absence of WEEV envelope 
proteins, inhibited IRF3 nuclear translocation, we co-transfected BE(2)-C/m cells     
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Figure 3.15.  A WEEV structural gene, possibly capsid, inhibits IRF3 
nuclear translocation.  A.  BE(2)-C/m cells were transfected with a vector 
control or pStructural for 48 hours followed by mock stimulation or stimulation 
with pIC (50 g/ml) for 2.5 or 5 hours.  Cells were also co-transfected with an HA-
tagged -galactosidase transfection control.  Samples were separated into 
cytosolic and nuclear fractions and subjected to western blot analysis for IRF3, 
HA, -actin, and Oct-1.  Blots were visualized via chemiluminescence using 
HRP-conjugated secondary antibodies; however, assessment of IRF3 was 
achieved by amplifying with a biotin-conjugated antibody and visualized using 
HRP-conjugated streptavidin.  B.  BE(2)-C/m cells were transfected with a vector 
control or pCapsid along with an empty vector or psa.IRF3.  Cells were also co-
transfected with an HA-tagged -galactosidase transfection control.  24 hours 
later cells were processed and analyzed as in A.  C.  BHK21-T7/C3 cells were 
transfected with a vector control or pCapsid and stained for WEEV capsid via 
immunofluorescence.  Total magnification is 1000X.  Data are representative of 
one trial for A, four for B, and one for C. 
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with either an empty vector or psa.IRF3 along with either a control vector or 
pCapsid.  We used psa.IRF3 as a PRR stimulus as opposed to psa.TRIF or 
pMDA5 because pCapsid inhibited constitutively active IRF3 expression the least 
(Fig 3.14.B).  Twenty-four hours post transfection, lysates were harvested, 
separated into cytosolic and nuclear fractions, and analyzed by western blotting 
(Fig 3.15.B).  Transfection of pCapsid reduced the expression of constitutively 
active IRF3 by 20% relative to a vector control (densitometry of lane 4 versus 3).  
However, transfection of pCapsid reduced the nuclear accumulation of 
constitutively active IRF3 by 40% relative to a vector control (densitometry of 
lane 8 versus lane 7: p < 0.05 when comparing the ratio of IRF3 in the 
cytoplasmic fraction to that in the nuclear fraction).  These data indicated that 
WEEV capsid may inhibit IRF3 nuclear translocation in neuronal cells.    
To assess where capsid is expressed in cells and to begin asking if it 
might also inhibit nuclear pore function, we performed immunofluorescence 
staining for WEEV capsid in BHK21-T7/C3 cells transfected with a vector control 
or WEEV capsid.  We viewed cells via epifluorescence, and in most transfected 
cells, we observed cytoplasmic capsid staining with more intense punctuate 
staining in a region surrounding nuclei.  In approximately 25% of cells, we also  
observed intense nuclear staining.  Importantly, an intense signal surrounding 
DAPI-stained nuclei was observed in approximately 30% of transfected cells (Fig 
3.15.C), a pattern which is reminiscent of VEEV capsid localization to the nuclear 
pore complex (3).  Together these data demonstrated that a WEEV structural 
gene, likely capsid, inhibits IRF3 nuclear translocation potentially by disabling 
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nuclear pores, and that this activity, along with suppression of host gene 
expression, may account for the ability of WEEV to inhibit neuronal cell antiviral 
PRR signaling.   
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Discussion 
Early cellular innate immune responses are often vital for effective 
pathogen control and may ameliorate the destruction of CNS neurons by 
neurotropic arboviruses, the extent of which is often an important determinant in 
the severity and clinical outcome of these infections.  In this report, we examined 
the functional impact of previously identified neuronal PRR pathways (44) on 
neurotropic viral infections primarily using WEEV as a model neurotropic 
arbovirus, whose primary target cell type within the CNS is the neuron.  We drew 
five main conclusions which are graphically represented in Figure 3.16.  First, 
WEEV activated neuronal PRR pathways via recognition by RIG-I and/or MDA5 
and subsequent induction of an IRF3-dependent transcriptional response.  
Second, IRF3 mediated a neuronal cytoprotective response to WEEV which was 
likely dependent on IRF3-mediated induction of cell-intrinsic factors with 
cytoprotective properties and independent of autocrine/paracrine antiviral type-I 
IFN signaling.  Third, the neurotropic arboviruses, WEEV, SLEV, and LACV all 
specifically inhibited neuronal antiviral PRR pathways at early times post 
infection.  Fourth, WEEV capsid was the main WEEV gene responsible for 
inhibition of neuronal antiviral PRR pathways.  Fifth, WEEV capsid likely inhibited 
neuronal antiviral PRR signaling by a combination of early inhibition of IRF3 
nuclear translocation and late inhibition of host macromolecular synthesis.  
These results indicated that neuronal PRR-pathway responses may be important 
determinants of neurotropic arbovirus pathogenesis. 
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Figure 3.16.  Interactions of neuronal PRR pathways with WEEV.  Following 
infection and replication of neuronal cells, WEEV may be recognized by RIG-I 
and MDA5, which mediate a transcriptional and cytoprotective response, 
depending on the neuronal culture model.  Future work using alternative 
neuronal models will have to definitively assess the role these two proteins play 
in neuronal PRR responses to WEEV.  On the other hand, IRF3 mediates both a 
transcriptional and cytoprotective response to WEEV in neurons.  Importantly, 
WEEV capsid inhibits antiviral PRR signaling in neurons possibly by inhibiting 
IRF3 nuclear translocation at early times post infection and shutting down host 
gene expression at late times post infection.  
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Previous studies investigating the role of PRR pathway signaling 
components on alphavirus infections suggested that old world alphaviruses, 
which are not naturally encephalitic, may be recognized by RIG-I (10) and MDA5 
(48) and require TBK1 for activation of IRF3 (10).  In contrast, the role of 
individual PRR signaling components on new world equine encephalitic 
alphaviruses has been much less studied, but it is known that equine encephalitic 
alphaviruses increase serum levels of type-I IFNs in mice (24, 33), and VEEV 
induces neuronal type-I IFN transcription (53, 60).  In this report, we examined 
the role of previously identified neuronal PRR signaling components (44) on a 
WEEV infection and found that RIG-I, MDA5, and IRF3 mediate a neuronal 
transcriptional response; however, only IRF3 consistently mediated a 
cytoprotective response to WEEV in both human neuronal cells and primary 
neurons, suggesting that cytosolic recognition of WEEV resulting in neuronal 
protection is likely complex and possibly redundant.  To clarify the role of 
individual neuronal PRR signaling components on neuron-protective responses 
to neurotropic arboviruses, future studies will require neuron-specific conditional 
knock-out mouse models to specifically analyze neuronal PRR responses in the 
neuron’s natural environment.   
In contrast to encephalitic alphaviruses, the neuronal PRR response to the 
neurotropic arbovirus WNV is fairly well characterized (15-17, 19, 57).  Similar to 
what we observed with WEEV, IRF3-/- primary neurons showed reduced 
induction of type-I IFNs following WNV infection and only modest increases in 
titers at late time points (15); therefore, it would be interesting to determine if a 
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neuronal IRF3-dependent cytoprotective response to WNV exists, especially 
since its relative, SLEV, induced a greater CPE in dominant negative IRF3 
overexpressing neuronal cells.      
 Many antiviral effector genes for old world alphaviruses have been 
identified (63), but to our knowledge, few have been tested for antiviral activity 
against intact new world alphaviruses (6).  Here, we identified the WEEV-
mediated, IRF3-dependent induction of several reported antiviral and potentially 
cytoprotective genes in neurons.  shRNA-mediated depletion of the most induced 
putative effector, OASL, revealed that OASL protects neuronal cells from a 
LACV-mediated CPE, but not from a WEEV- or SLE-mediated CPE.  To our 
knowledge, this is the first demonstration of an OASL-mediated cytoprotective 
effect in response to LACV, or any bunyavirus, in neuronal cells.  Little is known 
about how OASL exerts its antiviral and potentially related neuronal 
cytoprotective effect, but the antiviral activity of OASL against 
encephalomyocarditis virus, a picornavirus, requires its ubiquitin-like domain.  
Furthermore, the OASL-mediated antiviral effect against encephalomyocarditis 
virus is thought to be drastically different than the classic OAS genes because it 
lacks any 2’-5’ oligoadenylate synthetase activity (40).  The next most WEEV-
induced, IRF3-dependent, putative cytoprotective gene was MxB, which is 
currently being investigated for cytoprotective activity against neurotropic 
arboviruses.  In humans, MxB, unlike MxA, does not appear to have antiviral 
activity.  Moreover, MxB hasn’t been tested against most neurotropic 
arboviruses, and the high similarity between MxA and MxB suggests that MxB 
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may have an unobserved antiviral role.  MxA exerts its antiviral effect by 
disrupting the trafficking of viral components, which results in abrogated viral 
replication (50).  In contrast, the best described cellular function of MxB is to 
enhance nuclear import (32).  This suggests a particularly attractive hypothesis in 
which MxB may achieve a putative cytoprotective effect against WEEV by 
counteracting WEEV capsid’s ability to inhibit nuclear translocation of IRF3.  
Regardless, future studies will be required to further clarify the neuronal 
cytoprotective effects of these genes in response to neurotropic arboviruses.   
These future studies should be done in vivo as much as possible because 
important differences between tissue culture and animal models have been 
observed for antiviral effector responses to old world alphaviruses (63).      
 Many viruses block antiviral PRR signaling including the neurotropic 
arboviruses WNV (18, 22, 38, 59) and LACV (7).  Here we confirm the PRR 
pathway inhibitory capability of LACV and also demonstrate that WEEV and 
SLEV block neuronal antiviral PRR signaling.  We are unaware of any 
documented ability of SLEV to inhibit antiviral PRR signaling, and future work will 
be required to determine how SLEV achieves this, and if it does so in a manner 
similar to the related flavivirus WNV.   
Previous studies demonstrated that a panel of old and new world 
alphaviruses failed to induce type-I IFNs in MEFs and that the old world 
alphavirus, Sindbis virus, blocked SeV and poly(I-C)-mediated induction of type-I 
IFNs (10).  However, the PRR pathway inhibition by Sindbis virus and WEEV are 
in conflict with reports documenting that many new and old world alphaviruses 
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increase serum levels of type-I IFNs in mice (14, 24).  These conflicting data 
suggest that, in vivo, alphavirus antiviral PRR pathway countermeasures may not 
be completely effective in all cell types.    
We mapped the WEEV-mediated inhibition of neuronal antiviral PRR 
signaling to the capsid gene, which in the related new world alphaviruses, VEEV 
and eastern equine encephalitis virus (EEEV), blocks host transcription (25, 26).  
VEEV capsid also blocks nuclear translocation by “clogging” nuclear pores, and 
an attenuated VEEV strain blocked nuclear pores less efficiently leaving others to 
postulate that capsid-mediated blockade of nuclear pores and inhibition of host 
transcription may inhibit antiviral pathways (3, 4).  Accordingly, we tested and 
confirmed that a WEEV structural gene, likely capsid, inhibits IRF3 nuclear import 
and that WEEV capsid inhibits host gene expression, but future studies will have 
to definitively assess whether WEEV capsid localizes to and disrupts nuclear 
pores.  Future studies will also have to rule out a role for WEEV envelope 
proteins in the WEEV-mediated disruption of IRF3 nuclear translocation.  Since 
capsid expression had no effect on type-I IFN signaling and also blocked a 
TNF-mediated activation of NFB in neuronal cells, future studies will also have 
to determine the selectivity and specificity of WEEV-mediated inhibition of 
nuclear import.   
Based on these data, we speculate that WEEV capsid blocks neuronal 
antiviral PRR signaling early by inhibiting nuclear translocation and late through a 
combined inhibition of nuclear translocation and inhibition of host gene 
expression.  We base this hypothesis on the observation that IRF3 nuclear 
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translocation was robustly inhibited at early times post WEEV infection (Fig 
3.15.A), and this correlated well with early inhibition of neuronal antiviral PRR 
signaling (Fig 3.9.C).  In contrast, robust inhibition of host gene expression 
occurred much later (Fig 3.13.B).   
Despite the ability of WEEV to inhibit neuronal antiviral PRR signaling, a 
functional cell-intrinsic, IRF3-dependent, type-I IFN- independent, neuronal 
cytoprotective response remained.  One explanation for this paradox could be 
that the cytoprotective pathway is more responsive to low levels of PRR signal 
transduction reaching the nucleus than the antiviral type-I IFN-dependent 
pathway.  However, this hypothesis will need to be specifically addressed.  
Finally, future studies should also confirm that neuronal PRR pathways are 
indeed inhibited from responding to a WEEV stimulus, as opposed to a poly(I-C) 
stimulus, by identifying WEEV capsid mutants or generating WEEV virus-like 
particles lacking structural genes that robustly induce antiviral type-I IFNs in 
neuronal cells.  In conclusion, our data indicate that neuronal PRR pathways may 
be important determinants of neurotropic arbovirus pathogenesis and that 
neuronal PRR pathways, and viral countermeasures to them, may be exploited to 
develop more efficacious vaccines and anti-neurotropic arboviral treatments.                  
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Supplemental Figure S3.1.  Effect of PI3K p110 depletion on neuronal 
responses to WEEV.  A.  BE(2)-C/m cells stably expressing a vector control or 
shRNA targeting PI3K p110 were infected with WEEV (MOI 1) for 20 hours.  
RNA was harvested, and quantitative RT-PCR was used to assess IFN and 
rRNA transcript expression.  B.  BE(2)-C/m described in A were mock infected or 
infected with WEEV as indicated.  48 hours later cell viability was assessed by an 
MTT assay.  Averages and SEMs are displayed from 2 trials for A and B. 
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Supplemental Figure S3.2.  TRIF and TLR3-independent neuronal response 
to WEEV.  A.  BE(2)-C/m cells stably overexpressing an empty vector or 
dominant negative TRIF were mock infected or infected with WEEV as indicated.  
Cell viability was assessed 48 hours later via an MTT assay.  B and C.  BE(2)-
C/m cells were transfected with either a vector control (B and C), wild-type TLR3 
(B), or dominant negative TLR3 (C).  48 hours after transfection cells were 
infected and analyzed as in A.  Averages and SEMs are displayed from 3 
independent trials for A.  Representative experiments are displayed from 2 
independent trials for B and C.  
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Supplemental Figure S3.3.  IFN-mediated induction of MDA5 is transient 
relative to IFN-mediated induction of RIG-I in neuronal cells.  A.  BE(2)-C (C) 
or BE(2)-C/m (C/m) cells were mock stimulated or stimulated with IFN-A/D (100 
U/ml) for the indicated times.  Lysates were collected and analyzed by Western 
blotting for MDA5, RIG-I, and GAPDH.  B.  BE(2)-C cells stably expressing a 
control shRNA or an shRNA targeting MDA5 were mock stimulated or stimulated 
with IFN-A/D (1000 U/ml) for the indicated times.  Lysates were collected and 
analyzed as in A.  Data represent one trial.    
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Supplemental Figure S3.4.  Wild-type and constitutively active neuronal 
PRR pathway component-dependent responses to WEEV.  A.  BE(2)-C/m 
cells were transiently transfected with a vector control (pVector), wild-type RIG-I 
(pRIG-I), wilt-type IRF3 (pIRF3), or a constitutively active IRF3 (psa.IRF3) for 48 
hours.  Transfected cells were infected with WEEV as indicated, and viability was 
assessed 48 hours post infection via an MTT assay.  B.  BE(2)-C/m cells 
transiently overexpressing the indicated constructs were infected with WEEV 
(MOI 0.1).  Supernatants were harvested 72 hours post infection, and WEEV 
titers were determined via a plaque assay.  C.  Supernatants from BE(2)-C/m 
cells transfected with the indicated constructs were harvested at the indicated 
times and stored at -80o C.  Thawed supernatants were serially diluted and used 
to stimulate BE(2)-C/m ISRE reporter cells.  ISRE activation mediated by these 
supernatants was compared to a standard curve of IFN-A/D-mediated activation 
of an ISRE in neuronal cells.  Therefore, the amount of type-I IFNs in these 
supernatants harvested from PRR component-transfected neuronal cells are 
expressed in relative IFN units.  D.  BE(2)-C/m ISRE-SEAP reporter cells were 
transfected with the constructs listed in A as well as wild-type TLR3 (pTLR3) and 
wild-type MDA5 (pMDA5).  Six hours after transfection, cells were washed and 
incubated with fresh media containing a control antibody or a mix of IFN (500 
neutralizing U/ml) and IFN (500 neutralizing U/ml) neutralizing antibodies.  48 
hours after transfection, supernatants were harvested and SEAP activity was 
measured.  Averages and SEMs are displayed from 3 trials for A and 2 trials for 
C and D.  Data in B represent averages and standard deviations from duplicate 
wells for one trial.  *p < 0.05.        
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Supplemental Figure S3.5.  SeV-mediated activation and induction of IRF3 
in neuronal cells.  Lysates from BE(2)-C/m cells described in Figure 3.6.A were 
analyzed by Western blot for IRF3.  Data are representative of 3 independent 
trials.   
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Supplemental Figure S3.6.  Neuronal cell bioassay for viral-induced cell-
extrinsic factors capable of modulating a WEEV-mediated CPE.  
Supernatants from producer BE(2)-C/m cells mock infected, WEEV infected at 
the indicated MOI for 24 hours, or media treated with 80 U/ml IFN-A/D were 
conditioned to inactivate and remove viral particles and used to pretreat target 
BE(2)-C/m cells (bars 1,2,4, and 5) for 18 hours.  As a positive control, target 
BE(2)-C/m cells were pretreated with unconditioned media containing 80 U/ml 
IFN-A/D (bar 3).  Following pretreatment, target BE(2)-C/m cells were mock 
infected or infected with WEEV MOI 0.1 and cell viability relative to mock infected 
controls was assessed 48 hours post infection by a MTT assay.  Averages and 
SEMs are displayed from three independent trials.  *p-value < 0.05.      
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Supplemental Figure S3.7.  Kinetics of WEEV-mediated induction of IFN 
mRNA in neuronal cells.  BE(2)-C/m cells were mock infected or infected with 
WEEV MOI 5.0.  RNA was isolated at five and twenty hours post infection, and 
IFN, WEEV envelope protein-1 (WEEV-E1), and actin transcript expression was 
assessed via RT-PCR.  Data are representative of 2 independent trials.        
 
 
 
 
 
 
233 
 
 
 
Supplemental Figure S3.8.  WEEV inhibits PRR signaling but not type-I IFN 
signaling independent of its cytopathic effect in neuronal cells.  A.  ISRE-
reporter BE(2)C/m cells were mock infected or infected with WEEV MOI 1.0 for 
4.5 hours followed by mock stimulation or stimulation with IFN-A/D (100 U/ml) 
for 15 hours.  SEAP reporter activity and cell viability were assessed 15 hours 
after stimulation and presented as percents of mock infected controls.  B.  NFB 
reporter BE(2)-C/m cells were treated and analyzed as in Figure 3.9.B except 
they were pre-stimulated for 7.5 hours.  Averages and SEMs are displayed from 
three independent trials.  *p-value < 0.05 compared to either percent viability or 
matched mock-infected percent reporter activity.    
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Supplemental Figure S3.9.  WEEV inhibits neuronal cell PRR pathways but 
not type-I IFN pathways at early times post infection.  BE(2)-C/m cells were 
treated and analyzed as in Figure 3.9.C except MxB, OASL, and Viperin 
transcripts were assessed via RT-PCR.  Data are representative of 3 trials for 
Viperin, 2 for OASL, and 1 for MxB.      
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Supplemental Figure S3.10.  LACV and SLEV-mediated inhibition of 
neuronal type-I IFN signaling parallels virus-mediated cytopathic effect.  
BE(2)-C/m ISRE reporter cells were infected with either LACV (left panel) or 
SLEV (right panel) at a MOI of 1.0 for 10 hours followed by mock stimulation or 
an IFN-A/D (100 U/ml) stimulation.  SEAP reporter activity and cell viability were 
assessed 15 hours after stimulation and presented as percents of mock infected 
controls.  Averages and SEMs are displayed from three independent trials.      
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Supplemental Figure S3.11.  V5-tagged WEEV capsid inhibits neuronal PRR 
pathway signaling.  BE(2)-C/m ISRE reporter cells were treated and analyzed 
as in Figure 3.14.A except a C-terminal V5-tagged version of capsid was used.  
Averages and SEMs are displayed from 2 trials.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
237 
 
 
 
 
Supplemental Figure S3.12.  WEEV capsid causes death of BHK21-T7/C3 
cells.  BHK21 or BHK21 cells stably expressing a bacteriophage T7 RNA-
polymerase (BHK21-T7/C3) were transfected with the indicated constructs 
described in Figure 3.13.A.  100X, live-cell, phase-contrast images were acquired 
48 hours post transfection using an Olympus IX70 inverted microscope.  Data 
are representative of 2 trials.     
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Chapter IV 
 
The Identification of Thieno[3,2-b]pyrrole Derivatives as Novel Small 
Molecule Inhibitors of Neurotropic Alphaviruses 
 
 Neurotropic alphaviruses such as western, eastern, and Venezuelan 
equine encephalitis viruses cause serious and potentially fatal central nervous 
system infections in humans and are high priority potential bioterrorism agents.  
There are currently no widely available vaccines or effective therapies for these 
virulent pathogens.  To identify potential novel antivirals, we developed a cell-
based assay with a western equine encephalitis virus replicon expressing a 
luciferase reporter gene and screened a small molecule diversity library of 
51,028 compounds.  We identified and validated a thieno[3,2-b]pyrrole 
compound with a 50% maximal inhibitory concentration of less than 10 M, 
toxicity:activity ratio greater than 20, and potent activity against live virus in 
cultured neuronal cells.  Furthermore, a structure-activity relationship analysis 
with twenty related compounds identified several with enhanced activity profiles, 
including six with submicromolar 50% maximal inhibitory concentrations.  In 
conclusion, we have identified a novel class of promising inhibitors with potent 
activity against virulent neurotropic alphaviruses. 
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Introduction 
The Alphavirus genus within the Togaviridae family contains about 30 
mosquito-borne, enveloped, positive-stranded RNA viruses, one third of which 
cause significant diseases in human and animals worldwide (16).  For example, 
neurotropic alphaviruses such as western, eastern, and Venezuelan equine 
encephalitis viruses (WEEV, EEEV, and VEEV, respectively) infect the central 
nervous system (CNS) and can lead to severe encephalitis in humans with 
fatality rates of up to 70%, and survivors often bear long-term neurological 
sequelae (7, 8).  Neurotropic alphaviruses are also important members of the 
growing list of emerging or resurging public health threats (17) and are listed as 
CDC and NIAID category B bioterrorism agents, due in part to numerous 
characteristics that make them potential biological weapons: (i) high clinical 
morbidity and mortality; (ii) potential for aerosol transmission; (iii) lack of effective 
countermeasures for disease prevention or control; (iv) public anxiety elicited by 
CNS infections; (v) ease with which large volumes of infectious materials can be 
produced; and (vi) potential for malicious introduction of foreign genes designed 
to increase alphavirus virulence (38). 
There are currently no licensed vaccines or antiviral drugs for alphaviruses. 
Formalin-inactivated vaccines for WEEV or EEEV and a live attenuated VEEV 
vaccine (TC-83 strain) are available on an investigational drug basis and are 
limited primarily to laboratory workers conducting research on these viruses (38).  
However, these vaccines have poor immunogenicity, require annual boosters, 
and have a high frequency of adverse reactions.  The development of alternative 
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live attenuated, chimeric, and DNA-based alphavirus vaccines is being actively 
pursued, and several candidates have been tested in animal models (3, 9, 29, 
37, 40, 41, 44, 46).  Nevertheless, the broad clinical application of these newer 
generation vaccines is likely years away.  Furthermore, combined active 
vaccination and antiviral therapy may be a more effective response to an 
outbreak due to either natural transmission or intentional exposure to a viral 
pathogen (4). 
Several compounds have been reported to inhibit alphavirus replication, 
including the nucleoside analogs ribavirin and mycophenolic acid (27), (-)-
carbodine (20), triaryl pyrazoline (35), and seco-pregnane steroids from the 
Chinese herbs Strobilanthes cusia and Cynanchum paniculatum (25).  
Nevertheless, there is still a pressing need to identify new antiviral drugs to treat 
these virulent pathogens.  To this end, we developed a cell-based assay 
amenable to high-throughput screening (HTS) and analyzed a diversity library of 
>50,000 compounds for activity against WEEV RNA replication.  We identified 
and validated several compounds with potent inhibitory activity against WEEV 
and related alphaviruses.  Furthermore, we conducted limited structure-activity 
analyses with one of these compounds and identified a series of thieno[3,2-
b]pyrrole derivatives as novel inhibitors of neurotropic alphaviruses. 
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Materials and Methods 
Cells and Viruses 
Human neuroblastoma (BE(2)-C), African green monkey kidney (Vero), and baby 
hamster kidney (BHK) cell lines were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) and cultured in Dulbecco's Modified Eagle 
Medium containing 5% bovine grown serum (HyClone, Logan, UT), 10 U/mL 
penicillin, and 10 g/mL streptomycin.  BSR-T7/5 cells, which are BHK cells that 
constitutively express bacteriophage T7 RNA polymerase (5), were generously 
provided by K. Conzelmann (Max von Pettenkofer-Institut, Munich, Germany) 
and were cultured in Glasgow Minimum Essential Medium containing 10% heat-
inactivated fetal bovine serum, 10% tryptose phosphate broth, 1% sodium 
pyruvate, 0.1 mM non-essential amino acids, 10 U/mL penicillin, 10 g/mL 
streptomycin, and 100-500 g/mL G418 for selection.  BHK cell lines 
VEErep/SEAP/Pac and EEErep/SEAP/Pac, which stably express double 
subgenomic VEEV or EEEV replicons with secreted alkaline phosphatase 
(SEAP) reporter and puromycin resistance genes (33), were generously provided 
by I. Frolov (UTMB, Galveston, TX) and were cultured in Dulbecco's Modified 
Eagle Medium containing 7% fetal bovine serum, 10 U/mL penicillin, 10 g/mL 
streptomycin, and 5 g/mL puromycin for selection.  Infectious WEEV 
corresponding to strain Cba87 was generated as described (6), and all 
experiments that involved infectious WEEV were conducted under BSL-3 
conditions in approved facilities at the University of Michigan.  Fort Morgan virus 
(FMV) strain CM4-146 was purchased from ATCC, and SINV strain Toto64 was 
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generously provided by R. Kuhn (Purdue University, West Lafayette, IN).  FMV 
and SINV stocks were prepared and quantified using Vero cells as described for 
WEEV (6). 
 
WEEV Replicon 
We generated the WEEV replicon plasmid pWR-LUC using the full-length 
genomic clone pWE2000 (37), generously provided by M. Parker (USAMRIID, 
Frederick, MD).  This cDNA clone contains a T7 polymerase promoter to initiate 
precise transcription and produce viral RNA with authentic 5’ termini.  We 
amplified the firefly luciferase (fLUC) gene from pTRE2hyg-LUC (Clontech, Palo 
Alto, CA) by PCR without an ATG initiator codon but with engineered AvrII and 
BstXI sites and inserted the resultant fragment into the AvrII-BstXI site of 
pWE2000.  This strategy replaced the majority of the WEEV structural genes with 
the fLUC reporter gene, but retained the first 27 amino acids of the capsid protein 
to preserve the predicted stem-loop region within the structural gene translation 
enhancer previously identified in alphaviruses (11).  We further modified pWR-
LUC by placing a hepatitis  ribozyme and T7 terminator downstream of the 
polyadenylation region to ensure efficient transcription termination and produce 
authentic viral 3’ termini (Fig 4.1.A).  To generate the control replicon pWR-
LUC, we deleted the NheI-NheI fragment to remove the non-structural protein 
(nsP) coding region that included the majority of nsP2, 3, and 4. 
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Primary HTS, Dose-Response, and Secondary Validation of Candidate 
Compounds 
BSR-T7/5 cells at approximately 60-70% confluence in 10 cm tissue culture 
plates (~2 x 106 cells/plate) were transfected with 15 g pWR-LUC using 22 L 
TransIT LT-1 (Mirus, Madison, WI) according to the manufacturer’s instructions.  
Six hours after transfection cells were detached with 0.05% trypsin, diluted to 
6.25 x105 cells/mL, and 20 L cell suspension per well was dispensed into 384-
well plates preloaded with individual compounds in 30 L media at approximately 
5-10 M.  All plates contained a series of 32 wells each of negative and positive 
controls, which consisted of dimethyl sulfoxide and 100 M ribavirin, respectively.  
Plates were cultured at 37°C and 5% CO2 for 18 h, 40 L media was removed 
and replaced with 10 L per well Steady-Glo luciferase reagent (Promega, 
Madison, WI), and luminescence was read on a PHERAstar multi-mode plate 
reader (BMG Labtech, Durham, NC).  Individual compounds identified as primary 
hits as described below and in table 1 were validated by dose-response analyses 
using a similar 384-well format, but with 3.3-fold serial dilutions of compounds 
from 100 M to 10 nM assayed in duplicate wells.  Selected compounds were 
purchased from the original supplier and were further analyzed by repeat dose-
response and toxicity studies using a 96-well format, where cell viability was 
quantitated by either 3-[4,5-dimethylthizol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) assay as previously described (6) or with Alamar Blue (AbD Serotec, 
Oxford, UK) per the manufacturer’s instructions.  For secondary validation we 
used VEErep/SEAP/Pac and EEErep/SEAP/Pac cell lines cultured for 24 h with 
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compounds but without puromycin selection and measured SEAP reporter gene 
expression in supernatants using QUANTI-Blue (InvivoGen, San Diego, CA) per 
the manufacturer’s instructions. 
 
Final Verification of Candidate Compound Activity with Infectious Virus 
Human BE(2)-C neuroblastoma cells were incubated simultaneously with 
candidate compounds and infectious WEEV, FMV, or SINV at a multiplicity of 
infection (MOI) of 1 or 0.1, and MTT viability assays, Northern blots, and 
infectious virus quantitation by plaque assay were done at 6 to 48 h after 
infection as previously described (6).  For RT-PCR analyses, total RNA was 
isolated at 6 h after infection with TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions, digested with RQ1 DNAse 
(Promega), and RNA concentrations and integrity were determined by 
spectrophotometry and denaturing agarose gel electrophoresis.  First-strand 
cDNA synthesis was performed with the SuperScript First-Strand Synthesis 
System (Invitrogen) using equal amounts of total RNA with oligo(dT)12-16 
primers.  For semi-quantitative RT-PCR, we amplified 200-600 bp fragments of 
the WEEV nsP2 and E1 genes using cDNA serial dilutions and rRNA as the 
loading control, and analyzed products by agarose gel electrophoresis and 
ethidium bromide staining.  For quantitative RT-PCR, we amplified ~200 bp 
fragments of the WEEV or FMV E1 gene and rRNA as an internal control using 
iQTM SYBR Green Supermix (BioRad, Hercules, CA) according the 
manufacturer’s instructions in a 96-well format with triplicate wells.  Amplification 
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and detection were done with an iCycler iQ system, and fluorescence threshold 
values were calculated using SDS 700 system software (Bio-Rad). 
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Results 
Development and Validation of WEEV Replicon Cell-Based Assay for HTS  
The alphavirus life cycle includes three general steps that are viable targets for 
antivirals: (i) attachment and entry; (ii) genome replication; and (iii) encapsidation 
and release.  We focused on the second step, genome replication, in an attempt 
to identify novel alphavirus inhibitors.  The alphavirus genome is an 11-12 kb 
single-stranded positive-sense RNA molecule that is divided into two major 
domains (16).  The 5’ two-thirds of the alphavirus genome encodes the non-
structural proteins nsP1 through nsP4, which are initially synthesized as one or 
two polyproteins that undergo regulated autocatalytic processing to form an 
active replication complex.  This enzymatic complex subsequently synthesizes 
via a negative strand intermediate both full-length genomic RNA and a 4 kb 
subgenomic RNA.  The latter RNA segment encodes the structural capsid protein 
and envelope glycoproteins, which are not required for genome replication and 
therefore can be readily replaced by foreign genes to produce alphavirus vectors 
that are self-replicating, termed replicons (10). 
 To generate a WEEV replicon amenable to HTS, we replaced the majority 
of the structural genes in the full-length genomic clone pWE2000 (37) with the 
fLUC reporter gene (Fig 4.1.A).  To facilitate the host cell transcription necessary 
to “launch” the WEEV replicon from a plasmid we used a highly transfectable  
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Figure 4.1.  Cell-based WEEV replicon system for HTS.  A.  Schematic of 
WEEV replicon pWR-LUC.  Authentic 5’ and 3’ viral termini are generated by 
precise placement of T7 polymerase promoter (T7P) and hepatitis  ribozyme 
(Rz)/T7 terminator (T7T).  The final composition of the replicon transcript is 
indicated by the bar above the schematic.  Transcription of the fLUC reporter 
gene is controlled by the viral subgenomic promoter (SGP).  Region deleted for 
the control plasmid pWR-LUC is indicated by the dashed lines.  U, untranslated 
region; An, polyadenylated tail.  B.  fLUC reporter gene activity in BSR-T7/5 cells 
transfected with empty vector, pWR-LUC, or control pWR-LUC.  Results are 
expressed as relative luciferase units (RLU).  C.  BSR-T7/5 cells transfected with 
pWR-LUC were treated with no inhibitor, 50 M ribavirin (Rib), or 5 M 
mycophenolic acid (MPA), and fLUC activity was measured after 18 h.  Results 
are expressed as percentage of fLUC activity relative to untreated control. 
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BHK cell line derivative, BSR-T7/5 cells, which constitutively express 
bacteriophage T7 RNA polymerase (5).  One potential complication with using 
cell-based assays to identify antiviral compounds is the possibility that candidate 
compounds will induce type I interferon production and hence suppress virus 
replication indirectly.  The use of BSR-T7/5 cells minimizes this potential 
complication as BHK cells are deficient in both the production and response to 
type I interferons (2, 22, 28). 
BSR-T7/5 cells transiently transfected with the pWR-LUC replicon produced 
fLUC levels approximately three logs above background (Fig 4.1.B).  Reporter 
gene expression was dependent on viral RNA replication, as essentially no fLUC 
expression was detected in cells transfected with pWR-LUC, a control plasmid 
in which the majority of the nsP2-4 region had been deleted (Fig 4.1.A and B).  
Furthermore, both ribavirin and mycophenolic acid, which have previously been 
shown to inhibit alphavirus replication (27), suppressed fLUC expression in pWR-
LUC transfected BSR-T7/5 cells by approximately 80% (Fig 4.1.C).  We 
concluded from these results that the pWR-LUC:BSR-T7/5 system would 
function as a convenient and robust platform to identify small molecule inhibitors 
of WEEV RNA replication. 
  
Primary HTS and Validation of Candidate Antivirals Against Neurotropic 
Alphaviruses   
We initially optimized the pWR-LUC:BSR-T7/5 system to a 384-well HTS format 
and obtained Z’-scores greater than 0.6 (47), and subsequently used this 
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optimized system to screen a diversity library of 51,028 compounds at the 
University of Michigan Center for Chemical Genomics (CCG).  This composite 
library consisted of compounds from four smaller collections: Chembridge 
(13,028 compounds), ChemDiv (20,000 compounds), Maybridge (16,000 
compounds), and MS Spectrum 2000 (2,000 compounds), the latter of which 
included FDA-approved drugs.  Table 4.1 provides a composite overview of the 
experimental systems, criteria, and results from the HTS and subsequent 
validation steps.  For the primary HTS, we selected parameters to identify 
compounds with inhibitory activity that suppressed fLUC signal to at least 70% of 
the level obtained with the positive control ribavirin and obtained a hit rate of 
0.4%.  We further excluded 82 compounds that had activity in previous LUC-
based screens run at the CCG, thus reducing the selection of toxic compounds 
or those with direct activity against the reporter gene.  We subjected the 
remaining 114 compounds to dose-response analysis for primary validation, 
where 76% of these compounds had 50% maximal inhibitory concentration (IC50) 
values of less than 100 M. 
 We purchased new material from the original suppliers for 46 available 
compounds with the lowest IC50 values, and conducted secondary validation 
studies with cell-based replicons derived from VEEV or EEEV that incorporated a 
SEAP reporter gene rather than fLUC.  This step allowed us to further exclude 
compounds that were active against fLUC but also increased the potential of 
identifying compounds with broad activity against neurotropic alphaviruses.  
Eleven compounds showed activity in the secondary validation assays and were 
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Table 4.1.  Identification and validation steps in the discovery of novel 
small molecule compounds that inhibit neurotropic alphavirus replication. 
Step 
Experimental 
system/resource 
Criteria 
Number of 
compounds 
 
CCG chemical 
diversity library 
 51,028 
HTS 
pWR-LUC replicon 
and BSR-T7/5 cells 
Reduction in fLUC activity 
either: 
1) >2 S.D. per plate from 
negative control; or  
2) >90% per plate of 
positive control 
196 
  
No activity in previous 
CCG LUC-based screens 
114 
Primary 
validation 
pWR-LUC replicon 
and BSR-T7/5 cells 
Dose-response with IC50 
<100 M 
87 
Secondary 
validation 
EEEV/VEEV-SEAP 
replicon-bearing 
BHK cells 
Dose-response with IC50 
<100 M 
11 
Tertiary 
validation 
Repeat dose-
response with pWR-
LUC replicon and 
BSR-T7/5 cells 
Toxicity:activity ratio >5 4 
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evaluated in tertiary validation assays with repeat detailed dose-response and 
toxicity assessment to calculate precise 50% cytotoxicity concentration (CC50) 
and IC50 values using the original pWR-LUC:BSR-T7/5 system.  Four compounds 
had toxicity:activity (T:A) ratios (CC50/IC50) greater than 5 and were selected as 
candidates for further development as alphavirus inhibitors.  One of these 
compounds, designated CCG32091, was particularly potent with a T:A ratio of 
greater than 20 (Fig 4.2.A).  For comparison, ribavirin had an IC50 of 16.0 M 
and T:A ratio of 19 with the pWR-LUC:BSR-T7/5 system.  We chose CCG32091, 
which has a thieno[3,2-b]pyrrole core structure with a 4-fluorobenzyl R1 group 
attached to the pyrrole nitrogen and a 2-furanylmethylamine R2 group 
incorporated into the terminal carboxamide (IUPAC name, 1-({4-[(4-
fluorophenyl)methyl]-4H-thieno[3,2-b]pyrrol-5-yl}carbonyl)-N-(furan-2-
ylmethyl)piperidine-4-carboxamide), as our initial lead antiviral compound for final 
verification studies with live virus and structure-activity relationship (SAR) 
analysis (Fig 4.2.B). 
 
Verification of CCG32091 Antiviral Activity with Live Virus and Cultured 
Neuronal Cells 
The primary target cell of neurotropic alphaviruses is the CNS neuron (16), and 
thus we performed a final verification of the antiviral activity of CCG32091 using 
an in vitro model with human neuronal cells previously used to study WEEV 
pathogenesis (6).  For initial experiments with infectious virus we used FMV, an 
alphavirus closely related to WEEV, and SINV, the prototypic alphavirus used to 
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Figure 4.2.  CCG32091 potently inhibits WEEV replicon activity with 
minimal cytotoxicity.  A.  Dose-response curves of BSR-T7/5 cells transfected 
with pWR-LUC and treated with increasing concentrations of CCG32091.  fLUC 
reporter gene activity (closed circles) was measured by luciferase assay and 
viability (open circles) was measured by MTT assay.  Results are expressed as 
percentage of untreated controls.  Calculated concentrations that produced a 
50% inhibition of fLUC activity (IC50) or 50% cytotoxicity (CC50) compared to 
untreated controls are shown.  B.  Structure of CCG32091.  The R1 and R2 
groups central to the SAR (see Table 4.2) are highlighted by boxes. 
 
 
 
 
253 
 
study pathogenesis (16).  Both of these viruses can be handled safely under 
BSL-2 conditions.  One characteristic of alphavirus replication in cultured 
mammalian cells is the rapid development of cytopathic effect (CPE), which is 
due in part to virus-mediated disruption of host cell transcription and translation 
(12, 13, 15).  We infected BE(2)-C cells with FMV or SINV in the presence of 
12.5 M CCG32091 or 50 M ribavirin and measured cell viability at 48 h after 
infection by MTT assay (Fig 4.3.A).  Treatment with CCG32091 suppressed 
virus-induced CPE and increased cell viability from 20% in infected but mock-
treated cells to 50% or 70% for SINV- or FMV-infected cells, respectively.  
Furthermore, CCG32091 effectively suppressed FMV-induced CPE at 
concentrations as low as 3 M, the lowest concentration that we tested in this 
assay (data not shown). 
We also directly assessed the ability of CCG32091 to inhibit virus replication 
by examining infectious virion production (Fig 4.3.B) and viral RNA replication 
(Fig 4.3.C and D).  CCG32091 suppressed infectious FMV production by >90%, 
similar to the level of suppression seen with the positive control ribavirin (Fig 
4.3.B).  Furthermore, when we examined viral RNA replication by RT-PCR with 
either WEEV- or FMV-infected BE(2)-C cells, CCG32091 reduced the 
accumulation of viral RNAs encoding either nsP2 or E1 by 80-90% (Fig 4.3C and 
D).  Northern blotting confirmed that CCG32091 reduced both genomic and 
subgenomic RNA accumulation after infection (data not shown).  These results 
demonstrated that CCG32091 suppressed virus replication in infected neuronal 
 
254 
 
 
 
 
Figure 4.3.  CCG32091 inhibits alphavirus replication in cultured human 
neuronal cells.  A.  Human BE(2)-C neuronal cells were infected with FMV 
(black bars) or SINV (white bars) at an MOI of 0.1 and simultaneously treated 
with no inhibitor, 12.5 M CCG32091, or 50 M ribavirin (Rib), and cell viability 
was determined at 48 h after infection by MTT assay.  B.  BE(2)-C cells were 
infected with FMV at an MOI of 1, treated with inhibitors as described above, and 
virus titers in culture supernatants were determined at 24 h after infection by 
plaque assay.  C.  BE(2)-C cells were infected with WEEV at an MOI of 1, treated 
with CCG32091, and viral RNA corresponding to nsP2 and E1 regions were 
analyzed by RT-PCR at 6 h after infection.  rRNA levels are shown as a loading 
control.  D.  BE(2)-C cells were infected with FMV (black bars) or WEEV (grey 
bars) and treated with CCG32091 as described above, and viral RNA levels 
corresponding to the E1 gene were determined by quantitative RT-PCR. 
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cells, inhibited virus-induced CPE, and had broad activity against several 
alphaviruses. 
 
SAR Analysis with CCG32091   
To optimize the therapeutic profile of candidate antivirals in anticipation of future 
in vivo animal studies, we compared the structure of CCG32091 (Fig 4.2.B) with 
those of compounds in the entire CCG library.  We identified 20 compounds that 
contained a core thieno[3,2-b]pyrrole moiety but had different combinations of R1 
and R2 groups compared to CCG32091 (Table 4.2).  We had previously 
identified 6 of these compounds as “hits” in the primary HTS and had already 
completed dose-response analyses for validation (CCG32075, 32089, 32090, 
32092, 32095, and 32096).  We completed dose-response analysis of the 
remaining 14 compounds to obtain a limited SAR for CCG32091 (Table 4.2).  
This analysis revealed an approximate 250-fold range of IC50 values, from a high 
of 46.8 M to a low of 0.2 M, where 6 compounds had submicromolar IC50 
values (CCG32084, 32087, 32088, 32093, 32094, and 32095).  We also 
completed toxicity studies with these 20 compounds and found that 90% had 
CC50 values >100 M, including 5 of the 6 compounds with submicromolar IC50 
values (Table 4.2).  Although the data set was limited, several aspects of the 
SAR could be elucidated.  At R1, there appeared to be little difference between 
methyl and ethyl groups (compare the 4-methylbenzylamides CCG32055 and 
CCG32019).  However, substantially better activity was observed when the small 
alkyl group at R1 was replaced with 4-fluorobenzyl (compare CCG32088 with  
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CCG32052).  A direct comparison between 4-fluorobenzyl and 4-chlorobenzyl at 
R1 (2-furanylmethyl amides CCG32091 and CCG32095) also suggested that 4-
chlorobenzyl may represent a further optimization of R1.  Among the amines 
incorporated at R2, none were clearly superior to the others.  In fact, a variety of 
amines were seen with potent inhibitors, including 4-methylpiperidine 
(CCG32087), benzyl (CCG32088), isopentyl (CCG32093), and 4-(2-
furanylcarboxy)piperazine (CCG32084).  With regard to the internal piperidine 
carboxamide, the two 3-carboxamide analogs CCG32001 and CCG32009 had 
distinctly inferior activity compared to the closely related 4-carboxamide analogs 
CCG32025 and CCG32084, respectively.  Overall, these results identified 
several additional compounds with enhanced potency but similar toxicity 
compared to the original lead compound CCG32091, and provide a useful initial 
dataset to begin targeted design for optimized antiviral compound synthesis 
based on the core thieno[3,2-b]pyrrole structure. 
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Discussion 
 The neurotropic alphaviruses represent emerging pathogens with the 
potential for widespread dissemination and the ability to cause substantial 
morbidity and mortality (17, 38), but for which no licensed therapies currently 
exist.  In this report, we describe the identification of a novel class of thieno[3,2-
b]pyrrole compounds with inhibitory activity against WEEV and several related 
alphaviruses.  Heterocyclic compounds that contain a thieno[3,2-b]pyrrole core 
have been previously identified as possessing physiological activity with potential 
clinical applications, including uses as anti-inflammatory agents (23), glycogen 
phosphorylase inhibitors for diabetes treatment (45), and hepatitis C virus (HCV) 
inhibitors (30).  The latter use is particularly relevant for the work presented in 
this report, as thieno[3,2-b]pyrroles were identified as allosteric inhibitors of the 
HCV RNA polymerase (30), which is a plausible potential mechanism of action 
for their activity against alphaviruses (see below).  Significantly, the lead 
compound identified in this report, CCG32091 (Fig 4.2), is a PubChem registered 
compound (CID: 3240671) and part of the NIH Molecular Libraries-Small 
Molecule Repository (MLSMR), and has been identified as an active compound 
in only 5 of ~250 HTS assays conducted through the NIH Molecular Libraries 
Screening Center Network (MLSCN).  This indicates that the spectrum of its 
biological activity is fairly narrow, which is a highly desirable attribute in a 
potential lead compound.  In addition, Ilyin et al. recently described a solution-
phase strategy for the synthesis of novel combinatorial libraries containing a 
thieno[3,2-b]pyrrole core (19), thus providing the opportunity to further explore 
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and potentially exploit these compounds as therapeutics for a range of human 
diseases, including infections with neurotropic alphaviruses. 
 The mechanism(s) underlying the antiviral activity of thieno[3,2-b]pyrroles 
against neurotropic alphaviruses is unknown, but the use of a replicon-based 
assay for the HTS and validation steps (Fig 4.1 and Table 4.1) implicates viral 
replicase proteins as potential targets.  This hypothesis is supported by the 
observation that CCG32091 reduced viral RNA accumulation after infection of 
neuronal cells (Fig 4.3).  Furthermore, the broad activity of CCG32091 against 
infectious virus or replicons derived from WEEV, EEEV, VEEV, FMV, and SINV 
suggests that a highly conserved viral enzymatic activity may be targeted.  
Alphavirus nsPs contain several distinct enzymatic activities, including 
methyltransferase (nsP1) (1), protease and helicase (nsP2) (14, 18), and RNA 
polymerase (nsP4) (34).  In vitro assays have been developed for several of 
these activities (1, 39, 43), which provides a convenient approach to target 
identification.  An alternative approach that takes advantage of the intrinsically 
high error rate of viral RNA polymerases previously used successfully for antiviral 
target identification is the isolation and characterization of viral escape mutants 
(24, 26, 36). 
The preclinical utility of candidate novel antiviral agents rests on their ability to 
either prevent or treat established disease in animal models while exhibiting 
minimal toxicity.  The treatment of CNS infections presents an additional hurdle 
to overcome, as the blood-brain-barrier (BBB) represents a formidable obstacle 
for drug penetration (32).  The BBB is a highly effective physiologic barrier whose 
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primary function is to closely regulate access of blood stream components to the 
CNS.  Although infectious and inflammatory CNS diseases often disrupt BBB 
function and increase permeability, drug penetration remains an important aspect 
to consider in the development of antiviral agents against neurotropic 
alphaviruses.  Multiple physical-chemical factors influence CNS penetration of 
drugs, including lipophilicity, ionization properties, molecular flexibility, polar 
surface area (PSA), and size (31).  The latter two properties are particularly 
important, where studies of marketed CNS and non-CNS drugs indicate that PSA 
values less than 60-90 Å2 and MW less than 450 Da are required for adequate 
penetration (21, 42).  The lead thieno[3,2-b]pyrrole compound identified in this 
report, CCG32091 (Fig 4.2.B), has a calculated PSA of 67.5 Å2 and MW of 466 
Da (PubChem database; http://pubchem.ncbi.nlm.nih.gov).  Several of the 
compounds identified in the SAR (Table 4.2) had lower PSAs and MWs than 
CCG32091, and we are currently using the SAR results to refine the 
development of alphavirus inhibitors with reduced toxicity, enhanced potency, 
and optimal CNS penetration. 
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Chapter V 
General Discussion 
 
Summary of Results 
Neurotropic arboviruses cause severe and potentially fatal CNS infections 
where the extent of virus-mediated destruction of neurons is an important 
determinant in the severity and clinical outcome after infection.  Early cellular 
innate immune responses mediated by pattern recognition receptors are often 
vital for effective pathogen control, and an effective neuronal innate immune 
response may be crucial to prevent the essentially irreversible loss of critical 
central nervous system neurons by neurotropic arboviruses.  In this body of work 
I studied two complementary strategies of preventing death of neurotropic 
arbovirus-infected CNS neurons.  The first approach investigated the interaction 
of neurotropic arboviruses with neuronal innate immune pattern recognition 
receptor pathways where the goal was to identify host and viral targets for the 
development of more effective neurotropic arbovirus vaccines and therapeutics.  
The second approach identified novel small molecules which inhibited 
neurotropic arbovirus replication and enhanced the viability of neuronal cells 
infected with neurotropic arboviruses.  These studies significantly advance our 
knowledge of neuronal pattern recognition receptor signaling and neurotropic 
arbovirus biology by identifying specific, highly active PRR pathways in neurons 
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that mediate a neuron-protective response when challenged with neurotropic 
arboviruses.  In addition, these studies demonstrate the potent countermeasures 
that neurotropic arboviruses deploy against neuronal antiviral PRR pathways, 
and advance our understanding of how a particular neurotropic arbovirus, WEEV, 
subverts these antiviral pathways.  Finally, these studies identify a promising 
class of small molecules with anti-neurotropic arbovirus properties that may be 
clinically useful.  In this chapter, I further summarize these studies and discuss 
their implications, significance, and potential future directions.         
  
Neuronal Antiviral PRR Pathways 
To investigate the hypothesis that neuronal PRR pathways influence neurotropic 
arbovirus pathogenesis, I first asked what PRR pathways are present and active 
in neurons.  This was an important first step because PRR pathways are highly 
cell type-specific and few studies had investigated PRR signaling in neurons.  
Furthermore, the PRR signaling field progresses rapidly, suggesting that our 
knowledge of these pathways was, and likely still is, very incomplete.  Thus, 
establishing a basic molecular framework for PRR signaling in neurons would 
greatly facilitate future studies aimed at investigating their impact on neurotropic 
viral infections.  To accomplish this, I employed several neuronal culture models 
and used both global and targeted genetic and biochemical approaches to 
examine PRR expression and pathway activity in response to RLR and TLR 
ligands.  I discovered that human CNS neurons selectively respond to TLR3-, 
TLR4-, MDA5-, and RIG-I-mediated stimulation (Fig 5.1) and failed to 
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observe any TLR7/8 or 9-mediated stimulation.  TLR3, RIG-I and MDA5-
mediated stimulation was dependent on the transcription factor IRF3 and 
activated NFB resulting in the production of IFN and subsequent 
autocrine/paracrine ISRE activation mediated by the type-I IFN receptor.  In 
contrast, TLR4-mediated stimulation failed to activate an ISRE but did produce a 
neuronal NFB response.  In comparison to neurons, LPS stimulation of TLR4 in 
the human monocytic cell line, U937, robustly activated both NFB and an ISRE 
(Supplemental Fig S2.4), which suggested to us that neuronal TLR4 was 
unlikely to mediate a classical innate antiviral response and was not studied 
further.  Finally, detailed genetic and pharmacologic studies revealed that TLR3- 
and possibly MDA5-mediated neuronal responses are positively regulated by the 
PI3K pathway, and in particular the PI3K p110 subunit.  These results 
demonstrated that CNS neurons are immunologically active and possess specific 
and non-redundant functional PRR pathways.  In particular, those pathways 
typically stimulated by viral pathogens via nucleic acid recognition are especially 
active in neurons, and therefore may play a protective role in neurotropic virus 
pathogenesis.  In the time since these studies were conducted, several other 
viral PRRs were characterized including NOD2 (63) and DAI (67).  Due to this, 
the model depicted in Figure 5.1 in no way defines an absolute set of viral PRRs 
in neurons, and future studies should investigate the neuronal relevance of these 
newly identified PRRs. 
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Figure 5.1.  Neuronal PRR pathways.  Neuronal PRR pathways identified by 
the studies in chapter II are depicted.  Note that TLR4 does not appear to 
activate IRF3, and it is unclear if PI3Ks in neurons directly influence TLR3-
dependent activation of IRF3.  See text for further details.  pIC-polyinosinic-
polycytidylic acid, LPS-lipopolysaccharide, SeV-Sendai virus, T-pIC-transfected 
polyinosinic-polycytidylic acid. 
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Neuronal PRR Pathway Response to Neurotropic Arboviruses  
After establishing a basic molecular understanding of neuronal PRR pathways, I 
then tested whether these PRR pathways influenced neuronal responses to 
neurotropic viral infections.  To address this hypothesis I coupled targeted 
genetic and molecular techniques with several neuronal culture models including 
immortal neuronal cell lines, primary cortical neurons from mice with deletions in 
key PRR pathway component genes, and human embryonic stem cell-derived 
neurons.  I began studying the interaction between neuronal PRR pathways and 
neurotropic arbovirus infections by first asking if WEEV could induce neuronal 
IFN transcription, a hallmark of PRR pathway activation.  I found that 
replication-competent WEEV induced neuronal IFN transcription in a RIG-
I/MDA5 and IRF3-dependent manner (Fig 3.16).  These data are important 
because they greatly increase our knowledge of PRR pathway detection of 
encephalitic alphaviruses and subsequent downstream signaling in an 
appropriate target cell.   
Next, I determined if neuronal PRR pathway components mediated a 
cytoprotective or antiviral effect when challenged with a neurotropic arbovirus.  
Interestingly, IRF3 consistently mediated a neuron-protective response to WEEV 
and SLEV, but had no effect on a LACV challenge (Fig 3.16).  The differentiated 
human neuronal culture model, BE(2)-C/m, suggested that RIG-I and MDA5 also 
mediated a neuron-protective and possibly antiviral effect when challenged with 
WEEV, but these phenotypes were not recapitulated in the primary mouse 
neuronal culture model.   This discrepancy between neuronal culture models will 
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ultimately require further experimentation to settle the potential neuron-protective 
and antiviral role of RIG-I and MDA5 in response to WEEV.   
In differentiated human neuronal cells, IRF3 also appeared to have a 
small antiviral effect reflected by an approximate one-log10 reduction in WEEV 
titer, but this did not validate in primary cortical neurons derived from IRF3-/- 
mice.  Due to these discrepancies between neuronal culture models, I focused 
further experiments on the consistent neuron-protective effect of IRF3 and found 
it to be independent of the induction of antiviral type-I IFNs and likely due to 
direct IRF3-dependent induction of cytoprotective genes.  Candidate WEEV-
induced, IRF3-dependent, cytoprotective genes included OASL and MxB, where 
depletion of the most induced candidate, OASL, enhanced a LACV-mediated 
CPE but had no effect on WEEV or SLEV.  Curiously, OASL may mediate a 
neuronal response to LACV independent of IRF3, as cells stably overexpressing 
a dominant negative mutant of IRF3 responded normally to LACV.  Nevertheless, 
these results suggested that cell-intrinsic factor(s) downstream of IRF3 may be 
responsible for the IRF3-dependent, cytoprotective response to WEEV.  Further 
analysis of other neurotropic arbovirus-induced, IRF3-dependent, putative 
cytoprotective genes, such as MxB, may identify genes which are protective 
against WEEV and SLEV.  With this in mind, MxB is an attractive candidate 
because it is closely related to the well characterized antiviral effector gene MxA, 
which has antiviral effects against old world alphaviruses, bunyaviruses, and 
flaviviruses (64).  In contrast to MxA, which exerts its antiviral effect by disrupting 
the trafficking of viral nucleocapsids resulting in abrogated viral replication (60), 
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MxB is not known to be antiviral, but it has not been tested against many 
neurotropic arboviruses including WEEV.  The best described cellular function of 
MxB is to enhance nuclear import (41).  This suggests a particularly attractive 
hypothesis in which MxB may achieve a putative cytoprotective effect against 
WEEV by counteracting WEEV capsid’s ability to inhibit nuclear translocation of 
IRF3.  Future studies will be required to test this hypothesis. 
As mentioned above, the ability of OASL to mediate a neuron-protective 
effect against LACV is somewhat puzzling because OASL is an IRF3-dependent 
gene (50), yet IRF3 appeared to have no effect on an LACV-mediated CPE 
(Chapter III).  These results may indicate that in neurons infected with LACV, an 
alternate pathway independent of IRF3 induces OASL.  The antiviral effects of 
OASL are poorly characterized in comparison to the classic OAS genes (49), and 
future studies will need to address the mechanism of OASL-mediated 
cytoprotection against LACV as well as clarify whether OASL’s neuron-protective 
effects are direct or indirectly related to an antiviral effect.  In addition, future 
studies should be done in vivo as much as possible because important 
differences between tissue culture and animal models have been observed for 
antiviral effector responses (76).  In summary, these data extend the protective 
effect of OASL from picornaviruses (49) to now include a neurotropic arbovirus in 
Bunyaviridae.  More broadly, these studies establish neuronal PRR pathways as 
potentially important determinants in neurotropic arbovirus pathogenesis.   
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Neurotropic Arbovirus Countermeasures to Neuronal PRR Pathways 
Viral PRR pathways protect host cells and tissues against viral infections, yet 
many viruses, including the neurotropic arboviruses WNV and LACV, possess 
PRR pathway countermeasures allowing them to efficiently replicate, avoid 
immune detection, and cause disease (13, 51, 74).  I suspected that WEEV may 
also potently block these pathways given that IFN transcription was not robustly 
induced until late in infection, and that I could not detect any WEEV-induced 
antiviral type-I IFN protein production.  As suspected, WEEV, SLEV, and LACV 
all potently and specifically blocked induction of neuronal antiviral PRR pathways 
at early times post infection.  To my knowledge this is the first demonstration of 
WEEV and SLEV inhibiting PRR signal transduction in a relevant cell type.  It will 
be interesting to see if SLEV employs homologous mechanisms of PRR inhibition 
to that of other members of Flaviviridae, such as WNV and hepatitis C virus (4, 
18).  Since WNV, SLEV, LACV, and WEEV all inhibit PRR pathways, I postulate 
that this may be a general virulence mechanism for neurotropic arboviruses.     
Alphavirus inhibition of antiviral signaling is often attributed to non-specific 
inhibition of host gene expression mediated by nsP2 for old world viruses and 
capsid for new world viruses (25).  Recently, VEEV capsid has also been shown 
to inhibit nuclear translocation, and it was proposed that this may also contribute 
to the inhibition of antiviral signaling (3), although this hypothesis was not directly 
tested.  I decided to systematically and directly explore how WEEV inhibits 
neuronal PRR signaling at a molecular level, and similar to VEEV, I mapped the 
antiviral PRR pathway inhibitory capacity of WEEV to the capsid gene.  WEEV 
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capsid inhibited antiviral PRR signaling downstream of IRF3 activation, and a 
WEEV structural gene(s), likely capsid, inhibited IRF3 nuclear translocation.  
Further studies found that WEEV capsid also inhibited host gene expression, 
suggesting a dual mechanism for capsid-mediated inhibition of neuronal antiviral 
PRR signaling (Fig 3.16).  Interestingly, this mechanism appears to be distinct 
from that of nsP2 for old world alphaviruses in which IRF3 efficiently reaches the 
nucleus in SINV (7) and Semliki Forest virus-infected cells (5).   Altogether these 
studies examining the interaction of neuronal PRR pathways with neurotropic 
arboviruses indicated that neuronal PRR pathways are important determinants in 
neurotropic arbovirus pathogenesis.  These studies also suggest that neuronal 
PRR pathways and viral countermeasures to them may be exploited to develop 
more efficacious vaccines and anti-neurotropic arboviral treatments. 
It is somewhat paradoxical that WEEV activates neuronal IFN 
transcription, yet a functional cell-intrinsic, IRF3-dependent, type-I IFN-
independent, neuronal, cytoprotective response remains.  One explanation for 
this paradox could be that the cytoprotective pathway is more responsive to low 
levels of PRR signal transduction reaching the nucleus than the antiviral type-I 
IFN-dependent pathway.  Adding to this paradox, new and old world alphaviruses 
increase serum levels of type-I IFNs (14, 24) in mice, suggesting that PRR 
pathway inhibition may be incomplete or ineffective in alternate cell types.  
Reassuringly, there is literature precedence for the simultaneous requirement for 
host antiviral signaling to effectively resolve infection of viruses that deploy potent 
countermeasures to the very same required host antiviral pathways (4), and one 
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well studied example is that of the neurotropic arbovirus WNV (19).  Hence, it 
appears that there is an intense interplay between viruses and host antiviral PRR 
pathways possibly indicating that viruses and host PRR pathways generally co-
evolve in a way that strikes a balance between the need to efficiently replicate 
yet not be overly burdensome on the host such that transmission remains 
efficient.  Since humans are often dead end hosts for neurotropic arboviruses, it 
could be argued that neurotropic arboviruses and humans may have come into 
contact with each other relatively recently, and that over time host antiviral 
pathways and viral countermeasures to these antiviral pathways will reach an 
equilibrium such that neurotropic arboviruses are less pathogenic and that 
humans become natural participants in the transmission cycle of neurotropic 
arboviruses.  Of course, these hypotheses will need to be specifically addressed.  
One way of testing these hypotheses would be to determine if WEEV is less able 
to inhibit PRR signaling in hosts that participate in its natural enzootic cycle.  
Additionally, future efforts should also confirm that neuronal PRR pathways are 
indeed inhibited from responding to a neurotropic arbovirus stimulus, as opposed 
to a poly(I-C) stimulus.  For WEEV, this could be accomplished by identifying 
WEEV capsid mutants or generating WEEV virus-like particles lacking structural 
genes that robustly induce antiviral type-I IFNs in neuronal cells.       
 
Neurotropic Alphavirus Replication Inhibitors 
Finally, I took a different approach to preventing death of neurotropic arbovirus 
infected neurons by searching for small molecules that block neurotropic 
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arbovirus replication.  To achieve this, ~51,000 small molecules were screened 
for the ability to inhibit a WEEV replicon harboring a luciferase reporter.  I 
identified thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of 
neurotropic alphaviruses.  Importantly, these molecules decreased alphavirus 
titers and protected human neuronal cells from alphavirus mediated cytopathic 
effect.  There is a great need for drugs to treat neurotropic arbovirus infections; 
therefore, these inhibitors are actively being pursued for clinical use by 
performing in vivo studies and optimizing the lead compound for reduced 
cytotoxicity, increased potency, increased efficacy, and greater CNS penetration.  
Perhaps small molecules derived from this screen will one day be partnered with 
small molecule modulators of PRR pathways to form a highly effective, anti-
neurotropic arbovirus, multi-component therapy.  
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Unanswered Questions and Future Directions 
 The studies in this body of work give rise to many important questions 
including: 
1. What is the mechanism and downstream factors of PI3K in neuronal 
antiviral PRR signaling? 
2. What is the role of PI3K in neuronal responses to neurotropic 
arboviruses? 
3. What other factors mediate the IRF3-dependent, neuron-protective 
response to WEEV? 
4. How does a WEEV structural gene(s), likely capsid, inhibit IRF3 nuclear 
translocation? 
5. What is the in vivo relevance of neuronal PRR signaling for WEEV 
pathogenesis? 
6. How do neuronal PRR responses interact with PRR responses by other 
resident CNS cell types? 
7. What is the mechanism of thieno[3,2-b]pyrrole derivatives’ inhibition of 
alphaviruses? 
8. Are neuronal PRR pathways and viral countermeasures to these 
pathways viable targets for development of therapeutics?   
 
The following pages will discuss these questions and potential future directions 
that could be taken to address them.   
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What is the mechanism and downstream factors of PI3K in neuronal 
antiviral PRR signaling? 
The PI3K pathway mediated by p110 and its receptor subunit p85 activate a 
number of downstream signaling molecules.  One well characterized pathway 
activates the kinase Akt which has been linked not only to mTOR activation and 
subsequent enhancement of translation (15), but also to activation of NFB (28, 
53, 56).  In addition, a PI3K/Akt/mTOR/S6-kinase pathway has been implicated 
in TLR9-mediated induction of IFN in dendritic cells (8).  In chapter II I identified 
PI3Ks as important mediators of neuronal RLR and TLR pathways, but the 
mechanism of PI3K-mediated antiviral PRR signaling remains obscure.  The 
majority of work investigating the role of PI3Ks in PRR signaling has focused on 
its effects during TLR-initiated signaling (32), where it appears to be necessary 
for full activation of IRF3.  Other studies determined that PI3K/AKT pathways are 
essential for neuronal development and survival (11, 12, 35), suggesting a 
potential link between antiviral PRR pathway activation and the ability of neurons 
to overcome an infection until an adaptive immune response can be fully 
established.  The kinase inhibitor library studies in chapter II suggested that Akt, 
mTOR, and glycogen synthase kinase 3 may be downstream of PI3K responses 
in neurons.  All of these kinases participate in PI3K signaling and have been 
implicated in innate immunity in non-neuronal model systems (8, 10, 39, 40, 42, 
55).  Furthermore, preliminary studies demonstrated that poly(I-C) induced rapid 
phosphorylation of Akt and S6K in neuronal cells, and the mTOR inhibitor, 
rapamycin, demonstrated a similar neuronal PRR pathway inhibitory profile as 
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the PI3K inhibitor LY294002 suggesting that a common pathway was targeted by 
each drug (Supplemental Fig S5.1).  Nevertheless, additional studies will be 
required to further delineate the precise PI3K pathway components involved in 
neuronal antiviral PRR activation.  
 Another potential hypothesis for how PI3K mediates antiviral PRR 
signaling is suggested by a recent interesting study demonstrating an antiviral 
PRR co-activator pathway.  The authors of this study demonstrated that the host 
protein LRRFIP1 binds viral PAMPs and interacts with -catenin, thereby 
promoting the interaction of IRF3 with its co-activator p300 (73).  -catenin is a 
known downstream target of PI3K/Akt signaling (21), suggesting that PI3K/Akt 
signaling may influence innate antiviral signaling via a similar co-activator 
pathway.  In a co-activator-like pathway, PI3K-mediated signals would be 
transmitted in parallel to canonical IPS-I dependent antiviral signals until they 
united at the level of transcription.  This hypothesis will need further study, but I 
have conducted a preliminary experiment consistent with a co-activator role for 
neuronal PI3K p110.  In this experiment, I asked if overexpression of a 
constitutively active p110 (61) could induce a neuronal ISRE.  Interestingly, it 
did not induce a neuronal ISRE unless a PRR pathway stimulus was also given 
(Supplemental Fig S2.5.B).  This is in stark contrast to most constitutively active 
direct PRR pathway signaling molecules (Chapter III).  Furthermore, microarray 
analysis revealed that LRRFIP1 transcripts are elevated in PRR pathway 
competent differentiated versus PRR pathway incompetent undifferentiated 
neuronal cells (Supplemental Table S2.1). Altogether these data suggest that 
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the canonical IPS-I dependent pathway may be parallel to a co-activator-like, 
PI3K-dependent pathway in neuronal cells.        
 The PI3K pathway has been tentatively implicated in cytoplasmic RLR-
initiated signaling (50), and in chapter II, I showed that PI3K inhibitors block 
MDA5-mediated signaling in neuronal cells.  However, depletion of p110 in 
neuronal cells had no effect on induction of an MDA5-mediated stimulation.  This 
may be due to insufficient depletion of p110, redundancy among the p110s for 
MDA5-mediated signaling, or off target effects of these drugs.  Because the 
PI3Ks are known druggable targets (33), the precise role of PI3K in RLR-
mediated signaling would be worth determining, especially if modulation of RLR 
pathways proves beneficial for autoimmune or neuroinflammatory diseases.  This 
could be accomplished in many ways, but one approach would be to explore 
RLR responses in animals with deletions of PI3K-components or attempting to 
deplete PI3K levels further.   
In addition to PI3K inhibitors and associated downstream signaling 
molecules, the kinase inhibitor screen in chapter II also implicated several 
kinases not known to be involved in PRR signaling.  Further investigation of 
these molecules and those kinases that showed preference to either a TLR3 or 
MDA5/RIG-I-mediated stimulus may provide novel insight for PRR signaling 
pathways. 
 
 
 
280 
 
What is the role of PI3K in neuronal responses to neurotropic arboviruses? 
PI3K signaling dramatically affected neuronal PRR pathway signaling (Chapter 
II), yet depletion of PI3K expression had no effect on WEEV-mediated induction 
of IFN mRNA (Chapter III and Supplemental Fig S3.1.A).  Curiously, depletion 
of PI3K expression slightly protected neurons from a WEEV-mediated cytopathic 
effect (Supplemental Fig S3.1.B).  These preliminary data indicated that the 
dominant effect of neuronal PI3K signaling on a WEEV infection may not be to 
promote antiviral signal transduction.  One alternative hypothesis consistent with 
the decreased WEEV-mediated CPE in PI3K-deficient neurons is that PI3K 
signaling may promote WEEV replication.  In support of this alternative 
hypothesis, previous studies found that ribosomal protein S6, a target of 
PI3K/Akt/mTOR/S6K signaling, interacts with alphavirus nsP2 and mediates 
enhanced expression of alphavirus messages (52).  While the observation that 
PI3K signaling may actually enhance WEEV replication in neurons was 
unexpected given the positive role PI3Ks play in neuronal antiviral PRR 
pathways, further examination of the interaction of alphaviruses and potentially 
other neurotropic arboviruses with PI3K-mediated pathways may provide novel 
insights about host factors involved in alphavirus replication.      
 
What other factors mediate the IRF3-dependent, neuron-protective 
response to WEEV? 
In chapter III I demonstrated an IRF3-dependent, neuron-protective response to 
WEEV that is independent of type-I interferons and likely due to direct, IRF3-
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dependent induction of cytoprotective genes.  IRF3 directly promotes an antiviral 
state independent of type-I IFNs (27), but very recently, a novel model for RLR- 
and IRF3-dependent but type-I IFN-independent signaling was presented.  The 
authors of this model described an antiviral PRR pathway dependent on 
peroxisomal as opposed to mitochondrial IPS-I that is independent of type-I IFN 
induction (20), which provides a potential mechanism for the neuronal response I 
observed.  While interesting, this potential model will need experimental 
verification in a neuronal system, and its dependence on IPS-I will have to be 
rectified with the apparent lack of dependence I observed for responses to 
WEEV in IPS-I-/- neurons.  Nevertheless, this study highlights the complexity of 
antiviral PRR pathways and suggests that antiviral signaling independent of type-
I IFNs is a relatively common phenomenon.     
The innate antiviral effect of PRR pathways and the type-I IFN pathway 
are often dependent on multiple antiviral effector genes (2, 64, 72).  In chapter III, 
I identified OASL and MxB as WEEV-induced, IRF3-dependent, putative 
cytoprotective genes against neurotropic arboviruses in neuronal cells.  Depletion 
of the most induced candidate cytoprotective gene, OASL, rendered neuronal 
cells more susceptible to LACV but had no effect on neuronal responses to 
WEEV or SLEV.  These data highlighted the pathogen-specific nature of antiviral 
effector genes and indicated that alternative cytoprotective genes mediate the 
neuronal cell response to WEEV and SLEV.  One candidate cytoprotective gene 
is, as mentioned above, MxB, which is actively being investigated.  However, 
other candidate genes may exist.  One way of discovering these candidate genes 
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would be to perform a microarray experiment comparing WEEV-infected control 
and IRF3-deficient neurons, and then studying those genes with diminished 
induction in the IRF3-defective neurons.  Of course, this approach assumes the 
IRF3-dependent response is transcriptional in nature.  I believe this is a valid 
assumption given that the dominant negative IRF3 construct used to identify the 
IRF3-dependent phenotype lacked a DNA binding domain, thereby rendering it 
incapable of inducing transcription but still capable of receiving PRR pathway-
mediated activation signals. The microarray approach outlined above is likely to 
identify several candidate genes, but rigorously and systematically characterizing 
the role these candidate genes play in the neuronal response to neurotropic 
arboviruses, including WEEV and SLEV, may be beneficial for future 
therapeutics development. 
  
How does a WEEV structural gene(s), likely capsid, inhibit IRF3 nuclear 
translocation? 
Work by others demonstrated that VEEV capsid localizes to nuclear pores and 
inhibits nuclear translocation (3), and other RNA viruses that do not require 
nuclei for their replication, including polio, rhino, rabies, and vesicular stomatitis 
viruses, have evolved mechanisms for efficient interference of nucleo-
cytoplasmic trafficking (29, 34, 38, 71).  In chapter III, I showed that a WEEV 
structural gene(s), likely capsid, inhibits IRF3 nuclear translocation in neuronal 
cells, and that WEEV capsid-staining in BHK cells showed intense capsid 
expression in a ring surrounding the nucleus.  These data provided a potential 
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mechanism, in conjunction with shut off of host gene expression, for the ability of 
capsid to inhibit antiviral PRR signaling.  Furthermore, these data supported the 
hypothesis that WEEV capsid, like VEEV capsid, inhibits nuclear pore function in 
neuronal cells.  However, given that a construct harboring the WEEV structural 
genes inhibited IRF3 nuclear translocation and that WEEV capsid’s ability to 
inhibit IRF3 nuclear accumulation could not be completely separated from its 
ability to inhibit host gene expression, future studies will have to rule out a role for 
WEEV envelope proteins in the WEEV-mediated disruption of IRF3 nuclear 
translocation.   
The ability of WEEV capsid to disrupt nuclear pore function also needs to 
be directly tested.  One approach would be to determine if WEEV capsid co-
localizes or immunoprecipitates with nuclear pore machinery or nuclear transport 
receptors.  In addition, the selectivity of the proposed capsid-mediated inhibition 
of nuclear translocation should also be tested given that an IFN-mediated 
transcriptional response, which also requires nuclear translocation of signal-
activated transcription factors, was not susceptible to capsid-mediated inhibition 
at early times post infection.  In a similar vein, TNF-mediated activation of NFB 
was inhibited by WEEV capsid, suggesting that a factor common to both 
pathways, potentially nuclear import of activated transcription factors, was 
inhibited by WEEV capsid.  Finally, it is unclear whether WEEV capsid-mediated 
CPE, shut off of host macromolecular synthesis, and interference with type-I IFN 
induction are the result of one common mechanism (e.g. disruption of nuclear 
pore function) or are all independent functions of capsid.  Efforts to identify 
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capsid mutants that differentially affect each of these functions may clarify this 
question.    
 
What is the in vivo relevance of neuronal PRR signaling for WEEV 
pathogenesis? 
While this question may seem intellectually trivial, its importance for this body of 
work could not be more paramount.  The studies I conducted used in vitro or ex 
vivo neuronal cultures to ensure that all phenotypes could directly be attributed to 
neurons.  However, these cultures do not perfectly mimic the natural environment 
of a CNS neuron.  Furthermore, PRR pathway responses also vary between in 
vitro and in vivo models.  For instance, DAI, a putative dsDNA sensor, was 
shown to detect cytosolic dsDNA and mediate an antiviral response in vitro (67), 
but when DAI was deleted, null mice responded normally to dsDNA (37).  The 
function of LGP2 may also vary between in vitro and in vivo models, where in 
vitro it may negatively regulate RLR signaling, but in vivo it appears to be 
required for RLR signaling (65).  Finally, important differences were observed 
between tissue culture and animal models for antiviral effector responses to old 
world alphaviruses (76).  In support of innate antiviral responses of resident CNS 
cells being relevant in vivo, studies in conditional knockout mice that have 
disrupted type-I IFN receptor expression in neuroectodermal cells, which 
includes neurons, indicated that responses to type-I IFNs are important to control 
virus spread within the CNS (17).  However, these responses may have been 
due to other neuroectoderm-derived cells such as astrocytes or 
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oligodendrocytes.  For this reason, future studies investigating the role of 
neuronal PRR pathways in vivo should generate neuron-specific deletions of key 
PRR pathway components, such as IRF3, by crossing mice containing loxP-
flanked alleles of interest (e.g. IRF3) with mice harboring the Cre-recombinase 
driven by the neuron-specific enolase promoter (43).  
 
How do neuronal PRR responses interact with PRR responses by other 
resident CNS cell types? 
The main target cell of neurotropic arboviruses in the CNS is the neuron, but this 
does not preclude other resident CNS cell types from eliciting an innate immune 
response.  For example, glial cells (astrocytes, oligodendrocytes, and microglia) 
are capable of producing an innate response, and microglia, which are the 
myeloid-derived resident cell-type in the CNS, contain highly active TLR-
mediated pathways (45, 62).  Glial cell PRR signaling may mediate the 
neuropathology of several diseases including viral encephalomyelitis, 
Alzheimer’s disease, amyotrophic lateral sclerosis, ischemic brain injury, and 
seizures (44, 62).  In addition, innate immune signaling by glial cells mediates 
pathology of bystander neurons in several diseases including a neuro-adapted 
Sindbis virus model of encephalomyelitis (16, 36, 54, 58, 59).  These studies 
suggest that PRR signaling by neurons and other resident cell types in the CNS 
may interact and be important for pathogenesis.  A research program utilizing 
mice deficient in various PRR pathway components could easily be designed to 
investigate how PRR responses in different CNS cell-types interact because 
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there are established protocols for the isolation, culture, and co-culture of all 
resident cell types in the CNS (6, 22, 48, 75).      
 
What is the mechanism of thieno[3,2-b]pyrrole derivatives’ inhibition of 
alphaviruses? 
The lack of antiviral medications and broadly approved vaccines highlights the 
urgent and pressing need for the development of broadly active antiviral agents 
against neurotropic arboviruses.  To address this need, I identified a class of 
small molecules with a thieno[3,2-b]pyrrole core structure that inhibited 
neurotropic alphavirus replication and protected human neuronal cells from 
alphavirus-mediated CPE (Chapter IV).  Although the mechanism underlying the 
antiviral activity of these molecules remains unknown, the fact that they were 
identified as inhibitors of neurotropic alphavirus replicons suggests that viral 
replicase proteins are potential targets, whereas early events in the viral life 
cycle, such as receptor engagement, internalization, and uncoating, are unlikely 
targets.  In addition, the broad activity of the lead compound, CCG32091, against 
infectious virus or replicons derived from WEEV, EEEV, VEEV, Fort Morgan 
virus, and SINV suggests that a highly conserved viral enzymatic activity may be 
targeted.  Alphavirus nsPs contain several distinct enzymatic activities, including 
methyltransferase (nsP1) (1), protease and helicase (nsP2) (26, 30), and RNA 
polymerase (nsP4) (57).  In vitro assays have been developed for several of 
these activities (1, 69, 70), which provides a convenient approach for target 
identification.  An alternative approach that takes advantage of the intrinsically 
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high error rate of viral RNA polymerases previously used successfully for antiviral 
target identification is the isolation and characterization of viral escape mutants 
(46, 47, 66).  Finally, affinity purification and identification of viral or cellular 
proteins that physically interact with antiviral agents, as well as identifying the 
spectrum of viruses susceptible to the lead compound, may aid target 
deconvolution.  All of these approaches, including optimizing the lead compound 
and testing its in vivo activity against diverse neurotropic arboviruses, are actively 
being pursued.  
 
Are neuronal PRR pathways and viral countermeasures to these pathways 
viable targets for development of neurotropic alphavirus therapeutics?   
Drug-resistant viral mutants quickly emerge due to intrinsically high error rates for 
viral RNA polymerases.  Moreover, when used in combination, antiviral therapy is 
much more effective due to the decreased probability of generating multiply 
resistant viruses.  One potential set of alternative antiviral drug targets are PRR 
pathways and viral countermeasures to these pathways.  Recent evidence 
suggests that developing such medications may be fruitful.  For instance, 
GSK983, a small molecule that induces a subset of ISGs independent of type-I 
IFN induction, inhibits replication of a wide array of viruses (31); and small 
molecules that block hepatitis C virus NS3/4A protease, a PRR pathway 
countermeasure, decrease viral replication and may be of clinical benefit (23, 
68).  Other examples include the TLR7 ligand imiquimod that is used topically to 
treat human papillomavirus, and the development of novel therapeutic platforms 
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that inhibit pandemic influenza replication such as gold nanorod delivery of the 
innate immune activator ssRNA (9).  Existing therapeutics activating innate 
antiviral pathways could be immediately tested for activity against neurotropic 
arboviruses, but generation of inhibitors of neurotropic arbovirus PRR pathway 
countermeasures, such as those targeting WEEV capsid, would require 
extensive research and development.  However, assays presented in chapter III 
could be easily modified and adapted for high throughput screening of small 
molecules that restore ISRE activation in neuronal cells transfected with WEEV 
capsid.          
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Overall Significance 
 The work presented here demonstrates that neurons are active players in 
the innate immune response to neurotropic arboviruses and that neuronal 
antiviral PRR pathways may be important determinants of neurotropic arbovirus 
pathogenesis.  Specifically, I showed that human neurons posses a compliment 
of highly active antiviral PRR pathways and that these pathways mediate 
neuronal responses to neurotropic arboviruses.  In addition, I demonstrated that 
neurotropic arboviruses posses PRR pathway countermeasures, and I 
determined that the neurotropic arbovirus WEEV subverts antiviral neuronal PRR 
pathways via inhibition of IRF3 nuclear translocation and host gene expression, 
both of which are likely mediated by WEEV-capsid.  Finally, I identified a novel 
class of neurotropic alphavirus replication inhibitors which may be useful for 
mono-therapy or in combination with potential therapeutics designed to enhance 
the neuronal innate immune response or inhibit viral countermeasures to the 
innate immune response.   
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Supplemental Figure S5.1.  Poly(I-C) induces Akt and S6K phosphorylation, 
and the mTOR inhibitor rapamycin disrupts neuronal PRR signaling.  A.  
BE(2)-C/m cells were serum starved for 24 hours in media containing 0.5% BSA.  
Following serum starvation, cells were mock treated or treated with pIC (100 
g/ml) for 5, 15, 30, or 60 minutes.  Then, lysates were collected and analyzed 
by Western blotting for phosphorylated Akt (pAkt-T308; Cell Signaling, Danvers, 
MA), phosphorylated S6K (pS6K-T389; Cell Signaling, Danvers, MA), or GAPDH.  
B and C.  BE(2)-C/m ISRE (B) or NFB (C) reporter cells were pre-treated with a 
DMSO control or serial dilutions of rapamycin (LC Laboratories, Woburn, MA) for 
30 minutes followed by a mock stimulation or stimulation with 100 g/ml pIC (B 
and C), 100 U/ml IFN-A/D (B), or 50 ng/ml TNF (C).  24 hours after 
stimulation, SEAP reporter activity and cell viability were assessed.  Reporter 
activity is presented as a percent of DMSO controls.  Rapamycin was not 
cytotoxic at any of the concentrations displayed (data not shown).  Data in A 
represent 1 trial.  Averages and SEMs from 2 trials are displayed for B and C 
except for the pIC stimulation of the NFB reporter cells which represents 1 trial.       
 
